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ABSTRACT 
Benzo[e]pyridoindoles are novel potent inhibitors of aurora kinases. We performed a 
SAR study to improve their activity and water solubility. Amino-benzo[e]pyridoindolones 
were found to be potent hydrosoluble anti-proliferative molecules. They induced a massive 
arrest in mitosis, prevented histone H3 phosphorylation as well as disorganizing the mitotic 
spindles.  Upon a delay, cells underwent binucleated and finally died. Taking into account their 
interesting preclinal characteristics, their efficiency towards xenografts in nude mice and their 
apparent safety in animals, these molecules are promising new anti-cancer drugs. They 
probably target a metabolic signaling pathway, besides aurora B inhibition. 
In addition to their possible applications, these inhibitors are tools for cell biology 
studies. C4, a low ATP affinity inhibitor of aurora B kinase, revealed that the basal activity of 
the kinase is required for histone H3 phosphorylation in prophase and for chromosome 
compaction in anaphase. These waves of activation/deactivation of the kinase, during mitosis, 
corresponded to different conformations of the passenger chromosomal complex. 
Key words: Cancer, mitotic kinases, kinase inhibitor, histone H3 phosphorylation, chromosome compaction. 
RÉSUMÉ 
Les benzo[e]pyridoindoles sont de puissants inhibiteurs des kinases aurora. Nous avons 
réalisé une étude structure/activité pour améliorer leur activité et leur solubilité. Les amino-
benzopyridoindolones se révèlent être des puissantes molécules antiprolifératives. Elles 
induisent un fort arrêt mitotique qui s’accompagne de l’absence de phosphorylation de 
l’histone H3 ainsi que de la désorganisation du fuseau mitotique. Après un délai, les cellules 
deviennent binuclées puis, elles meurent. Compte tenu de leurs caractéristiques précliniques, de 
leur efficacité sur des xénogreffes implantées chez la souris nude et de leur absence apparente 
de toxicité chez l’animal, ces molécules sont prometteuses pour les traitements anticancéreux. 
Elles ciblent probablement une voie métabolique tout en inhibant la kinase Aurora B. 
 Au de là de leurs possibles applications, ces inhibiteurs sont des outils pour la biologie 
cellulaire. La molécule C4, un inhibiteur d’Aurora de faible affinité pour l’ATP, révèle 
l’existence d’une activité basale de la kinase requise pour la phosphorylation de l’histone H3 
en prophase et pour la compaction des chromosomes en anaphase. Ces vagues 
d’activation/désactivation de la kinase Aurora B correspondent à différentes conformations du 
complexe passager.  
Mots clés : Cancer, kinases mitotiques, inhibiteur de kinase, phosphorylation de l’histone H3, compaction des 
chromosomes 
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CHAPTER 1: CELL CYCLE AND ITS REGULATION 
Cell is the most basic functional and structural unit of life. To ensure development of an 
organism, new cells are constantly formed through a growth and division process called cell 
cycle. In prokaryotic cells, the cell cycle occurs through a process called binary fission. 
Whereas, in eukaryotic cells, the cell cycle can be divided into two fundamental stages: the 
interphase, during which the cell grows and duplicates its DNA; and the M (mitosis) phase, 
during which the cell is split into two distinct cells (Figure 1). 
 
Figure 1: Stages of eukaryotic cell cycle. Interphase includes 4 phases: G0, G1, S and G2, 
preparing materials for mitosis. In M-phase, the cell goes though 5 phases: prophase, 
prometaphase, metaphase, anaphase and telophase for seperation of chromosomes and finally, 
the cytoplasm is divided through cytokinesis to form two daughter cells. The regulatory factors 
(cyclin and cyclin-dependent kinases - Cdks) which control the cell cycle are also indicated 
(modified from O’Connor, 2008). 
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1.1. DESCRIPTION OF THE CELL CYCLE 
1.1.1. Interphase 
This is the first stage of cell cycle where the cell is engaged in metabolic activity and 
prepares itself for mitosis. Interphase encompasses four phases (G0 G1, S and G2) and is mainly 
controlled by the interaction of cyclins and cyclin-dependent kinases (Cdks) (Fig. 1). In fact, 
G0 phase (G = gap) is a quiescent period when the cell is unable to get through the restriction 
point to G1. When stimulated by mitogenic growth factors or the availability of nutrients, Cdk4 
and Cdk6 will interact with three D-type cyclins (cyclin D1, cyclin D2 and cyclin D3) to form 
the Cdk-cyclin D active complexes. These complexes initiate partially phosphorylation of the 
retinoblastoma protein (Rb) that binds to the E2F transcription factors and inactivates its 
function as transcriptional repressor allowing the cell to enter the G1 phase. The G1 phase is the 
major period of cell growth in which the cell synthesizes RNAs, proteins and increases in size. 
In late G1 phase, active Cdk2-cyclin E complexes reinforce Rb phosphorylation leading to the 
release of E2F which participates in the expression of genes required for G1 to S phase 
transition and DNA synthesis. This transition is called the restriction point (G1 checkpoint), 
which allows the cell either to pause or to continue cell division. Subsequent to G1, the cell 
enters S phase for DNA synthesis. In this phase, Cdk1/2-cyclin A complexes 
hyperphosphorylate Rb activating checkpoint kinases to reduce DNA replication damage. 
Finally, G2 phase is the period for final DNA repairs, rapid growth of organelles as well as 
protein synthesis before initiation of Mitotic phase (M-phase). G2 checkpoint at the end of this 
gap determines whether the cells can enter mitosis or must extend G2 for further cell growth or 
DNA repair. Cdk1-cyclin B complex is a key regulator of the G2/M transition driving cells into 
mitosis through phosphorylation of many substrates that contribute to chromosome 
condensation, nuclear envelope breakdown and spindle assembly (Enserink et al., 2010; 
Lapenna et al., 2009).  
1.1.2. Mitotic (M) phase  
After successful interphase completion, somatic cells go through mitotic phase for cell 
division. Generally, M-phase is composed of two processes: mitosis and cytokinesis for 
separation of chromosomes into two identical daughter cells. Mistakes in this stage may lead to 
uncontrolled cell division, aneuploidy and genetic instability culminating in cancer 
development.  
Mitosis is divided into five phases: prophase, prometaphase, metaphase, anaphase and 
telophase (Fig.1). At prophase, chromosome condensation begins, the duplicated centrosomes 
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separate, and some mitotic checkpoint proteins, including Bub1 and BubR1, are recruited to 
kinetochores on the chromosomes. At the entry of prometaphase, nuclear envelope breaks 
down. Microtubules emerging from the centrosomes at the spindle poles reach the 
chromosomes and attach to the kinetochores. During metaphase, the kinetochore-microtubules 
pull the sister chromatids back and forth until they align along the equatorial plate – an 
imaginary plane locating midway between two centrosome poles. The mitotic spindle 
checkpoint is activated by the signals from unattached kinetochores that delays progression to 
anaphase until all sister chromatid pairs are attached to the spindle microtubules and properly 
aligned. When this checkpoint is turned off, anaphase starts. Within anaphase, kinetochores 
provide the pulling forces which allow two sister chromatids of each chromosome to pull apart 
toward opposite poles. Simultaneously, the midzone is organized by a redistribution of 
different molecules like actin and myosin to form the cleavage furrow. Finally, at telophase, 
chromatids complete their movement, a new nuclear membrane is formed around each set of 
sister chromatids and chromosomes start to decondense into chromatin. At the end of 
telophase, a contractile ring called midbody is formed to initiate the process of cytokinesis. 
Cytokinesis is the final stage of cell division, which distributes the cytoplasm of a 
parental cell into two daughter cells. The actomyosin ring constricts the plasma membrane in 
the equatorial region of a dividing cell to form a cleavage furrow between the cytoplasmic 
content of two daughter cells. The ingressing cleavage furrow compresses antiparallel 
microtubules of the midzone into a single large microtubule bundle that comprises the core of 
the midbody. A budge-like structure called the stem body is formed in the center of midbody. 
Midbody localizes the site of abscission where the two daughter cells will separate at the end of 
cytokinesis. In a recent study, Hu et al (2012) described the relocalization of midzone 
microtubule-interacting proteins during midbody formation. These proteins localize to three 
different parts of midbody: centralspindlin (Mklp1 and RacGAP1) and its partners (Cep55, 
Arf6 and Ect2) accumulate in the budge of midbody; Prc1 and Kif4 colocalize in the dark zone 
– a narrow region on the stem body unstained with tubulin; while CENP-E, Mklp1 and aurora 
B were observed in the flanking zone, outside of the dark zone. Mklp1 interacting with 
RacGAP1 forms the centralspindlin complex that might be required to recognize the 
antiparallel microtubule structure of the stem body (Hutterer et al., 2009). Kif4 localizes to 
plus-ends microtubules to inhibit their dynamics (Hu et al., 2011). Prc1 stabilizes the 
microtubule overlap. Together with Mklp1, Prc1 helps to transport Polo-like kinase 1 (Plk1), a 
key regulator of cytokinesis, on microtubules. Aurora B kinase and Plk1 act as master 
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regulators to ensure proper progression of abscission (Steigemann et al., 2009). Abscision, the 
final separation of daughter cells, requires coordination of many molecular machines, including 
endocytic and secretory vesicle trafficking proteins as well as ESCRT (endosomal sorting 
complex required for transport) proteins (Hu et al., 2012). 
1.2. IMPORTANT STRUCTURES IN MITOSIS: MITOTIC SPINDLE AND 
CENTROMERES/KINETOCHORES – UPDATED VIEWS:  
 New emerging super-resolution microscopy techniques and proteomic analyses have 
provided new insight into these known structures. 
1.2.1. Mitotic spindle 
The mitotic spindle is a bipolar, self-organizing microtubule-based machine that 
accurately segregates sister chromatids into the daughter cells during cell division. The major 
structural elements of the spindle are microtubule polymers, which are nucleated from the two 
centrosomes, major components of the spindle poles. 
As the main microtubule-organizing center of animal cells, the centrosome participates in 
the regulation of cell mobility, organelle positioning, intracellular transport and mitotic spindle 
assembly (Lawo et al., 2012). It comprises a centriole pair surrounded by a matrix of proteins 
called PeriCentriolar Material (PCM) (Figure 2).  
Centrioles are cylindrical structures composed of nine triplets of microtubules, similar to 
the basal bodies of cilia and flagella that are required for the formation of centrosomes, cilia 
and flagella (Nigg et al., 2009). In each centriole pair, there are two unequal centrioles in which 
the older carries appendages that are close to its distal end. During S-phase, each parental 
centriole (mother centriole) is duplicated by the formation of procentriole (daughter centriole) 
at the proximal end. Procentrioles then elongate until maximum length at the end of G2 and 
reach full maturation during late G2 and early M phase by the acquisition of appendages. At the 
end of mitosis, centrioles in each pair begin separation in a process called centriole 
disorientation.  
During centrosome maturation, the PCM increases in size and γ-tubulin ring complexes 
(γ-TuRC) are recruited from the cytosol, thereby promoting microtuble nucleation, the key role 
of centrosome. Previous studies only reported about a uniform amorphous electron-dense 
structure of PCM around the centrioles. Recently, by using 3D structured illumination 
microscopy (3D-SIM), the structure of PCM was elucidated (Figure 2).  It is composed of nine 
centrosome components (CPAP, centrin, CEP120, CEP192, CEP152, CDK5RAP2, NEDD1, 
6 
 
TUBG1, PCNT) organized in a toroidal manner around the proximal end of mother centriole in 
interphasic cells (Lawo et al., 2012). 
 
Figure 2: Structure of mitotic spindle. (A) Microtubules are nucleated from two centrosomes 
forming a mitotic spindle for chromosome separation in mitosis (B) Each centrosome is 
composed of two orthogonally arranged centrioles surrounded by an amorphous mass of 
pericentriolar material (PCM). Each centriole comprises nine triplets of microtubles; the older 
of the two centrioles (mother centriole) has two sets of appendages (additional proteins) along 
the exterior surface. Microtubules are nucleated from the γ-tubulin ring complexes (γ-TuRC) 
contained in PCM. (C) Organized-structure of PCM in interphase cells with 9 centrosome 
components: PCNT (Pericentrin), TUBG1 (γ-tubulin), NEDD1 (Neural precursor cell 
Expressed, Developmentally Down-regulated 1), CDK5RAP2 (CDK5 Regulatory subunit-
Associated Protein 2), CEP120/152/192 (CEntrosomal Protein of 120/152/192 kDa) (modified 
from Lawo et al., 2012). 
The key protein in the centrosome that nucleates assembly of microtubules is γ-tubulin 
(TUBG1). Complexes of γ-tubulin form ring structures that contain 13 γ-tubulin molecules and 
have diameters similar to those of microtubules. These γ-tubulin rings serve as nucleation sites 
for the assembly of microtubules and may remain bound to their minus ends. From these 
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points, α/β-tubulin-heterodimers are attached and polymerized at their plus end, their parallel 
arrangement around a hollow core form microtubules. 
1.2.2. Centromere - Kinetochore  
 Centromere is the center region of chromosome. Centromeric chromatin is epigenetically 
characterized by the presence of specialized nucleosomes in which the canonical histone H3 is 
replaced by the variant CENP-A (centromeric protein –A) (Gues et al, 2011).  HJURP 
(Holliday JUnction- Recognizing Protein) has been identified as a CENP-A chaperone, which 
directly interacts with newly synthesized CENP-A and guides CENP-A for its deposition into 
the centromeric nucleosomes (Dunleavy et al., 2009). The deposition of CENP-A at 
centromeres is an important marker for the recruitment of a group of 16 proteins constituting 
centromere-associated network (CCAN) (Westermann and Schleiffer, 2013) (Table 1). Recent 
studies have elucidated functions of CCAN proteins as an assembly platform for the 
microtubule-binding interface of the kinetochore, called KMN network, consisting of KNL1, 
Mis12 complex and Ndc80 complex. The connection between centromeric nucleosomes and 
microtubules through kinetochore enables for the equal chromosome segregation at anaphase. 
CCAN module Human subunit Centromere localization 
dependences 
Common functions 
Centromeric 
nucleosome 
CENP-A HJURP chaperone Centromere specification and propagation 
CENP-C CENP-C CENP-A Recognizes CENP-A nucleosome, 
Associates with Mis-12 complex of KMN 
CCAN-HF CENP-T 
CENP-W 
CENP-S 
 
CENP-X 
CENP-A 
CENP-T 
CENP-T 
 
CENP-T 
Associates with Ndc80-C of KMN 
Heterodimerizes with CENP-T 
Forms [CENP-S-CENP-X]2 tetramer, 
CENP-S-X-T-W heterotramer 
Associates with FancM (DNA remodeling 
enzyme) 
Module MNL CENP-N 
CENP-L 
CENP-M 
CENP-A 
 
Associates with CENP-A nucleosome 
Module HIK CENP-H 
CENP-I 
CENP-K 
CENP-C. CENP-T Requires for Ndc80 localization 
Module OPQUR CENP-O 
CENP-P 
CENP-Q 
CENP-U 
CENP-R 
CENP-C, CENP-T No data available 
Table 1: Overview of human centromere-associated network (CCAN) subunits (reviewed 
by Westermann and Schleiffer, 2013). 
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 Conventional electron microscopy studies indicated that the kinetochore has a layered 
structure with an electron dense inner plate that contacts centromeric chromatin, an outer plate 
that contacts microtubles and a “fibrous corona” middle zone that extends away from the outer 
plate (Figure 3). In recent years, advances in biochemical and proteomic approaches have 
greatly identified the components of kinetochore as well as their functions. Thereby, CENP-A 
and CCAN subunits form a core, conserved part in the inner plate of kinetochore. CCAN 
proteins recruit outer kinetochore components (KMN network) that attach to the spindle 
microtubules. In detail, the N-terminal region of CENP-C interacts with Nnf-1 and more 
weakly with Nsl1, both subunits of the outer plate Mis12 complex (Screpanti et al., 2011; 
Przewloka et al., 2011). Through the connection with KNL1 and Ndc80 complexes, Mis12 
complex enhances the binding of microtubules to kinetochores. How the microtubules are 
attached to kinetochore? The Ndc80 complex contains four proteins forming two dimers 
Ndc80/Nuf2 and Spc24/Spc25 linked by long α-helical coiled-coil rod domains. First, the 
Hec1/Nuf2 component of the Ndc80 complex attaches with the plus-end of microtubule; then 
the Spc24/Spc25 heterodimer of the Ndc80 complex interacts with the histone-fold protein 
Cnn1/CENP-T and Nsl1 of Mis12 complex to establish the linkage with the inner kinetochore 
(DeLuca and Musachio, 2012; Malvezzi et al., 2013). Meanwhile, the KNL1 complex is 
composed of Knl1 and Zwint1 (Zwi) proteins. The C-terminal of Knl1 protein directly interacts 
with Nsl 1 (Mis12 complex) and its N-terminal binds microtubules (Figure 3). 
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Figure 3: Eukaryotic kinetochore structure from three different views: 1) light 
microscopy; 2) electron microscopy (EM) and 3) biochemical and proteomic analyses to map 
the molecular structure. Complexes participating in kinetochore-microtubule attachment are 
presented. The centromere-associated network (CCAN) subunits are divided into sub-modules 
and assembled on the centromeric chromatin. The CENP-H/I/K- and CENP-O/P/Q/U/R-
containing complexes link to CENP-T/W/S/X complex. The N-terminus of CENP-T directly 
interacts with the Ndc80 complex in the outer kinetochore through Spc24/25, while 
Ndc80/Nuf2 of Ndc80 complex binds to microtubules. In parallel, the CENP-L/M/N complex 
is associated with CEN-A nucleosomes. CENP-C, recruited by CENP-A, connects to Mis12 
complex through Nsl1 and Nnf1. Nsl1 also binds to KNL1 complex through Knl1 proteins. All 
make thus a link between kinetochores and microtubules (modified from Takeuchi et al., 
2012). 
1.3. QUALITY CONTROL OF CELL CYCLE: CHECKPOINTS 
In order to minimize mistakes in DNA synthesis as well as to ensure the proper 
segregation of chromosomes during cell cycle, cells have checkpoint controls at the specific 
phase-to-phase transitions. Normally, checkpoints consist of at least three components: a 
sensor for detecting the mistakes, a signal generated by the sensor via a signal transduction 
pathway and finally, a responsive element in the cell cycle machinery to prevent cell cycle 
progression until the errors are repaired (Rieder et al., 2011). There are four known checkpoint 
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controls during the cell cycle:  the DNA damage and replication checkpoints, the spindle 
assembly checkpoint (SAC) and the NoCut checkpoint (Morgan, 2007; Manuel et al., 2009). 
1.3.1. DNA damage/replication checkpoints 
During the development of living organisms, DNA damage might happen by the impact 
of various chemical and environmental agents or by errors in DNA replication. These mistakes, 
if not repaired properly, may lead to mutation, cancer or cell death. However, from G1 to 
G2/M, the cells can induce DNA repair mechanisms. The DNA damage/replication 
checkpoints include damage sensor proteins such as the Rad9-Rad1-Hus1 (9-1-1) complex and 
the Rad17–RFC complex to detect DNA damages. They transduce signals to ATM, ATR, 
Chk1 and Chk2 kinases and finally phosphorylate p53 and Cdc25 for various responsive 
pathways throughout the cell cycle (Figure 4) (Jeremy and Randy, 2010). 
The dominant checkpoint response to DNA damage through G1 depends on p53-p21 
pathway and is responsible for a G1 arrest. Through both ATM and ATR, p53 is 
phosphorylated at serine 15 and subsequently stimulates the transcription of p21 CIP1/WAF1, 
the inhibitor of cyclin-dependent kinases. As a result, p21 inhibits Cdk2-cyclin E and thus 
stops G1/S progression. In addition, p21 also binds to the Cdk4-cyclin D complex and prevents 
Rb phosphorylation, thereby suppressing the Rb/E2F pathway and causing a sustained G1 
blocking. Simultaneously, in late G1, in response to genotoxic stress the ATR-activated Chk1 
increases Cdc25A phosphorylation accelerating its ubiquitilation and proteolysis, thereby 
inhibiting Cdk2-cyclin E. This pathway is rapidly implemented independently of p53 and only 
delays the G1/S transition for a few hours, unless the sustained p53-dependent signal prolongs 
the G1 arrest (Kastan and Bartek, 2004). 
During S phase, the DNA damage/replication checkpoint is related to Cdc25A-
dependent pathway. Zhou et al (2004) distinguished 3 types of S-phase checkpoints: the 
replication checkpoint, the S-M checkpoint and the intra-S phase checkpoint. The replication 
checkpoint is initiated to delay DNA replication in response to dNTP depletion or DNA 
polymerase inhibition. This checkpoint firstly inactivates Cdk2-cyclin E to wait for DNA 
repair and then, allows cell cycle ongoing (Jares et al., 2000). The S-M checkpoint is activated 
when cells end S phase with incomplete replicated DNA. In this case, the checkpoint inhibits 
Cdk1-cyclin B and stops the cell cycle. The intra-S phase checkpoint works in response to 
DNA Double-Strands Breaks (DSBs) occurring at any random locus in the genome. DSBs 
activate ATM autophosphorylation that next phosphorylates Chk2. The combination of 
activated Chk2 by ATM and Chk1 by ATR increases Cdc25A phosphorylation leading to 
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down-regulation of CDC25A, thereby inhibiting Cdk2-cyclin A and delaying S-phase (Zhou et 
al., 2004). 
Finally, the G2/M checkpoint prevents cells from initiating mitosis if DNA damage 
occurs during G2 or if cells enter in G2 with unrepaired DNA lesions. The G2/M checkpoint 
inhibits Cdk1-cyclin B, the mitosis-promoting complex, by p53 pathway or through the 
degradation of CDC25C as above mentioned. 
 
Figure 4: Schematic organization of the DNA damage checkpoints throughout cell cycle. 
DNA damages are specifically recognized by Rad9-Hus1-Ras1 complex or Rad17-RFC 
complex to activate ATM/ATR/Chk1/Chk2 kinases. While Chk1 inhibits Cdc25 pathway; 
Chk2 phosphorylates and activates p53 leading to the inhibition of Cdk-cyclin complexes. As a 
result, a delay in mitotic phases happens for DNA repair or induction of apoptosis (modified 
from Jeremy and Randy, 2010). 
1.3.2. Spindle Assembly Checkpoint 
In order to minimize the mis-segregation of chromosomes and aneuploidy during cell 
cycle, there is a checkpoint control at the metaphase-anaphase transition called spindle 
assembly checkpoint (SAC) (Muchaccio and Salmon, 2007). The mechanism of SAC is 
displayed in Figure 5. The SAC function delays the anaphase onset throughout inhibitory 
activity on Cdc20, a key cofactor of APC/C until each chromosome is bipolarly attached to 
spindle microtubules (Nilsson et al., 2008). Briefly, chromosome segregation is mediated by 
the anaphase-promoting complex/cyclosome (APC/C), an E3 ubiquitin ligase that normally 
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targets cyclin B for degradation by the 26S proteasome. By inhibiting the APC/C, the SAC 
keeps cyclin B levels high and arrests the cell in metaphase until all kinetochores are attached 
to spindle microtubules. Once chromosomes are properly aligned on the metaphasic plate, SAC 
is turned off, the inhibitory complex dissociates and APC/C gets activated initiating the onset 
of anaphase. At that time, separase will cleave cohesin to resolve sister-chromatids cohesion 
for chromosome segregation. Separase is inactivated by securin and cyclin B. Thus, when 
Cdc20 binds and activates APC/C, securin and cyclin B are ubiquitylated and degraded, in 
turn, it leads to the activation of separase for the dissociation of sister chromosomes.  
 
Figure 5: The mechanism of SAC (modified from Karess, 2005) 
Chromosome segregation is triggered by the APC/C throughout the SAC turn-off. At 
microtubule-unattached kinetochores, SAC promotes the formation of a Cdc20 inhibitory 
complex, which inhibits APC/C activity. When each chromosome is bipolarly attached to 
spindle microtubules, SAC signaling is turned off, the inhibitory complex dissociates; Cdc20 
binds to and activates APC/C promoting ubiquitylation of Securins and Cyclin B and thus, 
their degradations. 
The core spindle checkpoint proteins are Mad1, Mad2, BubR1/Mad3, Bub1, Bub3 and 
Mps1 which specifically localize at the unattached kinetochores and become depleted after the 
proper microtubule attachment (May and Harwick, 2006). BubR1, Bub3 and Mad2, as key 
factors, directly bind to Cdc20 and form a mitotic checkpoint complex (MCC) which can 
function as an inhibitory complex preventing APC/C activity (Karess, 2005; Herzog et al., 
2009). Recent studies have elucidated how the SAC proteins are recruited to unattached 
kinetochore and KNL1 is determined as an important factor in the kinetochore-based SAC 
activation (reviewed by Foley and Kapoor, 2013). KNL1 is a crucial substrate of Mps1 and its 
phosphorylation by Mps1 creates a docking site for the SAC kinase Bub1. Kinetochore-
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localized Bub1 is necessary and sufficient for recruiting the SAC protein Bub3. BubR1 
localizes at outer kinetochore in a Bub3-dependent manner. Additionally, BubR1 also 
functions as a mechanosensor monitoring CENP-E activity (Chan et al., 1999). CENP-E is a 
kinetochore motor protein, involved in the attachment of microtubule to kinetochore (Mao et 
al., 2010). Interaction of CENP-E and BubR1, at the unattached kinetochore is thought to 
stimulate BubR1 activation in the absence of microtubule attachments (Mao et al., 2005; 
Weaver et al., 2003) and conversely, inactivate BubR1 activity in the proper attachment of 
kinetochore-microtubules (Muchassio et al., 2007). BubR1 is considered to play an important 
role in the inhibition of the APC/C, together with Mad2 (Muchassio et al., 2007). The Mad2 
attachment to kinetochore requires docking protein like Mad1. Mad1, a stably kinetochore-
bound protein, is essential for Mad2 kinetochore localization. Interaction between Mad1 and 
Mad2 results in the conformational modification of Mad2 enabling to bind to Cdc20. Mps1 
contributes to the SAC activity by recruiting Mad and Bub proteins to unattached kinetochores 
(Lan & Cleveland, 2010) and by promoting Mad2 activation (Hewitt et al., 2010; Maciejowski 
et al., 2010). Furthermore, Mps1 prevents the dissociation of the inhibitory complex 
(Maciejowski et al., 2010). All these numerous actors playing together integrate kinetochore 
functions, SAC activation, microtubule attachments and SAC silencing to ensure accurate 
timely chromosome segregation (Foley and Kapoor, 2013). The balance of kinase and 
phosphatase activities has a crucial role in kinetochore functions and is not fully described.  
In the presence of spindle poison like Taxol, kinetochores are unable to form proper 
attachments to spindle microtubules. This leads to the permanent activation of the SAC, the 
prolongation of mitotic arrest for hours. However the SAC cannot prevent a slow but 
continuous degradation of cyclin B that ultimately drives the cell out of mitosis (Brito and 
Rieder, 2006). Mitotic checkpoint slippage leads to 4N-multinucleated cells exhibiting a 
micronuclei phenotype. 
1.3.3. NoCut Checkpoint (Abscission checkpoint control) 
Cell abscission is the last step of mitosis and it does not occur until all chromatids are 
pulled out of the cleavage plane. In budding yeast and human cells, this event is monitored by 
the NoCut checkpoint, which involves the activities of the chromosome passenger aurora B 
kinase and Plk1 (Carmena, 2012; Chen et al., 2012). When the NoCut checkpoint detects the 
presence of chromatins in the cleavage furrow, it is turned on. Active Plk1 phosphorylates a 
centrosomal protein of 55 kDa (Cep55) and prevents its association with the midbody (Bastos 
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and Barr, 2010). Cep55, that efficiently bundles microtubules, binds to Mklp1 in vitro and 
associates with the Mklp1-MgcRacGAP centralspindlin complex in vivo. 
Meanwhile, aurora B still phosphorylates mitotic kinesin-like protein 1 (Mklp1) and 
prevents furrow ingression (Steigmann et al., 2009). Normally, aurora B activity gradually 
decreases at cytokinesis, to be null upon abscission. If aurora B is prematurely inactivated, the 
NoCut checkpoint is turned off, leading to the formation of binucleated cells (Chen et al., 
2012). 
At the end of mitosis, once chromosomes are segregated away from the cleavage furrow, 
the NoCut checkpoint is turned off, Plk1 is degraded allowing the interaction of Cep55 with 
kinesin Mklp1 at the midbody enabling the recruitment of subsequent midbody components for 
the abscission initiation.  In a recent study, Carmena clarified the molecular mechanism by 
which the CPC controls the timing of abscission through regulation of ESCRT-III (Carmena, 
2012). 
The ESCRT (endosomal sorting complex required fortransport) complexes are proteins 
involved in membrane fission events, including six complexes (ESCRT-0, -I, -II, -III, ALIX 
and VSP4) in human. Different ESCRT complexes are recruited sequentially to the site of 
scission, ending with the recruitment of the ESCRT-III complex that brings about membrane 
scission (Figure 6). In cytokinesis, after Cep-55 is associated with kinesin Mklp1, it interacts 
with Tsg101 (ESCRT-I) and ALIX, which in turn recruit ESCRT-III, the complex responsible 
for the abscission activity. ESCRT-III can assemble in filaments around the abscission site and 
makes the membrane curve, eventually driving the final break between daughter cells 
(Carmena, 2012). This study defines a cellular mechanism that links centralspindlin to Cep55, 
which, in turn, controls the midbody structure and membrane fusion at the terminal stage of 
cytokinesis. 
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Figure 6: The sequential recruitment of ESCRT complexes to the midbody. After Plk1 
degradation, dephosphorylated Cep-55 binds to Mklp1. Cep-55 then recruits Tsg101 (ESCRT-
I) and ALIX, which in turn attract the ESCRT-III complex. ESCRT-III forms filaments around 
the abscission site and drive the final cut (Carmena, 2012). 
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CHAPTER 2: AURORA KINASES 
Aurora kinases are a family of serine/threonine protein kinases that have been recognized 
as regulators of mitosis with key roles from mitotic entry to cytokinesis (Carmena et al., 2009). 
The first aurora kinase was discovered in Saccharomyces cerivisae, based on a pioneering 
genetic screen for mutations that lead to the increase of chromosome mis-segregation, was 
named IPL1 for increase-in-ploidy (Chan et al., 1993). Schizosaccharomyces pombe also 
expresses an aurora kinase, formerly called aurora-related kinase (ARK1) (Petersen et al., 
2001). While yeast has only a single aurora kinase, there are two aurora kinases (aurora-A and 
aurora-B) in Drosophila melanogaster, Caenorhabditis elegans and Xenopus laevis 
(Schumacher et al., 1998). In mammals, this family has 3 members known as aurora kinase A, 
B and C (Bischoff et al., 1999). Aurora A and B are expressed in many cell types, whereas 
aurora C is mostly found in testicular tissue and is involved in spermatogenesis (Kimmins et 
al., 2007). 
2.1. LOCALIZATION OF AURORA KINASES 
Aurora kinases show different cellular localization during mitosis (Figure 7). At late S 
phase, as soon as centrioles are duplicated, aurora A localizes on the centrosomes and is still 
there, in prophase. Then, from metaphase to anaphase, it associates along the microtubules 
close to the spindle poles. Aurora A concentrates in the midbody during cytokinesis and 
finally, it is degraded in early G1 of the following cycle (Katayama et al., 2003). Whereas, 
aurora B, a member of the chromosome passenger complex (CPC), is mostly absent in 
interphase. In prophase, aurora B is localized first in pericentromeric chromatins, then along 
the length of the condensing chromosomes and it gradually concentrates in the inner 
centromere at prometaphase. Thereafter, it transfers from chromosomes to microtubules, 
localizes to the spindle midzone in anaphase. Finally, like aurora A, it is associated with the 
midbody during cytokinesis. Aurora C is also a chromosomal passenger protein with a similar 
sub-cellular location to aurora B; it is localized to centromeres during the prophase to 
metaphase and is redistributed to midzone microtubules during anaphase (Sasai et al., 2004; 
Tang et al., 2006; Chen et al., 2005). 
 The different localizations of aurora kinases correspond to their distinct functions 
during mitosis. Interestingly, recent studies reported that the mutated G198A aurora A 
mimicked the asparagine 142 of aurora B and rescues aurora B mitotic functions (Hans et al., 
2009; Fu et al., 2009). These data demonstrated that both aurora kinases share structural 
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similarities but a few different key amino acids in their structure decide their distinct targets, 
functions and localizations. 
 
Figure 7: Comparative localizations of aurora kinases A and B during mitosis. DNA is 
stained in blue and microtubules are in red. (A) Aurora A (in green) localizes around 
centrosomes in prophase, on the microtubules near the spindle poles in metaphase and on polar 
microtubules during anaphase and telophase. (B) Aurora B (in green) localizes first in 
pericentromeric chromatins in prophase, concentrates in the inner centromere during 
prometaphase and metaphase, transfers to spindle mid-zone microtubules in anaphase and 
finally is associated with the midbody during cytokinesis (photo was modified from 
Kollareddy et al., 2008). Aurora C, when overexpressed in cells, shares the localization and 
functions of aurora kinase B. 
2.2. STRUCTURE OF AURORA KINASES 
Aurora kinases are composed of a highly conserved C-terminal catalytic domain and a 
short N-terminal domain that varies in size (Chemtham et al., 2002, Giet et al, 1999). The three 
mammalian aurora kinases range from 275 to 402 amino acids. Like other protein kinases, the 
highly conserved catalytic domain of aurora kinase consists of an activation loop, a hinge 
region binding ATP, a hydrophobic pocket and an allosteric site. 
In efforts to develop kinase inhibitors, the structural features of ATP-binding sites of 
aurora kinases have been elucidated by X-ray crystallography. Until now, most of the available 
data on the ATP-binding site are from aurora A studies because aurora B itself has not been 
crystallized in the absence of its inhibitors (Girdler et al., 2008; Sessa et al., 2005). Results 
showed that aurora A has a peculiar DFG (Asp-Phe-Gly) motif in the ATP-binding sites that 
adopts different conformations:  the active DFG-in and the inactive DFG- out states (Dodson et 
al., 2010; Martin et al., 2012; Liu and Gray, 2006). In the active DFG-in conformation, the 
activation loop is oriented away from the ATP site and accessible for phosphorylation. 
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Conversely, in the inactive-DFG state, in the presence of aurora inhibitors, the phenylalanine 
side chain points outwards and interacts with inhibitors, preventing the phosphorylation of the 
activation loop (Figure 8). 
 
Figure 8: Conformational changes of aurora A activation loop: the active DFG-in (left) and 
the inactive DFG- out states (Liu and Gray, 2006) 
In complex with INCENP and an aurora kinase inhibitor (VX-680), the structure of 
aurora B has recently been determined (Elkins et al., 2012). The overall structure of human 
aurora B resembles that of human aurora A with the exception of the conformation of the 
activation loop (Figure 9A and 9B). The catalytic domains of human aurora A and aurora B are 
76% identical at the primary sequence level, and their ATP-binding pockets differ by just three 
amino acids in which Leu215, Thr217 and Arg220 in aurora A are replaced by Arg159, Glu161 
and Lys164 respectively in aurora B (reviewed in Dodson et al., 2010). Remarkably, in 
complexes with the same inhibitor, both aurora kinases showed a significant spatial difference 
of the DFG motif (Figure 9C). In aurora A, the DFG motif is arranged with the Phe underneath 
the αC helix; while in aurora B, the αC helix is moved further out from the ATP- binding site 
and the Phe residue is to side to the helix whereas Asp is not well-ordered in the structure 
(Elkins et al., 2012). 
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Figure 9: Comparison of human aurora A and aurora B structures. (A) Structure of 
human aurora B with INCENP stained green and activation loop stained red. (B) Structure of 
human aurora A with TPX2 colored in green and activation loop colored in red. (C) 
Differences in DFG motif between aurora B (in yellow) and aurora A (in pink). (modified from 
Elkins et al., 2012).   
2.3. SUBSTRATES, FUNCTIONS AND REGULATION OF AURORA KINASES 
2.3.1. Aurora A 
During mitosis, aurora A interacts with different substrates for its activation and 
regulation, corresponding to its distinct roles (Table 2). Aurora A is involved in centrosome 
maturation, mitotic entry, separation of centriolar pairs, accurate bipolar spindle assembly and 
alignment of metaphase chromosomes. Major substrates, inter-actors and co-factors are listed 
in Table 2. 
Aurora A is activated by its phosphorylation and by the binding of activator proteins 
(Dodson and Bayliss, 2012).  Recent studies have described several activators of aurora A such 
as TPX2  (Dodson and Bayliss, 2012; Giubettini et al., 2011), HEF1 (Pugacheva et al., 2007), 
Bora (Hutterer et al., 2006), Arpc1b (Molli et al., 2010) and Nucleophosmin/B23 (NPM) 
(Reboutier et al., 2012). The role of Ajuba as aurora A activator is still controversial (Hirota et 
al., 2003; Sabino et al., 2011).  
Autophosphorylation of aurora A on Thr-288 within its activation segments requires the 
binding to TPX2, a microtubule-associated protein (Dodson and Bayliss, 2012). Upon TPX2 
binding, the autophosphorylation activity of aurora A is increased and its desphosphorylation 
by PP1 phosphatase is prevented (Eyers et al., 2003; Kufer et al., 2002; Tsai et al., 2003). The 
binding to TPX2 is required for the localization of aurora A to the mitotic spindle but not to the 
centrosome (Carmena and Earnshaw, 2009). 
Besides TPX2, at G2-M transition, aurora A binds to Bora inducing Plk1 phosphorylation 
and mitotic entry (Hutterer et al., 2006). Additionally, the interaction of aurora A and HEF1 is 
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necessary to phosphorylate and activate HDAC6, promoting ciliary disassembly at the basal 
body (Pugacheva et al., 2007).  Alternatively, Arpc1b, a centrosomal protein, is required for 
the activation of aurora A and in turn, aurora A phosphorylates it on Thr21, a signal for mitotic 
entry (Molli et al., 2010). More recently, aurora A was found to be activated by 
Nucleophosmin/B23 for centrosome maturation. Nucleophosmin/B23 (NPM) binds to aurora A 
and strongly induces its autophosphorylation on serine 89 (Reboutier et al., 2012).  
Table 2: Partners of aurora A and their roles 
Substrate Interactor Co-factors Function 
Aurora A(T288) TPX2  Maximal activity of aurora A 
 AurKAIP1 GSK-3β Degradation of aurora A  
 HEF1  Aurora A activation (centrosome amplification) 
 Arpc1b  Aurora A activation (mitotic entry) 
Aurora A (S89) NPM  Aurora A activation (centrosome maturation) 
TPX2 
TPX2  
(Ser 204) 
Plk1 
Localization of aurora A to centrosome ; aurora 
A activation; spindle length /MT nucleation 
from chromosome 
Plk1 (T210) BORA BORA G2/M entry activation of Cdk1; liberation of aurora A and recruitment of TPX2 
Xl-p53(S129/190) 
H-p53 (S315) 
TPX2 
 Stabilisation of p53 (Met II meiosis) 
Ubiquitination by Mdm2 and proteolysis 
 Cyclin B1  Stabilisation of cyclin B (prevents APC interaction) 
Cdc25B (S553)   Cdk1-cyclin B1 activation for G2-M transition 
Lats 2 (S83)   Centrosomal localisation Lats 2 kinase 
Hs-TACC3 
/maskin (S558) 
D-TACC1(S863) 
 
MAP215 
Interaction with microtubule-associated-proteins 
(dynamic of spindle pole MT) 
Stabilisation of centrosome-associated 
microtubules 
HDAC6 HEF 1/Cas-L (NEDD9) 
 Primary cilium disassembly (microtubule 
deacetylation) 
D-Par 6 
 
Numb 
Neuronal polarity/ asymetric division 
Spindle orientation 
 Ajuba  Aurora A activation 
(TPX2 : microtubule-associated protein; AurKAIP1 : aurora-A kinase interacting protein 1; HEF1 : focal 
adhesion scaffolding protein; Plk1: polo-like kinase 1; Lats2, a novel serine/threonine kinase, member of the Lats 
kinase family that includes the Drosophila tumour suppressor lats/warts; TACC : transforming acidic coiled-coil; 
MAP : microtubule associated protein; HDAC : histone deacetylase; NEDD9 neural precursor cell expressed, 
developmentally down-regulated 9; Par-6, partitioning defective 6 homolog alpha, is a regulatory subunit of 
atypical protein kinase C (aPKC); Xl: Xenopus laevis,  D: drosophila and Hs Human sapiens) (reviewed by 
Molla, 2010). 
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In order to become fully functional after duplication and separation, in G2 phase, 
centrosomes must recruit several proteins in a process known as maturation. This process 
requires the function of aurora A.  Aurora A activity depends on other kinases such as Pak1, 
Plk1, Cdk11 for centrosomal localization (Zhao et al., 2005; Petretti et al., 2006; Macůrek et 
al., 2008). Of these, Pak1 directly binds and phosphorylates aurora-A. Next, aurora A 
phosphorylates transforming acid coiled-coil (TACC) protein and the activated TACC-aurora 
A complex is recruited to the centrosome, together with microtubule-associated proteins like 
Msps/XMAP215, centrosomin and γ-tubulin, promoting the centrosome maturation (Ikezoe, 
2008). 
After maturation, the centriolar pairs separate and migrate to two opposite positions 
around the nuclear envelop for bipolar mitotic spindle formation. This event also requires 
aurora-A function; thus inhibition or depletion of aurora-A can lead to monopolar spindles and 
prevent chromosome segregation in mitosis (Vader and Lens, 2008). Aurora A phosphorylates 
Eg5, a conserved BimC-like kinesin involved in centrosome separation (Giet et al., 1999). 
After centrosome separation, spindle assembly initiates in early prophase. Nachury et al (2001) 
has shown an interaction between Ran-GTP and aurora A in spindle assembly. Ran-GTP binds 
to Importin-β causing the release of important microtubule-assembly factors such as TPX2 
near chromosomes. The liberated TPX2 then binds to aurora A at the centrosome and this 
interaction is required for microtubule nucleation from chromosomes and in turn, for building a 
spindle of correct length (Nachury et al., 2001; Kufer et al., 2002, Bird and Hyman, 2008). 
Aurora A also regulates mitotic entry through activation of Cdk1-cyclinB. During G2, 
aurora A together with Bora phosphorylates Plk1 at Thr-210 and Cdc25B at Ser-353 (Dutertre 
et al., 2004; Seki et al., 2008). Activated Plk1 regulates Cdk1-cyclinB activity through 
phosphorylation of Cdc25B phosphatase and degradation of the Cdk1 inhibitory activity Wee1 
that allows cell to enter mitosis (Macůrek et al., 2009). 
Aurora-A is degraded early in next G1 by the proteasome and the ubiquitin- dependent 
pathway. Its degradation depends on both intact A and D boxes. The level of aurora A 
decreases in interphase due to its ubiquination by the E3-ligase Cdh1-activated APC/C 
(Honda et al., 2000; Walter et al., 2000). 
2.3.2. Aurora B 
Like aurora A, aurora B interacts with different substrates corresponding to distinct roles 
during mitosis as reviewed in Table 3. 
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Table 3: Substrates of aurora B: roles and time of action during mitosis. 
Substrate Phase in 
mitosis 
Function 
Aurora B (Thr232) Mitose Maximal activity of aurora B 
INCENP (TSS893-895) Mitose Localization and activation of aurora B;  
checkpoint function 
Histone H3 (Ser10 and 28) 
 
G2-
metaphase 
Chromosome alignment 
Dam1 (Ser20, Ser257, Ser265 and 
Ser292) 
S- 
metaphase 
Correction of improper kinetochore- 
microtubule connections. 
Complex Ndc80 (Ser55 and 62) Metaphase 
Correction of improper kinetochore- 
microtubule connections. 
Hs-Mis13 (Ser100 and 109) Metaphase Kinetochore function/recruitment of Ndc80/Hec1 
CenP-A (Ser7) Metaphase Mitosis ongoing; cytokinesis completion 
MCAK (Xl-S196, Xl-T95) Metaphase Kinetochore microtubule dynamic/  
recruitment of MCAK on chromatin 
Survivin (Thr117) Anaphase Anaphase onset and cytokinesis 
Stathmin/Op18 (Ser16) Anaphase Spindle assembly 
MgcRacGap (Ser387) Cytokinesis Cytokinesis completion 
Kinesin 6 : Zen4/MKLP1(Ser708) Cytokinesis Cytokinesis completion 
Desmin (Thr16) Cytokinesis Cytokinesis completion 
(CenP-A :Centromeric Protein A ; CPC : Chromosomal Passenger Complex ; INCENP : INer 
CENtromeric Protein ; MCAK: Mitotic Centromere-associated Kinesin ;  Ndc 80 complex composed of 
Ndc80/H-Hec, Nuf2, Spc24, and Spc25is an essential core element of kinetochores; MgcRacGap: Rac 
GTPase activating protein (modified from Molla, 2010). 
Aurora B is a passenger protein, together with INCENP, Survivin and Borealin. They 
form the Chomosomal Passenger Complex (CPC). The expression of CPC members peak in 
mitosis and these proteins are interconnected. Invalidation of the expression of a CPC protein 
leads to the degradation of the partners (Klein et al., 2006). In fact this complex has a peculiar 
localization since it concentrates in the centromere from where it controls kinetochore tension 
then, when the SAC is turned off at anaphase onset, it transfers to the midzone. Finally, it 
concentrates in the midbody and participates to the NoCut checkpoint. The association with its 
partners ensures the correct localization of the kinase on the inner centromere as described in 
Figure 10. Aurora B is the unique enzymatic member of the CPC, and its maximal activation 
depends on a functional complex (Petsalaki et al., 2011).  Activation of aurora B occurs 
through a two-step mechanism: first, aurora B binds to the C-terminal IN-box sequence of 
INCENP and is then autophosphorylated at threonine 232 (Thr232) within its activation loop 
(Honda et al., 2003; Yasui et al., 2004). In the second step, aurora B phosphorylates INCENP 
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at the TSS sequence and is subsequently fully activated.  
Together with INCENP, Survivin and Borealin also participate in the right localization of 
the entire passenger protein complex to centromeres through the recognition of two specific 
epigenetic marks present on chromatin: 1) Haspin-dependent phosphorylation of histone H3 on 
Thr3 (H3-Thr3ph) and 2) Bub1-dependent phosphorylation of histone H2A on Thr120 (H2A-
Thr120ph) (Xu et al., 2009). In details, the Bir domain of Survivin recognizes phospho-histone 
H3 (Thr3), allowing its recruitment on chromatin. Meanwhile, in centromeric nucleosomes, 
histone H2A is phosphorylated by Bub1, on Thr 120, in turn, recruiting Shugoshin that 
interacts with Borealin, a CPC member. The concomitance of the two phosphorylations on 
centromeres triggers the specific recruitment of the CPC (Figure 10) (Campbell and Desai, 
2013; Kelly et al., 2010). Simultaneously, Mps1 activity enhances H2A-T120ph and is also 
critical for Shugoshin recruitment to centromeres, thereby promoting aurora B centromeric 
localization (van de Walls et al., 2012). As shown in Figure 10, when fully activated, aurora B 
exercised a retro control on Haspin. (Wang et al., 2011) 
 
Figure 10: Recruitment of the CPC on centromere. Concomitance of the phosphorylations 
of histone H3 on Thr3 (H3Thr3P) and histone H2A on Thr120 (H2AThr120P) allows the 
recruitment of the CPC at the centromere. Survivin (SVN) interacts directly with chromatin 
whereas the stabilisation is provided by the interaction of Borealin (Bor) with Shugoshin 
(Sgo1/2). Within the CPC, aurora B is fully activated and exercises a retro control on Haspin 
(modified from Xu et al., 2009). 
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Interestingly, aurora kinase B activity is also enhanced through priming of its 
substrates. A recent report shows that the phosphorylation of Survivin on Ser20 by Plk1 also 
activates aurora B in centromeres (Chu et al., 2011). Moreover, the full CPC activation requires 
two cofactors: the telophase disc 60 protein (TD-60) and microtubules (Rosasco-Nitcher et al., 
2008; Wang et al., 2011). 
Besides, there are two other kinases directly involved in the activation of aurora B: the 
Checkpoint kinase 1 (Chk1) and Tousled-like kinase 1 (Tlk1). Chk1 kinase is a major 
component of DNA damage and DNA replication checkpoints. It was recently found to 
phosphorylate aurora B on Ser331 during unperturbed pro-metaphase and during spindle 
disruption by Taxol. This phosphorylation is required for optimal phosphorylation of INCENP 
on its TSS sequence, a motif involved in aurora B full activation (Petsalaki et al., 2011). 
Related to Tlk1, in C. elegans, it is a substrate and activator of AIR-2 (the C. elegans homolog 
of aurora B) and this activation requires the presence of the C. elegans homolog of INCENP 
(ICP-1) (Han et al., 2005). However, evidence for a role of Tlk1 in aurora B activation in 
mammal is unknown at the moment. 
Aurora B is involved in chromosome condensation and cohesion, microtubule-
kinetochore attachment, mitotic spindle checkpoint regulation, chromosome segregation and 
cytokinesis. 
- Chromosome condensation: Condensation of chromosome into compact structures is a 
prerequisite for the accurate segregation of chromosomes and is driven by Condensin 
complexes (Condensin I and II in human) (Takemotor et al., 2007; Hirano, 2006). Depletion of 
aurora B impairs the localization of Condensin I on chromosomes and consequently, 
chromosome condensation (Lipp et al., 2007) showing the role of aurora B in this process. 
Moreover, aurora B is a well-known primary mitotic kinase responsible for the 
phosphorylation of histone H3 on Ser10 and Ser28 during mitosis (Baek, 2011). This 
phosphorylation has long been thought to regulate chromosome condensation during mitosis 
(Wei et al., 1999; Cerutti and Mollano, 2009). Other reports demonstrated that histone H3 
phosphorylation is only required for the initiation rather than the maintenance of condensed 
state of chromatin (Van Hoosser et al., 1998); and is also dispensable for meiotic chromatin 
condensation (Schmitt et al., 2002). Therefore, the role of aurora B and histone H3 
phosphorylation in chromosome condensation is still controversial and needs further studies. 
- Chromosome cohesion: During S phase DNA is replicated then, it condenses into 
chromosomes in G2. Therefore the two sister chromatids require a cohesion system to keep 
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together. This is accomplished by a ring-like Cohesin complex that consists of Smc1, Smc3, 
Scc/Rad21 and Scc3/SA (Nasmyth and Haering, 2009). The cohesin complex is released from 
chromatin in two steps: along chromatid arms in prophase and finally, at centromere in 
anaphase (Remeseido and Losada, 2013). Aurora B is reported to promote the chromosome 
recruitment of separase for the complete removal of cohesin, in anaphase (Yuan et al., 2009). 
- Bi-oriented microtuble-kinetochore attachment: In order to ensure the proper 
chromosome segregation, microtubules must attach sister kinetochores to opposite sides of the 
mitotic spindle (bi-orientation). Errors such as syntelic attachments (both kinetochores bind 
microtubules from the same pole); merotelic attachments (one kinetochore attaches to both 
mitotic spindle poles) or monotellic attachments (single attachment of one kinetochore in two 
sister chromatids) exert the less tension on kinetochore-to-pole connection (Figure 11). Aurora 
B triggers the phosphorylation of kinetochore substrates in a tension dependent manner and 
thereby, facilitates the bi-orientation of kinetochore-spindle pole connection. Studies in yeast 
showed that aurora B/Ipl1 corrects syntelic attachment by the phosphorylation of an important 
kinetochore-microtubule-capture factor (Dam1-ring complex), which facilitates the turnover of 
kinetochore-microtubule attachments (Keating et al., 2009). Similarly, the phosphorylation of 
Ndc/Hec1 in KMN by aurora B is observed to increase in the merotelic attachment correction 
(DeLuca et al., 2006). Another study shows the enrichment of MCAK, at points of merotelic 
attachment, in an aurora B-dependent manner. The kinesin-13 microtubule depolymerase 
MCAK is phosphorylated and could then depolymerize the improperly attached microtubules 
(Knowlton et al., 2006). However, how aurora B senses tensions for correction is still 
controversial to date. Using FRET (fluorescence resonance energy transfer)-based biosensors 
(with labeled centromere- and kinetochore-specific substrates), Liu and Lampson (2009) 
proposed a mechanism by which tensions can be converted into biochemical changes in the 
cell, through modulation of the spatial separation of aurora B from its substrates. In weak 
tension, at the inner centromere, aurora B is close to its kinetochore substrates and induces 
their phosphorylation for correcting wrong attachments. Conversely, when spindle 
microtubules pull bi-oriented sister kinetochores in opposite directions, away from the inner 
centromere, kinetochore substrates are dephosphorylated favoring the microtubule attachment 
stability.  
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Figure 11: The model of kinetochore-microtubule attachments. Aurora B corrects 
abnormal mis-attachments such as monotelic, syntelic or merotelic attachments and induces bi-
oriented attachments (Cimini and Degrasssi, 2005). 
 
- Mitotic spindle checkpoint regulation: Aurora B also plays a role for spindle assembly 
checkpoint (SAC). It activates the spindle checkpoint in response to a lack of kinetochore 
tension and prevents the activation of APC/C until proper bipolar spindle attachments are 
formed (Hauf and Watanabe, 2004). Aurora B targets two proteins for this regulation. Actually, 
the failure of microtubule stabilization caused by depletion of the chromosomal passenger 
complex was rescued by co-depletion of the microtubule-depolymerizing kinesin MCAK, 
whose activity is negatively regulated by aurora B (Sampath et al., 2004) and the microtubule-
destabilizing protein Stathmin/Op18 activity (Gadea and Ruderman, 2006). 
- Cytokinesis: At anaphase onset, aurora B relocalizes to both the central spindle and the cell 
cortex to regulate cleavage furrow formation (Bringmann, 2005; Yabe et al., 2009). Aurora B 
inactivation induces the delocalization of ZEN4/MKLP1, which is necessary for formation of 
the central spindle during anaphase (Guse et al., 2005). Further, aurora B phosphorylates 
Desmin, a protein of the cleavage furrow, leading to the destabilization of intermediate 
filaments, which are essential for the last stage of cytokinesis (Kawajiri et al., 2003). 
 Moreover, aurora B also phosphorylates MgcRacGAP in the midbody, at Ser387. This 
modification induces the conversion of MgcRacGAP to a RhoGAP, which is required for the 
contractile ring formation and the proper cytokinesis (Minoshima et al., 2003). Finally, aurora 
B is demonstrated to participate in the NoCut checkpoint as referred to in 1.3.3 above. 
 In summary, aurora B plays key roles during mitosis and its activity is also regulated 
through degradation. Related to the degradation of aurora B from metaphase chromosome 
arms, it is indicated to require a Cullin 3 (Cul3)-based E3 ubiquitin ligase. KLHL9 and 
KLHL13 form a complex with Cul3, which is necessary for ubiquitination of aurora B (Sumara 
et al., 2007). Similarly, the degradation of aurora B at the central spindle is also through Cul3-
dependent ubiquination when bound to KLH21 (Maerki et al., 2009). Moreover, in 
cytokynesis, aurora B interacts with APC/C through the Cdc27 subunit, it is ubiquitinated and 
then degraded by a proteosome pathway (Nguyen et al., 2005). 
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2.3.3.  Aurora C 
Aurora C is the least studied member of the aurora kinase family. Unlike aurora A and B, 
it is only present in germ cells and is involved in male meiotic cytokinesis (Dieterich et al., 
2009). As reported, aurora C localizes on chromosomes from prophase to metaphase and at the 
midbody from anaphase to telophase, like aurora B. Exceptionally, in tumor cells, it may be 
present at centrosome, in G2, like aurora A does (Dutertre et al., 2005). Aurora kinase C 
expression appears to be testis specific and this kinase is required for spermatogenesis and 
male fertility in mice (Kimmins et al., 2007). Tsou et al. (2011) found that the overexpression 
of aurora C, localized in centromeric region, decreases aurora B level resulting in 
tumourigenicity of epithelial cells. Additionally, aurora C is also reported to interact and 
phosphorylate Ser288 of TACC1, at midbody, for cytokinesis (Gabillard et al., 2011). 
2.4. COORDINATING ACTION OF AURORA WITH OTHER KINASES IN MITOSIS  
During mitosis, aurora kinases have interaction with other kinases for enhancing their 
activity. The understanding of this functional crosstalk might help us to well-approach the 
development of new anti cancer drugs.  
First, we could mention Polo-like kinases (Plk), a serine/threonine kinase family. 
Mammalian polo-like kinases include Plk1 (Xenopus Plx1), Plk2/Snk (Xenopus Plx2), 
Plk3/Prk/FnK (Xenopus Plx3), Plk4/Sak and Plk5. Other species have only one form of Plk: 
Polo (Drosophila), Plo1 (Schizosaccharomyces pombe) and Cdc5 (Saccharomyces cerevisiae). 
Among them, Plk1 has been the most studied. Besides Cdks and aurora kinases, Plk1 is also 
responsible for cell-cycle-dependent protein phosphorylations, which has been implicated in 
the regulation of centrosome maturation, bipolar spindle assembly, sister chromatid cohesion, 
activation of APC/C, and initiation of cytokinesis (Lowery et al., 2005; Lénárt et al., 2007; 
Petronozki et al., 2008). Aurora A, together with its cofactor hBora, was found to initiate the 
phosphorylation of Plk1, on Thr210, at G2/M transition which relates to its localization and 
activity during mitosis. In turn, Plk1 and Cdk1 induce the phosphorylation of hBora and target 
it for the proteosomal degradation (Chan et al., 2008; Seki et al., 2008). Interestingly, the 
coordination of aurora A and Plk1 activates Cdk1-cyclin B that is necessary for recovering 
from cell cycle arrest induced by DNA damage, and achieving a synergic effect (Zou et al., 
2011). Thus, the combined use of aurora A and Plk1 inhibitors after chemotherapy or 
radiography is potent in anti-cancer therapy. 
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Meanwhile, the Plks activity at kinetochore requires aurora B for its activation. Their 
collaboration regulates the kinetochore-microtubule attachments. Aurora B phosphorylates 
Polo/Plk1 at centromeres, relocalizing it from centromeres to kinetochores and promoting the 
detachment of kinetochore without tension. When tension stretches kinetochores, Polo/Plk on 
the outer kinetochore, moves away from aurora B presenting on the inner centromere, leading 
to the Polo/Plk dephosphorylation and thus the stabilization of attachment (Archambault and 
Carmena, 2012). Besides, Plk1 also indirectly enhance aurora B activity by phosphorylating its 
substrates. Briefly, the phosphorylation of Survivin on Ser20 by Plk1 also activates aurora B 
activity in the centromere (Chu et al., 2011). 
Secondly, Lats kinases are mostly known for their participation in the Hippo signalling 
cascade, which controls cell proliferation and apoptosis but they are also pivotal effectors of 
mitotic progression, including mitotic exit and cytokinesis (Bothos et al., 2005; Yabuta et al., 
2007; Pan, 2010). Yabuta et al (2007) have proposed that aurora kinases A and B are linked by 
the large tumor suppresors 1 and 2 (Lats1 and Lats2). Actually, aurora A was demonstrated to 
phosphorylate Lats2 on Ser83 and Ser380 during mitosis. The Ser380-phosphorylated Lats2 
protein colocalized at the central spindle with aurora B and in turn, aurora B is phosphorylated 
by Lats1. The Lats1/2 kinases “connect” the two aurora kinases to form an aurora A-Lats1/2-
aurora B axis that ensures accurate chromosome segregation. Moreover, the expression of 
mitotic regulators such as aurora B and Plk1 is suspected to be controlled by Lats2, thus 
indicating multiple interconnections between Last and mitotic kinases. 
2.5. AURORA KINASE ROLE IN TUMOR DEVELOPMENT 
 Because aurora kinases play essential roles during mitosis, changes in their signalling 
could result in mitotic errors and have been closely associated with chromosomal aneuploidy 
and genomic instability in cancer (Dar et al., 2010). Several studies reported the involvement 
of aurora kinases in cancer progression and even development.  
Human aurora A gene is located on chromosome 20q13.2, which is a region frequently 
altered in human cancers. In fact, overexpression of aurora kinase A was reported in many 
human cancers such as breast, glioblastoma, ovarian, cervical, colon, lung and pancreatic 
cancer (Katayama et al., 2003). Recently, the role of aurora A in tumorigenesis has been well-
studied. 
In non-transformed cells, aurora A is high expressed in G2/M transition for centrosome 
and mitotic spindle functions and then, it is degraded at cytokinesis. Meanwhile, in tumor cells, 
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it may be diffusely detected in all the cytoplasm, which allows the over-phosphorylation of 
substrates during G1/S or the wrong targeting of cytoplasmic proteins, resulting in neoplastic 
transformation. Moreover, overexpression of aurora A also affects the G2 checkpoint; thereby, 
cells with DNA damage still enter in mitosis and perform cell division. Additionally, the SAC 
can be perturbed allowing cell cycle to continue despite of improper mitotic spindle (Warren et 
al., 2009). 
The defects in centrosome maturation related to aurora A function have been described 
in breast, cervical and prostate carcinomas (Pihan et al., 2003). Centrosome amplification 
inducing multipolar mitotic spindle has been reported in head and neck cancers (Tasuka et al., 
2009). Additionally, the abnormal mitotic spindles cause cytokinesis failure and as a 
consequence, polyploid cells are present which likely result in aneuploidy (Meraldi et al., 
2002). In turn, aneuploid cells still undergo cell division due to G1 checkpoint inactivation. 
The abolishment of G1 checkpoint can be caused through a p53 pathway. Aurora A, in fact, 
phosphorylates p53, a tumour suppressor protein, at the serine 215 residue, inducing an 
inactivation of its transactivation activity (Liu et al., 2004) and at the serine 315 residue, 
facilitating MDM2-mediated p53 degradation (Katayama et al., 2004).  
Besides, in human ovarian and breast cancers, aurora A is found to bind c-Myc sites on 
the telomerase promoter, inducing its transcription and thus increasing its expression as well as 
its activity (Yang et al., 2004). Furthermore, the overexpression of aurora A potentiates 
oncogenic Ras-induced transformation suggesting that it may be responsible for oncogenic 
growth of cancer cells (Tasuka et al., 2009). Therefore, aurora A may play a role in malignant 
transformation and in tumor growth. 
Based on these strong lines of evidence, the enthusiasm of exploring anticancer 
therapeutic targets has initially been focused on aurora A, but recent studies have demonstrated 
that aurora B is also eligible.  Aurora B is located on chromosome 17p13.1, in the close 
vicinity with p53 gene. Aurora B can directly phosphorylate p53, resulting in the loss of p53 
activity, thereby accelerating tumorigenesis in transgenic mice (Lacroix et al., 2006). Although 
aurora B has not been mentioned as an oncogene, its overexpression is also found in several 
cancers such as hepatocellular carcinoma (Aihara et al., 2010, Lin et al., 2010), gastric (Honma 
et al., 2013), multiforme glioblastoma (Zeng et al., 2007), epithelial ovarian cancer (Chen et 
al., 2009), malignant mesothelioma (Lopez-Rio et al., 2006), hematological malignancies 
(Ikezoe et al., 2007)… More interestingly, the overexpression of aurora B, but not of aurora A, 
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might contribute to DNA aneuploidy in gastric cancers by promoting chromosomal instability 
(Honma et al., 2013).  
The inhibition of aurora B decreases the tumorigenic potency in many cases suggesting 
that it is an attractive target in anti-cancer therapy. For instance, using aurora B-null liver cells, 
a delayed DNA replication and a premature mitotic exit were observed, that could be explained 
by p21Cip1 pathway (Trakala et al., 2013). In the absence of aurora B, the p21Cip1, a Cdk 
inhibitor, is induced strongly and Cdk1 is diminished. Since Cdk1 activity is reduced, cells 
may eventually exit from the metaphase with high level of cyclin B as an adaptation to the 
SAC. As a result, the formation of tumors in the liver is hampered. In the other view, a recent 
study proposed a new pathway in using aurora B to prevent tumor growth (Sharma et al., 
2013). Aurora B is confirmed as a target downstream of V600EB-Raf in the MAP kinase 
signaling cascade relating to cell growth. V600EB-Raf is a popular target in melanoma cancer 
treatment but limited by drug resistance. Therefore, the inhibition of aurora B that is described 
to reduce the oncogenic growth of melanoma cells is a good alternative (Bonet et al., 2012; 
Sharma et al., 2013). 
The involvement of aurora C in carcinogenesis has been the least explored among aurora 
kinases. A few studies showed that aurora C was overexpressed in colorectal, breast and 
prostate cancer (Sasai et al., 2004). Furthermore, the phenotype obtained upon Aurora C 
overexpression (polyploid cells containing abnormal centrosome numbers) is aggravated in the 
absence of a functional p53 like in HeLa cells (Dutertre et al., 2005). These data suggested that 
aurora C might also be a target for cancer treatment, especially in the presence of mutated p53. 
In summary, the involvement of aurora kinases in tumor development makes them 
considered as potential targets in anticancer chemotherapy. Recently, a number of aurora 
kinase inhibitors have been developed and have attracted much attention from pharmaceutical 
companies. Further informations will be discussed in the next chapter. 
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CHAPTER 3: AURORA KINASE INHIBITORS AND CANCER THERAPY 
Even though much effort has been made in decreasing cancer mortality, cancer is still 
one of the major causes of death over the world. Up to date, anti-cancer therapy mainly relies 
on surgery, radiation therapy and chemotherapy, which can be used alone or in combination. 
Both surgery and radiotherapy are only local treatments and cannot control the metastatic 
tumors; whereas, chemotherapy is a systemic therapy in cancer treatment. Most 
chemotherapeutic anti-cancer drugs used in the clinic today target the cell cycle in order to 
inhibit the over-proliferation state of tumor cells and then inducing apoptosis (Lee and Schmitt, 
2003).  
Classical anti-cancer drugs interfere with DNA synthesis, DNA damage, or inhibit the 
function of the mitotic spindle. Among them, microtubule-binding drugs are the most 
exceptionally successful chemotherapeutic compounds currently used in the clinic.   
3.1. MICROTUBULE BINDING ANTI-CANCER DRUGS 
Traditional antimitotic chemotherapeutics, including taxanes and various Vinca 
alkaloids, are currently used to treat patients with breast, ovarian and non-small cell lung 
cancers (Lister-Sharp et al., 2000; O'Shaughnessy et al., 2013; Socinski et al., 2013; Ueda et 
al., 2013). Both types of drugs create unattached kinetochores in mitosis by altering 
microtubule dynamics and cause long-term mitotic arrest.  
Vinca alkaloids are a group of mitotic and spindle inhibitors that were originally 
extracted from the periwinkle plant Vinca rosea. Among them, only four drugs (vinblastine, 
vincristine, vinorelbine and vindesine) are approved for clinical uses in US and Europe. They 
bind to β-tubulin and disrupt the microtubules formation leading to the metaphase arrest 
(William et al., 2000). Their actions are highly dependent on the drug concentration. At 
relatively high concentrations, they cause microtubule depolymerization, dissolve spindle 
microtubules and arrest cells at mitosis. At even higher concentrations (milliMolar), they 
induce the aggregation of tubulin into paracrystalline arrays. In contrast, at low concentrations, 
the vinca alkaloids suppress microtubule dynamics without depolymerizing spindle 
microtubules, but remain able to arrest mitosis and induce apoptosis (Zhou and Giannakakou, 
2005). Vinca alkaloids are used to treat both hematological malignancies like leukemias and 
lymphomas and solid tumors of various organs like breast, ovary, testis, lung, colon, central 
nervous system, melanomas as well as Kaposi sarcomas.  
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Like Vinca alkaloids, taxanes are successful chemotherapeutic agents. The taxane 
paclitaxel/taxol is derived from the Pacific yew tree, Taxus brevifolia, and docetaxel/taxotere is 
a semisynthetic derivative of a compound from the European yew tree, Taxus baccata. The 
former was approved for anticancer treatment in 1992, and the latter, in 1996. Both agents 
stabilize microtubules by binding to β-tubulin, practically lining the inside of microtubules 
(Jordan and Wilson 2004). Interestingly, the effects of taxol or taxotere on additional cellular 
targets enhance their anticancer activity by promoting apoptosis and inflammation and 
inhibiting angiogenesis. Resistance mechanisms to taxol include mutation of the paclitaxel 
binding site of β-tubulin, lowering stability of microtubules especially as the wild type allele is 
lost (Wang et al. 2005, Hari et al. 2006). Taxanes are employed against a broad range of 
cancers: the breast, ovary, prostate, non small-cell lung, head and neck, esophagus, stomach, 
bladder and Kaposi’s sarcoma and they are also used when other chemotherapy regimens have 
failed.  
However, the drawback of these drugs is that they also inhibit the function of 
microtubules in normal cells. Lowering the blood counts and inducing peripheral neuropathies 
are the most common unwanted side effects. Therefore, current attempts not only try to 
improve novel anti-microtubule drugs, but also to develop drugs towards novel mitotic targets 
such as mitotic kinesins and mitotic kinases.  
3.2. MITOTIC KINESIN TARGETING DRUGS 
 Kinesins are a large superfamily of microtubule motor proteins that bind and move 
towards the plus end of microtubules in an ATP-dependent manner. To date, approximately 45 
unique kinesin superfamily genes have been identified in mammals, them self divided into 14 
families. They participate in intracellular transport of vesicles and organelles as well as various 
mitotic functions such as centrosome separation, spindle assembly and cytokinesis 
(Wordemann, 2010).  
 Among kinesins, the mitotic kinesin motor protein Eg5/KSP (kinesin spindle protein) is 
responsible for the establishment of spindle bipolarity by moving the duplicated centrosomes to 
opposite sides of the cell (Blangy et al. 1995). Inhibition of Eg5/KSP prevents centrosome 
separation leading to the formation of a monoastral spindle, which activates the spindle 
checkpoint and results in mitotic arrest. Upon prolonged treatment, cells escape from mitotic 
arrest and initiate apoptosis. Inhibition of Eg5/KSP is expected to be specific for mitosis and, 
thus, effective solely in proliferating cells. Therefore, Eg5/KSP inhibitors should not have the 
side effects associated with microtubule binding drugs. Especially, Eg5/KSP inhibitors are 
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effective even in taxol resistant cancer cells (Tao et al., 2007, Woessner et al., 2009). These 
data showed that kinesin proteins are new promising alternatives for replacing traditional anti-
microtubules drugs.   
 Monastrol was the first Eg5/KSP inhibitor to be identified (Mayer et al. 1999). 
Subsequently, more potent inhibitors like KSP-IA (Tao et al. 2005), Ispinesib (SB-715992 and 
its derivative SB-743921, GlaxoSmithKline; Davis et al. 2006), MK-0731 (Merck; Stein et al. 
2006) and ARRY-520 (Array Biopharma; Woessner et al. 2007) were developed and exhibited 
potent anti-proliferative efficacy in hematological tumors, breast and ovarian cancers, in 
clinical trials.  
3.3. KINASE TARGETING DRUGS 
Because of the drawbacks of microtubule targeting agents, many kinases, overexpressed 
in several types of cancer, have been identified as new potential targets in the development of 
anti-cancer drugs.  The first validation of small molecules targeting the ATP-binding site of a 
kinase, in cancer therapy, was obtained with Bcr-Abl inhibitors. 
3.3.1. Bcr-Abl inhibitors - the first kinase inhibitor in human cancer treatment 
Development of chronic myeloid leukemia (CML), a lethal hematopoietic stem cell 
malignancy, is characterized by t(9;22)(9q34.1)(22q11.2) chromosomal translocation leading 
to the production of the fusion oncogene Bcr-Abl. This oncoprotein is a constitutively active 
tyrosine kinase that perturbs numerous signal transduction pathways, causing uncontrolled cell 
proliferation and inducing apoptosis (Jabbour et al., 2007). Discorvered in 1992, Imatinib 
(Gleevec), the first generation of Bcr-Abl tyrosine kinase inhibitors, was first approved in the 
treatment of human cancer, in 2001. Imatinib is an ATP competitive inhibitor that prevents cell 
proliferation. More importantly, Imatinib targets specifically Bcr-Abl; hence it only inhibits the 
development of peculiar cancer cells, but do not kill all dividing cells. With the encouraging 
results in clinical trials, great hopes were opened in the use of this new target in anti-cancer 
therapy (Manly et al., 2002) and highlighted kinases as cancer targets. 
 Despite the obvious benefits of Imatinib over prior treatments, some patients may be 
intrinsically resistant to it, whereas others may acquire resistance during treatment. Resistance 
to Imatinib occurs at an annual rate of approximately 4% in patients with newly diagnosed 
CML and more often, in advanced-phase disease (Jabbour et al., 2007). In order to overcome 
drug resistance, many second generation of Bcr-Abl targeting drugs have been developed such 
as Dasatinib (BMS-345825) and Nilotinib (AMN107). Dasatinib is a multi-target kinase 
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inhibitor of five critical oncogenic enzymes: Bcr-Abl, Src, c-Kit, platelet-drived growth factor 
receptor (PDGFR) and ephrin A receptor kinases. Meanwhile, Nilotinib is a multi-target 
inhibitor of Bcr-Abl, PDGF and c-Kit receptors. Both compounds demonstrated the 
comparative effective clinical activity in chronic myeloid leukemia patients (Signorovitch et 
al., 2011) and have been FDA approved for patients with resistance to Imatinib. They are being 
currently studied further in response to other tumors.  
3.3.2. Mitotic kinase inhibitors 
a. Cyclin dependent kinase (Cdk) inhibitors 
Cdks are deregulated in several human cancers because of various genetic and epigenetic 
events that affect their regulatory pathways (Lapenna et al., 2009). Their overall effect is the 
loss of checkpoint control integrity, causing uncontrolled proliferation. Therefore, targeting 
Cdks probably limits tumor cell division. Moreover, the improved understanding of how Cdks 
regulate DNA damage and the repair pathway opens a potential approach by combining Cdks 
inhibition and DNA-damaging agents for the treatment of cancer (Johnson and Shapiro, 2010) 
Many Cdk inhibitors have been developed and are undergoing clinical trials (reviewed by 
Lapenna et al., 2009 and listed in table 4). However, until now, no Cdks inhibitor has reached 
the marketplace (Galons et al., 2013) suggesting that they need further investigations.  
b. Polo-like kinase (Plk) inhibitors 
The members of the Plk family of serine/threonine kinases function in centrosome 
maturation, Cdk1 activation at the G2/M transition, spindle assembly, regulation of the APC/C, 
chromosome segregation, and cytokinesis (Strebhardt and Ullrich, 2006, van Vugt and 
Medema, 2005). The development of Plk inhibitors for chemotherapy focused attention on 
Plk1 because it is often overexpressed in a variety of human cancers (Takai et al. 2005) and its 
function-targeting agents induce mitotic arrest and then, cell death (Guan et al., 2005; Liu and 
Erikson, 2003; Sumara et al., 2004; Schmidt et al., 2007; van Vugt et al., 2004).  
Two Plk1 inhibitors are in clinical trials and many others are currently in preclinical 
phase. One of the most common Plk1 inhibitors is BI2536 (Boehring Ingelheim). Results 
showed that BI2536 had anticancer activity in murine xenograft models especially solid tumors 
(Mross et al., 2005). It is currently in phase II of clinical trial for various tumor indications. 
Another Plk1 inhibitor is GSK461364A (GlaxoSmithKline), an ATP-competitive inhibitor. 
GSK461364A is currently in phase I for advanced solid malignancies (Olmos et al., 2013). 
35 
 
 
Inhititors 
(Company) 
IC50 
Invitro 
Clinical trial 
SNS-032 
(Sunesis) 
CDK9 (IC50 = 4 nM)  
CDK7 (IC50 = 38 nM)  
CDK2 (IC50 = 62 nM)  
 
•Phase I: B-lymphoid malignancies and  
advanced solid tumours  
 
ZK-304709 
(Bayer 
Schering 
Pharma AG) 
CDK2 (IC50 = 4 nM) 
CDK9 (IC50 = 5 nM)  
CDK1 (IC50 = 50 nM)  
CDK4 (IC50 = 61 nM) 
CDK7 (IC50 = 85 nM) 
• Phase I: advanced solid tumours 
PD-0332991 
(Pfizer) 
CDK4 (IC50 = 11 nM)  
CDK6 (IC50 = 16 nM) 
 
• Phase I: advanced cancer and mantle cell 
lymphoma.  
•Phase I–II: multiple myeloma (in 
combination with bortezomib and 
dexamethasone), hormone receptor-positive 
advanced breast cancer (in combination with 
letrozole) 
AT-7519 
(Astex) 
CDK9 (IC50 < 10 nM) 
CDK5 (IC50 = 13 nM)  
CDK2 (IC50 = 47 nM)  
CDK4 (IC50 = 100 nM)  
• Phase I: advanced or metastatic solid 
tumours, or refractory non-Hodgin leukemia 
(NHL) 
P276-00 
(Nicholas 
Priomal) 
CDK9 (IC50 = 20 nM) 
CDK4 (IC50 = 63 nM)  
CDK1 (IC50 = 79 nM)  
CDK2 (IC50 = 4 nM) 
CDK7 (IC50 = 85 nM) 
• Phase I–II: multiple myeloma, mantle cell 
lymphoma, head and neck cancers, and 
cyclin D1-positive melanoma 
R-547 
(Hoffmann 
LaRoche) 
CDK 1,2,4: Ki=1-3 nM • Phase I: advanced solid tumours and trial 
completed (2008) 
Flavopiridol, 
(Sanofi–
Aventis) 
CDK9 (IC50 = 3 nM) 
CDK4 (IC50 = 20-40 nM)  
CDK6 (IC50 = 60 nM)  
CDK1 (IC50 = 30-400 nM) 
CDK2 (IC50 = 100 nM) 
CDK7 (IC50 = 110-300 nM) 
•Phase I–II: various cancers, including 
leukaemia, multiple myeloma, lymphoma, 
sarcoma and solid tumours (as a single agent 
and in combination with DNA-damaging or 
other cytotoxic drugs) 
Roscovitine,  
also known  
as CYC202  
and seliciclib  
(Cyclacel) 
CDK2 (IC50 = 220 nM) 
CDK9 (IC50 = 230 nM)  
CDK5 (IC50 = 270 nM)  
CDK1 (IC50 = 330 nM) 
CDK7 (IC50 = 800 nM) 
• Phase I–II: NSCLC 
•Trials completed (2009); when administered 
at 800 mg twice daily for 7 days, it elicited 
limited tumor responses and dose-limiting 
toxicities (fatigue, skin rash and 
hypokalaemia) 
Table 4: Second-generation CDK inhibitors in confirmed clinical trials. Cdks inhibitors 
exhibit high activity towards in vitro Cdks and anti-proliferative potency in a variety of solid 
tumors and leukemia. (reviewed in Lapenna et al., 2009) 
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3.4. AURORA KINASE INHIBITORS 
 As mentioned in chapter 2, aurora kinases are key regulators of mitosis that are  
responsible for centrosome function, mitotic entry, spindle assembly, chromosome segregation, 
microtubule dynamics, spindle checkpoint and cytokinesis. Furthermore, they are frequently 
overexpressed in various human tumors, and such an overexpression correlates with a poor 
prognosis for patients, exemplifying their significance for tumor formation and progression. 
Therefore, aurora kinases have focused attention as potential targets in the development of 
anticancer drugs.  
 Because the domain kinase of aurora kinases are highly homologous, it is difficult to 
obtain aurora kinase inhibitors that are specific for one kinase. Consequently, most aurora 
kinase inhibitors in the market target multiple aurora kinase members. A series of pan-aurora 
kinase inhibitors are developed and undergoing in clinical trials as indicated in Table 5.  
 Among pan aurora kinase inhibitors, Tozasertib (VX-680, MK-0457) was the first aurora 
kinase inhibitor to be tested in clinical trials. It targets three aurora kinases in vitro with IC50 
of 0.7; 18 and 4.6 nM for A, B and C, respectively (Harrington et al., 2004). Preclinical tests 
reveal that it inhibits the tumor growth in prostate (Lee et al., 2006), thyroid (Arlot-
Bonnemains et al., 2008), ovarian (Lin et al., 2008), and oral squamous (Pan et al., 2008) 
cancer cell lines with IC50 values ranging from 15 to 130 nM. It induces the accumulation of 
cells arrested in a pseudo-G1 state with a 4N DNA content or the accumulation of cells with 
>4N DNA content, the latter population representing cells that exit mitosis and subsequently 
proceed through S phase in the absence of cell division. Continuous proliferation in the 
presence of aberrant mitosis and failed cytokinesis presumably result in cell death (Gizatullin 
et al., 2006). Tozasertib was reported to induce apoptotic cell death in aurora A-high primary 
leukemic blasts, but not in aurora-A-low acute myeloid leukemia (AML) or in normal bone 
marrow mononuclear cells (BMMCs); this suggests its potentially therapeutic use for  some 
leukemia patients (Huang et al., 2008). More interestingly, Tozasertib showed in vitro activity 
against Bcr-Abl bearing the Imatinib-resistant T315I or the Dasatinib-resistant V299L 
mutations (Giles et al., 2007; Young et al., 2006), opening the great hopes for these patients 
resistant to the former inhibitors.  
 The same positive effect towards the Imatinib-resistant cell lines harboring the T315I 
Brc-Abl mutation was reported upon PHA-739358 and AT-9283 treatment, two other pan 
aurora kinase inhibitors (Gontarewicz et al., 2008; Tanaka et al., 2008). The safety, tolerability 
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and preliminary efficacy of these compounds are currently evaluated in Phase I/II clinical 
studies.  
 Cells invalidated by siRNA for either aurora A or aurora B or both in combination, 
exhibited biological consequences and potential clinical outcomes, in accordance with the 
different functions of each kinase (Warner et al., 2006). In all cases, aurora kinase inhibitors 
lead to apoptosis and cell death. However, a rapid induction of apoptosis is observed in the 
cells without aurora A, whereas cells without aurora B show a gradual induction of apoptosis 
(Warner et al., 2006). The question is which aurora kinase is the best drugs target? Preclinical 
results demonstrated that targeting aurora A rather than aurora B is effective for pancreatic 
cancer cells (Warner et al., 2006). In contrast, aurora B is proposed for colon cancer treatment 
(Girdler et al., 2006). This demonstrated that the alternative role of auroras kinases depends on 
the type of tumor cells. Therefore, many specific aurora kinase inhibitors were developed and 
are undergoing clinical tests, as listed in Table 5. More interestingly, some pan aurora 
inhibitors such as upon ZM447439, with equal potency to aurora A and B in in-vitro kinase 
assay, exhibited an obvious aurora B inhibition phenotype in colon cancer cells (Girdler et al., 
2006). Similar observations were maid upon AT9283 treatment in aggressive B non-Hodgkin 
lymphomas (Qi et al., 2012). This suggests that aurora B currently seems an attractive anti-
cancer drug target.  
 From this hypothesis, our group started to search for aurora kinase inhibitors. A high 
throughput screen was performed on the French patrimonial library (around 10000 molecules). 
The test was based on an in vitro assay with recombinant aurora A catalytic domain and 
Histone H3 as substrate. The kinase and the substrate were expressed in E. coli and purified to 
homogeneity. The assay was run in the presence of a limited amount of ATP. The test started 
by the addition of the enzyme. The molecules were present at the concentration of 15 µM and 
Staurosporin was used as positive control. Remaining ATP was monitored by luminescence. 
The hits were confirmed at the concentration of 1.5 µM. The patrimonial library was formerly 
screened for CK2 inhibitors, we therefore withdrawn the common hits inhibiting both kinases 
and focused on the new hits. We realized that among them, benzo[e]pyridoindoles were over-
represented (Hoang et al., 2009). These molecules belong to the Institut Curie library and were 
synthesized by the Dr Chi-Hung Nguyen at CNRS (Orsay). Other hits were identified in the 
NIH library but we decided to focus our attention on the benzo[e]pyridoindole family. 
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 Among this family, the most potent hit was recalled C1 (Figure 12A) and was evaluated 
in vitro as well as in cells. This work was formerly as described in HOANG-Nhung’s thesis 
and in the publication (Hoang et al., 2009). 
 C1 was found to be an ATP-competitive inhibitor with a sharp selectivity in the kinome 
(Hoang et al., 2009). Within the aurora kinase family, it exhibited a broad specificity with a 
slight prevalence for aurora B (Figure 12 B). The potency of C1 towards aurora kinases was 
found to be similar to that of VX-680, the reference aurora kinase inhibitor (Cohen et al., 
2007). 
 Moreover, the ex vivo assays conducted in HeLa cells showed that C1 inhibited the 
activity of Aurora B mimicking the phenotype obtained after siRNA suppression of aurora B 
expression, and prevented cell division as well as delaying the development of tumor 
xenografts. These data confirmed that aurora B is a potential target for preventing cell 
proliferation and that benzo[e]pyrydoindoles are a new family of aurora kinase inhibitors. 
     (A)       (B) 
Figure 12: The structure of the hit aurora B inhibitor C1 (A) and the in-vitro IC50 
towards aurora kinases of C1 and VX-680 (B).  
3.5. PERSPECTIVE OF ANTI-CANCER THERAPY WITH AURORA KINASE 
INHIBITORS  
 The preclinical and clinical findings on the efficiency of aurora kinase inhibitors towards 
the growth of tumor cells, as listed in Table 5, demonstrated that aurora kinase inhibitors could 
be potential anticancer drugs in the future. 
 In anti-cancer chemotherapy, we are presently facing drug resistance in patients after 
prolonged treatment. Mutations of the oncogenic tyrosine kinase Bcr-Abl, in leukemia, is such 
an example of resistance upon inhibitor treatment. Luckily, as mentioned above, aurora kinase 
inhibitors have shown cross-reactivity with the mutated kinase and potency against drug 
resistant Bcr-Abl, opening great prospects in the treatment of leukemia patients. 
Kinase IC50 of C1 
nM 
IC50 of VX-680 
nM 
Aurora A 61 13 
Aurora B 29 37 
Aurora C 124 117 
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 In order to improve the anti-proliferative activity of the aurora kinase inhibitors in the 
clinic, the combined therapy with cytotoxic anticancer agents, radiotherapy, or other targeted 
agents might be a solution in the future. Many recent preclinical studies have proven for this 
strategy. For instance, the aurora A inhibitor (MLN8237) enhanced vincristine or docetaxel 
chemosensitivity in aggressive B-cell non-Hodgkin lymphoma (B-NHL) (Mahadevan et al., 
2012). Similarly, pan-aurora inhibitor SNS-314 also enhanced antitumor activity of 
microtubule-targeting agents in a colon carcinoma model (Vander-Porten et al., 2009). 
Treatment with AZD1152, an aurora B inhibitor, was found to be synergistic with a variety of 
chemotherapeutic agents, including irinotecan, docetaxel, vinorelbine, gemcitabine, oxaliplatin, 
and 5-fluorouracil (Nail et al., 2004), and with vincristine and topoisomerase inhibitors, in 
leukemia cell lines (Yang et al., 2007). Moreover, this compound also potentiates the radiation 
response in p53-deficient cancer cells, suggesting synergy with radiotherapy (Tao et al., 2007). 
 Besides, analysis for various off-targets is also required in the development of aurora 
kinase inhibitors. Cross-talk activity of aurora kinases with other mitotic kinases promises new 
pathways in increasing anti-tumor activity as well as overcoming the drug resistance of kinases 
inhibitors. 
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Compound 
(company) 
Aurora kinase 
inhibition 
Pre-clinical trial Clinical trial 
Pan aurora inhibitors   
VX-680  
(Vextec) 
Aurora A (IC50: 0.7 nM) 
Aurora B (IC50 : 18 nM) 
Aurora C (IC50 :4.6 nM) 
-Blocking cell cycle progression 
-Inducing apoptosis in human leukemia xenografts  
 
- Phase II: colorectal cancer, NSCLC, 
ALL, CM 
- Potency against drug resistant mutants of 
Brc-Abl. 
PHA-739358 
(Pfizer/ 
Nerviano) 
Aurora A (IC50: 13 nM) 
Aurora B (IC50 : 79 nM) 
Aurora C (IC50 : 61 nM) 
-Inhibiting FGFR1, BCR–ABL, RET and TRKA 
-Increasing p53 leading mitotic arrest with 4N DNA cells in wild types  
- Without mitotic arrest (4N) but > 8N DNA stage and then apoptosis in 
p53-deficient cells 
-Antitumor activity in different human tumour xenografts in nude mice  
- Phase II: CML and Ph+ALL 
- Potency against drug resistant mutants of 
Brc-Abl 
AT-9283 
(Astex) 
Aurora A (IC50: 3 nM) 
Aurora B (IC50 : 3 nM) 
 
-Inhibiting JAK3 (1.1 nM), JAK2 (1.2 nM) and ABL (4 nM) 
- Inhibiting the tumor growth of HCT116 cells (IC50: 30 nM) 
-Synergic effect in the combination with Docetaxel 
- Antitumor activity in lymphoma human tumour xenografts in nude mice 
-Phase I–II: advanced or metastatic solid 
tumours, NHL, AML, ALL, CML and  
myelofibrosis 
CYC-116 
(Cyclacel) 
Aurora A (IC50: 44 nM) 
Aurora B (IC50 : 19 nM) 
Aurora C (IC50 : 65 nM) 
-inhibiting VEGFR2 (IC50= 69 nM) 
-inhibiting the spindle checkpoint and cytokinesis, resulting in polyploidy 
and induction of apoptosis 
- Inhibiting the tumor growth of  AML cell line, MV4-11 (IC50: 30 nM) 
-Antitumor activity in various human solid tumour and leukemia 
xenograft models 
-Phase I: advanced solid tumors 
SNS-314 
(Sunesis) 
Aurora A (IC50: 9 nM) 
Aurora B (IC50 : 31 nM) 
Aurora C (IC50 : 3.4 nM) 
-inhibiting TRKA, TRKB, VEGFR3, CSF1R, DDR2 and AXL (IC50 < 
100 nM) 
- inducing defects in spindle checkpoint and cytokinesis, leading to 
multiple rounds of endoreduplication and cell death 
- preventing tumor growth in mice bearing a human colon carcinoma 
xenograft 
-Phase I: advanced solid tumors 
SUS-6668 
(Sugen) 
Aurora A(IC50: 850 nM) 
Aurora B (IC50 : 47 nM) 
 
- inhibiting VEGFR2, PDGFRβ, FGFR1 and TBK1 
- Inhibited angiogenesis and tumor growth in a diverse panel of human 
tumor xenografts  
• Preventing colon cancer liver metastasis in mice 
-Phase I: advanced solid tumors 
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Aurora A inhibitors   
MLN8054 
(Millennium) 
Aurora A (IC50:4 nM) 
Aurora B (IC50 :172 nM) 
 
-Inhibiting LCK (3.2 µM ), PHA(19 µM), Chk2 (28 µM) and CK2 (20.5 
µM) 
-Killing Hct116 through the development of deleterious aneuploidy 
-Binding to DNA-double-strand breaks leading to the radiosensity of 
androgen-resistant prostate cancer 
- Phase I: advanced solid tumours and 
other malignancies; trials discontinued 
MLN8237 
(Millennium) 
Aurora A (IC50:1.2 nM) 
AuroraB (IC50: 396 nM) 
(The second generation 
of MLN8054) 
-Inducing cytotoxicity and cell cycle arrest in G2–M phase in multiple 
myeloma cellular (MM) models (at 0.25 mM) 
- Up-regulating p53 and tumor suppressor genes p21 and p27 
-Synergic effect in MM cells in the combination with dexamethasone, 
doxorubicin, or bortezomib 
- Daily oral administration (20 mg per kg twice daily) to mice bearing 
lymphoma or leukaemia xenografts was well tolerated and significantly 
reduced tumour growth 
- Phase I–II: paediatric solid tumours or 
ALL 
-Phase II: adult NHL, leukaemia and 
MDS, and ovarian, fallopian tube and 
peritoneal carcinoma 
-Phase I: advanced solid tumours and 
haematological malignancies 
ENMD2076 Aurora A (IC50:14 nM) 
Aurora B (IC50 :350 nM) 
 
-inhibiting VEGFR2(80nM), KIT(40nM) PTK2(5 nM) SRC (100 nM) 
-preventing the tumor growth in various xenograft models such as 
breast, colon cancer and leukemia. 
-Synergic cytotoxic activity in the combination with lenalodomide in 
myeloma cell lines. 
-Phase II: platinum-resistant ovarian 
cancer 
Aurora B inhibitors   
AZD1152 
(AstraZeneca)
Aurora A(IC50:1368 nM) 
Aurora B (IC50 :0.37 nM) 
Aurora C (IC50 :4.6 nM) 
 
 
- Inducing growth arrest, polyploidy and promoted apoptosis in various 
human  tumour xenografts (colon, lung and hematologic) and AML cell 
lines 
- Synergic effect in the combination with viscristine and a topoisomerase 
II inhibitor, against the growth of MOLM13 and PALL-2 cells. 
- inducing apoptotic in myeloma cells at 500 nM 
- enhance radiotherapy-sensity of tumor cells 
-Phase II: Metastatic Solid Tumors and 
AML. 
GSK1070916 
(GlaxoSmith 
Kline) 
Aurora A (Ki: 490 nM) 
Aurora B (Ki :0,38 nM) 
Aurora C (Ki:  1,5 nM) 
- inhibition of phosphorylation on serine 10 of Histone H3 
-Antitumor activity in different human tumour xenografts in nude mice 
(breast, colon, lung, and two leukemia models) 
-Phase I: advanced solid tumors 
Table 5: Selected inhibitors of aurora kinases in clinical trials (Reviewed from How and Jee, 2012) 
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OBJECTIVES OF THE THESIS 
Since aurora kinases have been evaluated as potentially druggable targets in anti-cancer 
therapy, our group started to search for aurora kinase inhibitors. By in-vitro high-throughput 
screening in the molecule library of Institut Curie (France), we identified aurora kinase 
inhibitory activity of the benzo[e]pyridoindole family (Hoang et al., 2009). In this family, 
molecule 1 (C1) was confirmed as the most potent anti-proliferative compound based on its in-
vitro and in-cellulo activities (Hoang et al., 2009). However, C1 exhibits a low water-solubility 
that impairs its applications. A structure-activity relationship (SAR) study was undertaken to 
design more active and hydrosoluble molecules (partly described in the thesis of HongLien VU, 
2011).  As a result, a series of new compounds were synthesized and their aurora kinase 
inhibitory activities were initially confirmed in in-vitro assays. The first results from SAR study 
indicate the requirements for aurora kinase inhibition and give some directions for modifying the 
molecule and improving its potency. 
Moreover, among benzo[e]pyridoindoles, the molecule 4 (C4) was reported to only inhibit 
the phosphorylation of histone H3 in prophase, but not in metaphase. This is an unusual profile 
of histone H3 phosphorylation in mitosis, which is probably interesting in cell biology research.  
On the basis of these findings, the objectives of the thesis were: 
- To study the aurora B activity in mitosis through the unusual inhibition of histone H3 
phosphorylation by compound C4. 
- To improve the activity and water-solubility of benzopyridoindoles through SAR study 
and to identify the highest anti-proliferative compound. 
- To characterize the selected molecule, named C710 and to evaluate its anti-proliferative 
potency in human tumor cells as well as in mice xenograft models. 
 In order to address these objectives, all experiments were designed as described in the 
scheme presented on the following page. 
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OUTLINE OF EXPERIMENTS IN THE THESIS 
Identification of benzo[e]pyridoindole family 
- aurora kinase inhibitors - with the hit C1 
Improvement of the hit C1 through a 
Structure/Activity Relationship study 
Characterization of the hit C710 with 
the highest anti-proliferative activity  
Study on the basal aurora B activity 
through these inhibitors 
Expression of typical mitotic protein 
markers related to aurora B activity 
by: 
- Western Blots 
- Immuofluorescences 
- Time-lapse experiments 
- FRAP 
- Cell cycle analyses by FACS 
- In-vitro kinase profiling  
- In-vitro kinase IC50 determination
Evaluation of the in-cell kinase 
inhibitory activities and subsequent 
effects by:  
- Western Blots 
- Immuofluorescences 
- Time-lapse experiments 
Evaluation of the impacts on anti-
proliferative potency by: 
- 2D-cell culture models 
- 3D-spheroid models 
- Mice “xenograft” models 
Evaluation of aurora kinase B 
inhibition in cells by: 
- Western Blots 
- Immuofluorescences 
Evaluation of the anti-proliferative 
activity in cells by: 
- In-cell IC50 determination 
- Cell cycle analysis by FACS 
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MATERIALS AND METHODS 
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1. MATERIALS 
1.1. CELL LINES 
 Different human cancer cell lines were used in this thesis, to evaluate in-cell activity of 
compounds (Table 6). These cells were stored in liquid nitrogen or at minus 800C and were 
obtained from ATCC.   
1.2.  COMPOUND SYNTHESIS  
 Benzo[e]pyridoindoles used in all experiments of this thesis were synthesized by Dr. Chi-
Hung Nguyen (CNRS- Institut Curie, Orsay, France). The syntheses of compounds were 
described in Nguyen et al., 1990; Nguyen et al., 1992; Escude et al., 1995; Nguyen et al., 1998; 
and that of new compounds are present in this thesis. 
  The purity of compounds was estimated to be more than 95% by thin layer chromatography 
(TLC). The solubility of compounds was checked by the “shake-flask” method on a TechMed 
platform (Strasbourg, France). Briefly, 1 mg of compound was dissolved in 100 µL of water, the 
mixture was stirred for 1h at room temperature and then centrifuged. The supernatant was diluted 
1:100 in water/acetonitril (1/1). The concentration of the supernatant was analysed by HPLC by 
comparison with the stock solution in DMSO. 
1.3. REAGENTS  
 Antibodies were purchased from different companies listed in method below. Cell culture 
materials (culture medium, foetal bovine serum, penicillin/streptomycine, trypsin-EDTA) were 
supplied from PAA-GE Healthcare (USA). Nocodazole and Taxol are from Sigma. Reference 
inhibitors of aurora kinase such as VX-680 and AZD-1152 were supplied from Kavatechnology 
and Sigma, respectively. Salts and buffer reagents were of analytical grade and purchased from 
Sigma-Aldrich (USA), EuroBio (France), Euromedex (France).  
2. METHODS 
2.1.  CELL CULTURE AND MAINTENANCE 
2.1.1. Culture of human cells 
The frozen cells were rapidly thawed by placing the cryovial in a 37°C water bath until 
only a few ice crystals were remaining. Thawed cells were resuspended in 9 mL their prewarmed 
complete growth medium, and then centrifuged at 1200 rpm for 5 minutes. Supernatant was 
discarded, the cell pellet was gently resuspended in 10 mL prewarmed complete growth medium, 
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and then distributed with the ratio 1:1 and 1:10 into two petri dishes Ø10 cm (for adherent cells) 
or filtered cap flasks 15 mL (for non-adherent cells). 
Cell lines Origin Complete growth medium 
MCF-7 Breast DMEM (4.5 g/l Glucose) + 1 mM sodium pyruvate + 0.1 
mM NEAA 
BT20 Breast DMEM (1 g/l Glucose) + 1 mM Sodium pyruvate + 0.1 
mM NEAA + 7.5% sodium bicarbonate 
HeLa Cervix  DMEM (1 g/l Glucose) + 1 mM sodium pyruvate 
Hct116 Colon McCoy’s 5A 
U251 Glioblastoma 
(brain) 
DMEM (4.5 g/l Glucose) + 1 mM Sodium pyruvate 
U87 Glioblastoma 
(brain) 
DMEM (4.5 g/l Glucose) + 1 mM Sodium pyruvate 
Hek293 Kidney DMEM (1 g/l Glucose) + 1 mM Sodium pyruvate 
Malhavu Liver DMEM (4.5 g/l Glucose) + 1 mM sodium pyruvate + 0.1 
mM NEAA 
Hep3B Liver DMEM (4.5 g/l Glucose) + 1 mM sodium pyruvate 
Focus Liver RPMI 
H358 Lung RPMI 
JurKat T lymphocyte RPMI 
BL41 Lymphoma DMEM (4.5 g/l Glucose) + 1 mM Sodium pyruvate 
U2OS Sarcoma McCoy’s 5A 
HaCaT Skin DMEM (4.5 g/l Glucose) + 1 mM Sodium pyruvate 
SKMel28 Skin DMEM (4.5 g/l Glucose) + 1 mM Sodium pyruvate 
WM793 Skin DMEM (4.5 g/l Glucose) + 1 mM Sodium pyruvate 
A431 Skin DMEM (4.5 g/l Glucose) + 1 mM Sodium pyruvate 
Table 6: List of human cancer cell lines and growth medium (All medium were 
completed with 10% (v/v) FBS + 2 mM L-gtutamine and 100 IU/mL peniciline/streptomycine). 
 
Cells were cultured at 37°C in a humidified incubator with 5% CO2 in various medium as 
described in Table 6. The sub-culturing was performed after 2-3 days. Trypsin-EDTA solution 
(0.05% (w/v) trypsin, 0.02% (w/v) EDTA in PBS) was used to detach cells from the culture dish 
in the case of adherent cells. Briefly, 2 mL trypsin solution was added and cells were incubated 
for 5 minutes at 370C. After detachment from petri dishes, cells were harvested in 10 mL 
complete growth medium. The cells were then collected by centrifugation at 1200 rpm for 5 
minutes for sub-culturing.  
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2.1.2.  Conservation of cells 
For long term preservation of cell lines, healthy cells were recovered by centrifugation as 
described above and suspended in freezing solution (complete growth medium with 10% (v/v) 
DMSO); then transferred into a 1,5mL cryovial at the density of 106cells/mL. The vials were put 
into a passive freezer tank filled with isopropanol at minus 800C overnight and then stored at 
minus 800C or in liquid nitrogen. 
2.2.  PROTEIN ANALYSIS BY WESTERN BLOT 
Cells were treated in different conditions, then harvested and lysed in 9M urea 
supplemented with LaemmLi sample buffer. LaemmLi sample buffer 6X contains 10.28% (v/v) 
sodium dodecyl sulphate (SDS), 36% (v/v) glycerol, 5% (w/v) β-mercaptoethanol, 0.012% (w/v) 
bromophenol blue and 0.35M Tris-HCl, pH 6.8. Lysates were mixed carefully and boiled for 10 
minutes, at 1000C. They were used for protein analysis by Western blot and stored at 40C for use 
later. 
Proteins were resolved by electrophoresis in 8-15% SDS polyacrylamide gels, depending 
on the size range of the proteins of interest. Polyacrylamide gels were prepared by free-radical 
induced polymerisation of acrylamide with N,N’-methylenebisacrylamide as cross-linker. 
Amonium persulphate (APS) and N,N,N’,N’-tetramethylethylenediamine (TEMED) were added 
as provider and stabiliser of free radicals respectively. The separating gel solution was prepared 
with ingredients as follows: 
Gel concentration 8% 10% 12% 15% 
Acrylamide 30% 1.4 mL 1.7 mL 2 mL 2.5 mL 
Tris-HCl pH 8.8 1.3 mL 1.3 mL 1.3 mL 1.3 mL 
SDS 10% 0.05 mL 0.05 mL 0.05 mL 0.05 mL 
APS 10% 0.05 mL 0.05 mL 0.05 mL 0.05 mL 
H2O 2.2 mL 1.9 mL 1.6 mL 1.1 mL 
TEMED 0.002 mL 0.002 mL 0.002 mL 0.002 mL 
Polymerization started with the addition of TEMED. The solution were mixed well and 
poured into the gap between two glass plates of the slab gel system (Biorad) and carefully 
overlaid by water subsequently. When polymerization was completed after 30 min, the overlay is 
poured off and the excess was completely removed with the edge of a Whatman 3MM paper. 
Next, the stacking gel solution was prepared (1.4 mL H2O, 0.33 mL acrylamide 30%, 0.02 mL 
SDS 10%, 0.02 mL APS 10%, 0.25 mL Tris-HCl pH 6.8 and 0.002 mL TEMED added finally) 
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and poured onto the separating gel, together with inserting immediately comb to form wells for 
loading sample. After completing polymerization, the comb was removed and the slab gel 
system was inserted in the electrophoresis chamber (Biorad), filled with the electrophoresis 
buffer 1X (3 g Tris base, 18.8 g glycine, 5 mL SDS 20%, filled by H2O to 1000 mL).  
Protein samples were loaded on the stacking gel wells, together with protein ladder 10 ÷ 
250 kDa (Biorad). The gel was run in electrophoresis buffer at the current of 40 mA for 5 min to 
concentrate all samples on the same starting position before separation; subsequently at 20 mA 
per gel and the voltage was set up maximum. After SDS polyacrylamide gel electrophoresis 
(SDS-PAGE), separated proteins were transferred to nitrocellulose membrane (GE Healthcare) 
immediately after electrophoresis. The transfer sandwich was assembled in transfer buffer: on 
the black side of the transfer cassette, near the cathode site, the order was: a porous pad, a sheet 
of three Whatman 3MM papers, the gel, the nitrocellulose membrane, another sheet of three 
Whatman 3MM papers; rolling a plastic sheet over sandwich to remove air bubbles and finally a 
porous pad. The cassette was inserted in the blotting chamber with the membrane towards the 
anode. The chamber was filled with transfer buffer (20% (v/v) absolute ethanol, electrophoresis 
buffer 0.5X and H2O) to completely cover the electrode panels. The transfer was performed at 
the voltage of 110 V and the current was set up maximum, for 1 hour, at room temperature. 
After transfer, membrane was incubated in the blocking buffer (either 5% (w/v) non-fat 
milk or BSA in PBS) to cover free binding sites. Next, it was incubated with a primary antibody 
diluted in buffer I (PBS containing 0.05% (v/v) tween 20 and either 5% (v/v) lamb serum or 5% 
(w/v) BSA). The precise concentrations and incubation times are indicated in Table 7. 
Subsequently, membrane was incubated with secondary antibodies conjugated with horseradish 
peroxidase (Sigma, 1:5000) in buffer II (PBS containing 1% (w/v) non-fat milk, 0.2% (v/v) 
Tween20). After each antibody incubation step, membrane was washed 3 times by water; 
washed extensively with PBS-0.05% Tween 20 for 5 minutes and finally washed 3 times by 
water. Blots were developed using LuminataTM Forte Western HRP Subtrate Kit (Milipore) and 
imaged by ChemiDocTM MP System (Biorad). 
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Antibody Company Source WB dilution Incubation 
α-tubulin Sigma Mouse IgG1 1:5000/serum 1 hour, t0room 
β-actin Sigma Mouse IgG1 1:5000/serum 1 hour, t0room 
Histone H3-P-Ser10 Upstate Rabbit 1:2000/serum 1 hour, t0room 
Histone H3-P-Ser28 Upstate Rabbit 1:2500/serum 1 hour, t0room 
Histone H3-P-Thr3 Abcam Rabbit 1:2000/BSA Overnight, 40C 
Aurora B Epitomics Rabbit 1:5000/serum 3 hour, t0room 
Aurora A-P-Thr288 Cell signaling Rabbit 1:1000/BSA Overnight, 40C 
Aurora B-P-Thr232 Stressgen Rabbit 1:1000/serum 1 hour, t0room 
MPM2 Millipore Mouse 1:1000/serum 3 hour, t0room 
CENPA-P-Ser7 Cell signaling Rabbit 1:1000/serum Overnight, 40C 
Anti-mouse IgG Peroxidase Roche Sheep 1:5000 1 hour, t0room 
Anti-rabbit IgG Peroxidase Roche Donkey 1:5000 1 hour, t0room 
Table 7: Antibodies used in Western Blot (WB) experiments 
2.3.  MICROSCOPY TECHNIQUE 
2.3.1. Immunofluorescence 
Cells (10 000 cells/coverslips) were seeded on 12-mm-diameter glass coverslips (Knittel 
Glasser) in the 24-well-plates with 500µL of medium until they adhered to the coverslips. 
Depending on the experiment, they are treated with different compounds for 20 hours. After 
washed once by PBS, cells were fixed by warm paraformaldehyde 4% (Sigma) (200 µL/well) for 
15 min, at 370C and then, washed twice with PBS, 5 min per each time. The protocol was carried 
out at room temperature. Cells were permeabilized by Triton X-100 in PBS (0.2% v/v) (100 µL/ 
well) for 5 min and then washed once by PBS. To reduce background, free binding sites were 
blocked by BSA (0.5 mg/mL) (200 µL /well), for 15 min.  The cells were incubated first with 
specific antibodies diluted in buffer I at the concentrations indicated in table 2.3, for 30 min (200 
µL/well) and then, with fluorescence conjugated antibodies (1:500 in buffer I; 30 min, table 8). 
DNA was stained with Hoechst 33342 (Sigma) (1µg/mL in PBS). Each antibody incubation step 
was followed by washing 3 times with PBS + 0.2% Tween 20, 5 min per wash to remove non-
specific binding antibodies. Finally, coverslips were mounted on slides with fluorescent 
mounting medium (Dakocytomation). Images were collected by ZEISS LSM510 or LSM710 
laser scanning confocal microscope with a 63x oil-immersion objective and were analysed by 
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LSM510 or ZEN2010 software. Lasers were Argon2, Helium-Neon and biphoton Titanium 
(Tsunami) for excitation at 488 nm, 543 nm and 720 nm, respectively. 
Antibody Company Source IF dilution 
α-tubulin Sigma Mouse IgG1 1:2000 
Histone H3-P-Ser10 Upstate Rabbit 1:2000 
Histone H3-P-Thr3 Abcam Rabbit 1:250 
Aurora B Epitomics Rabbit 1:2000 
MPM2 Millipore Mouse 1:1000 
Histone H3-P-Ser28 Upstate Rabbit 1:2000 
Aurora A Abcam Mouse 1:1000 
Human centromere Immunovision Human 1:2000 
Survivin Norvus Rabbit 1:300 
INCENP Abcam Rabbit 1:1000 
β-tubulin III Epitomics Rabbit 1:250 
Shugoshin Abcam Mouse 1:200 
Anti-mouse Hylite fluorTM647-labeled Anaspec Goat 1:500 
Anti-rabbit Hylite fluorTM488-labeled Anaspec Goat 1:500 
Anti-mouse Cy3 Eurogentec Goat 1:500 
Anti-rabbit Cy3 Eurogentec Goat 1:500 
Anti-mouse Cy2 Eurogentec Goat 1:500 
Anti-human Dylight fluorTM488-labeled Invitrogen Goat 1:500 
Table 8: Antibodies used in Immunofluorescence (IF) experiments 
2.3.2. Time-lapse experiments 
 Hek cells stably expressing histone H2A-GFP and Tubulin-GFP as well as Hela cells 
stably expressing Survivin-GFP, INCENP-GFP and Aurora B-GFP were available (Delacour-
Larose et al., 2007; Delacour-Larose et al., 2004; Hoang et al., 2009). Cells were grown on Lab-
Tex chambered coverglass (Nalge Nunc International) for at least 24 hours. During imaging, live 
cells were still maintained under standard culture conditions (370C, 5% CO2). Images were 
acquired on a ZEISS LSM510 or LSM710 microscope using a Planapochromat 40x water-
immersion objective. GFP was excited with a 488 nm Argon2 laser (power varying from 0.1 to 
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2%). In each experiment, approximately 15 mitotic cells were followed and three independent 
experiments were performed.  
2.3.3.  FRAP (Fluorescent Recovery After Photobleaching) 
 One application of FRAP technique is to measure the dynamic of a molecule. FRAP 
experiments were performed on HeLa cells stably expressing GFP-INCENP or survivin-GFP or 
aurora kinase B-GFP. Cells were grown on Lab-Tek chambered coverglass (Nalge Nunc 
International) and maintained at 37°C, under controlled cell culture conditions. Photobleaching 
was performed on a ZEISS LSM510 system using a PlanApochromat 40x-water immersion 
objective. GFP was excited with a 488-nm Argon2 laser (power varying from 0.1 to 1%). For 
FRAP (Fluorescence Recovery After Photobleaching) experiments, outlined regions were 
bleached by 10 iterations of a full power laser and recovery was monitored every 20 seconds for 
4–5 minutes. Fluorescence intensities were quantified with homemade software and bleaching 
due to the acquisition was corrected. It was less than 10% in all experiments. Arbitrarily, the 
intensity of the region prior to bleaching was set at 1 while that of the background was set at 0. 
Relative intensities are represented as a function of time. Data were recovered in two 
independent experiments and 8 to 10 cells were followed in each mitotic stage. In mitotic cells, 
movement of fluorescent objects could be wrongly interpreted as a recovery of fluorescence. 
Therefore, we performed 3D-reconstitution all along the experiment. 
 
Figure 13: Scheme of the possible situations in a FRAP experiment. The square is the 
bleached fluorescent region and it appears black after photobleaching. Then the experiment 
consists in analyzing the fluorescent recovery area. Three situations can occur: 1) either the 
protein is fully mobile and it is immediately recruited in the bleach area or 2) it is fully immobile 
and the bleached area will not be fluorescent anymore or 3) in case of moderate mobility, the 
area will progressively recover fluorescent proteins. 
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2.4.  Cell cycle analysis by FACS (Fluorescence Activated Cell Sorting) 
2.4.1.  Principle of the method 
 The DNA content varied during the cell cycle and its analysis requires its staining  with a 
nucleic acid-specific fluorochrome such as propidium iodide (PI), which binds stoichiometrically 
to DNA and is excited with blue light (488 nm) in a flow cytometer. To allow the penetration of 
the dye, cells must be fixed by cold ethanol before staining. Moreover, PI can also bind RNA so 
that it is necessary to digest RNA from the cells by incubation with RNAase.  
 Besides, to ensure the homogeneity of cell population, it is important to synchronize the 
cells in the same phase of the cell cycle before compound treatments. 
2.4.2. Protocol 
a/ Synchronization of the cell 
• Synchronization of cells at Go/G1 by serum starvation 
 For Hela cells, the absence of serum in the culture medium induces a stop of the cell 
population in G0. In this experiment, cells were seeded into the petri dishes (Ø60 mm) at around 
40% of confluence (105 cells/ plate) and then incubated overnight.  The next day, cells were 
washed once by PBS and the medium replaced by DMEM without serum; the culture was kept, 
for 48 hours, under such conditions. Upon this treatment, cells were arrested at G0/G1 phase. 
• Synchronization of mitotic cells by Nocodazole arrest 
 This method was used for all cell lines because nocodazole prevents microbule 
polymerization. Cells were seeded into the petri dishes (Ø60 mm) with 105 cells/ plate and 
incubated overnight for cell adherence. Next, nocodazole (100 ng/mL) (Sigma) was added in 
complete medium and the culture kept for 15 hours. Then, nocodazole was removed by gentle 
washing with PBS. Upon this treatment, cells were arrested at prometaphase of mitosis. 
• Synchronization of cells at S phase by serum starvation and thymidine block 
 In the case of synchronizing cells at S phase, immediately following serum starvation as 
described above, cells were released into complete medium in the presence of 3 mM thymidine 
(Euromedex) for 20 hours. Upon this treatment, cells were mostly arrested at S phase. 
b/ Preparing cells for cell cycle analysis by FACS 
 After synchronizeation and incubation with compounds, at different concentrations, for 
various periods of time, cells were collected by centrifugation at 1200 rpm, for 5 minutes. The 
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pellet was washed once in PBS and cells carefully dispersed before being fixed in 5 mL of ice-
cold ethanol (70%) for 1 hour, at -200C. Next, the pellets were collected by centrifugation, 
washed once with PBS and then, incubated with a propidium iodide solution (50 mg/mL) in the 
presence of 0.2 mg/mL RNAase for 15 minutes, at 37°C. DNA content was measured using the 
BD Accuri C6 flow cytometer (BD Biosciences, US) and cell cycle profiles were analyzed by 
CFlow Plus software. 
2.5.  MEASUREMENT OF CELL PROLIFERATION 
 In this project, two methods were used for evaluating cell proliferation: 
2.5.1. Viable cell counting via Trypan blue exclusion method 
Trypan blue is a vital stain, the cells excluding it are viable. 
Viable cell numbers were accessed by counting cells using a Malassez haemocytometer 
(0,2 mm, 0,0025 mm2; Marienfeld, Germany) under a phase contrast microscope (Olympus, 
Japan), at 10x magnification. 50 μL of cell suspension from the cell culture were diluted 1:1 with 
Trypan blue (Sigma, Poole, UK 0.4% (w/v) in water). The mixture was transferred into the 
chamber of the hemocytometer. The unstained cells were counted in 5 grids and the number of 
viable cells was calculated as follows:  
 
 
 
2.5.2. Viable cell counting by using Colorimetric Cell Viability Kit 1  
 This method is based on the mitochondrial reductase activity of viable cells (Figure 14). 
Briefly, a yellow tetrazolium salt WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt) was bioreducted by alive cells to an orange 
formazan product, soluble in culture medium. This reaction only took place in living cells and 
involved the mitochondrial enzyme succinate-dehydrogenase. The amount of orange formazan 
produced was directly proportional to the number of alive cells and can be measured by an 
ELISA photometer, at 450 nm wavelength. 
Cell viability 
Number of cells counted 
x 2 x 104 cells/mL=
5 
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Figure 14: The mechanism of Colorimetric Cell Viability Kit 1 
 In order to evaluate anti-proliferative activity of compounds, we determined in-cell IC50 
(50% inhibititory concentration) value; IC50 means the concentration of compound reducing cell 
proliferation by half over a period  of treatment (96 hours) Cells were seeded in a 96-well plate 
with different cell numbers depending on cell lines (500 ÷ 2000 cells/ well). In the next day, they 
were treated under various conditions (compounds and concentrations of compound). Controls 
without cell and without treatment were simultaneously run. After 4 days of treatment, 10 µL of 
WST-8 solution were added, into each well, to the 100 µL of cell culture and incubation was 
pursued for 4 hours in the dark. The absorptions (OD) at 450 nm were measured. The ∆OD was 
calculated by deducting OD value of control without cell. OD values of untreated controls were 
set up at 100% of cell growth and the percentage of cell growth of treated samples was 
calculated based on this control. Mean IC50 was the average of at least three independent 
reproducible statistically significant measurements. 
2.6. KINASE PROFILING AND IN VITRO IC50 DETERMINATION 
 Assays were performed using a radioactive (33P-ATP) filter-binding assay (MRC, Dundee). 
The kinase profilings were determined with a range of recombinant kinases. Compound  C710 
was tested at the final concentration of 250 nM. All assays were run in duplicate and the ATP 
concentration adjusted at the Km value for of each kinase.  
 For in vitro IC50 determination, C710 was also tested against 6 kinases (NUAK1, PHK, 
Aurora B, SIK2, MELK, CHK2) in the assay by MRC (Dundee). ATP concentration adjusted at 
the Km value for each kinase. The compound was tested, in duplicate, at 10 concentrations 
varying from 0.03 nM to 1 µM, with serial 3-fold dilutions. Compound in vitro IC50 towards 
each kinase was defined as the concentration of compound inhibiting by 50% the kinase activity. 
 Besides, 13a, 13b and C710 were also tested against selected kinases in another assay 
performed by Reaction Biology Corp (USA). ATP concentration was 1 μM. Compounds were 
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tested, in duplicate, at 10 various concentrations from 2 pM to 10 µM with serial 3-fold 
dilutions. Staurosporine was used as internal control and tested at 10 concentrations. 
2.7. EVALUATION OF COMPOUNDS’ EFFECTS INTO THE TUMOR GROWTH. 
2.7.1. The multicellular tumor spheroid (MTS) model 
We have adapted the hanging-drop method to produce spheroids of similar diameters. A 
mixture of agarose 2% – culture medium (1:1) was coated on 24-well plates (500 µL /well) and 
then 500 µL culture medium was added. A drop of Hct116 cell suspension (20 µL with 750 
cells) was put on the lid of an agar coated 24-petri dish containing culture media. Cells were kept 
under standard culture conditions for spheroid formation. After 48 hours, the spheroids 
(approximately 0.01 mm) were transferred to the culture medium and after 1 day, they were 
treated with different concentrations of C710M (350 nM and 1µM) for 2 weeks. Control Hct116 
spheroids were grown under the same conditions, but without drug treatment. Spheroid volumes 
were measured before drug treatment (V0) and each two days during the drug treatment (Vn). 
The size of each spheroid was determined by measuring 2 orthogonal diameters (d1 and d2) using 
an inverted microscope. The volume was calculated according to the formula:  
V = 4/3πr3 in which r = 1/2 √d1 x d2.  
 Spheroid growth was calculated by measuring the variations in volume during the drug 
treatment using the formula: (Vn –V0)/V0. The mean values were determined by following at 
least 6 spheroids. 
 
Figure 15: MTS formation by the hanging-drop method. 
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2.7.2. In vivo test: Xenograft models 
The protocole was evaluated by the local ethic committee and was conducted by a 
habilitated researcher. In-vivo experiments were performed on four-week old female Swiss nude 
mice (Janvier, France). After one week of adaptation of the mice with their environment 
conditions in the animal keeping-house of Institut Albert Bonniot, cells were injected 
subcutaneously. Cells resuspended in PBS were mixed 1:1 with cold growth factor free matrigel 
(Beckton Dikinson) and 3.5x106 cells per mouse used for the establishment of Mahlavu tumours. 
Glioblastoma tumors were got by injection of 6x106 cells per mouse (U251).  
Tumors were established after 13 days (Mahlavu) or 9 days (U251-GFP), ready for 
compound injection. At this time, the mice were randomly divided into 3 groups, with the 
equivalent mean tumor size among groups. Each group (6 mice) received the treatment of either 
C710M or C21 in NaCl 0.45% (200 µg compound per each 20 gr of mouse weight) by an 
intraperitoneal injection (IP injection); whereas, the control group was only injected with NaCl 
0.45%. The injections were carried out 4 times per week, stopped 1 day between 2 continuous 
times.  Mice received 11 injections in the experiment with Mahlavu, and 13 injections in the case 
of U251. The size of the tumor and the weight of each mouse were determined twice per week. 
Tumor volume was determined by measuring two perpendicular diameters using a clipper and 
then calculated as follows: V = d1 x d1 x d2 in which d1 and d2 are the smallest and the largest 
diameter, respectively. The mean values for each group (6 mice) were determined and compared 
using Student’s t test.  At the end of the protocole, 38th day (Mahlavu tumor) or 48th day (U251 
tumor), mice were autopsied by a veterinary, tumors were collected and weighted. 
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CHAPTER 1: 
STUDY ON AURORA B ACTIVITY IN MITOSIS 
THROUGH BENZO[e]PYRIDOINDOLONE C4 
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Aurora kinase B plays key roles during mitosis through its activity towards various 
substrates. However, how it interacts selectively with substrates in different phases of mitosis is 
still an interesting question to be elucidated.  
When studying the benzo[e]pyridoindole aurora kinase inhibitors, we paid attention on 
compound C4 with an unusual profile of histone H3 phosphorylation. We realized that this 
compound only inhibits histone H3 phosphorylation in prophase but not in metaphase. Since 
histone H3 phosphorylation is the hallmark of mitosis and is required for mitotic events, we 
decided to follow what happens during mitosis upon C4 treatment.   
 The results showed that without histone H3 phosphorylation in prophase, cells enter into 
mitosis normally, assemble chromosomes and progress to metaphase. This reinforced the 
hypothesis of no relationship between histone H3 phosphorylation and chromosome 
condensation, which was suggested in previous studies (De la Barre et al., 2001; Hans and 
Dimitrov, 2001; Prigent and Dimitrov, 2003). More interestingly, except inhibition of histone H3 
phosphorylation in prophase, the expression and other activities of aurora kinase B were 
unchanged in these phases. In addition, we observed chromosome compaction defects in 
anaphase and afterwards, lagging chromosome leading to a delay in mitotic exit upon C4 
treatment. We demonstrated that anaphase defects were not related to the absence of histone H3 
phosphorylation, in prophase. Simultaneously, aurora kinase B was partly mis-localized in 
anaphase. 
We reproduced the same mitotic defects by treated cells with a selective well-known 
aurora kinase inhibitor, at a very low concentration. This result leads us to postulate that C4 
inhibited the low ATP-affinity of aurora B kinase, in other words its basal activity. Taking 
account of the independence of the noted defects: the absence of histone H3 phosphorylation in 
prometaphase and the compaction defects in anaphase, we could hypothesize the existence of 
waves of aurora kinase activation in mitosis. 
Moreover, in previous studies, we showed by FRAP experiments that the mobility of 
survivin varied from metaphase to anaphase suggesting the existence of different conformations 
for the chromosomal passenger complex (CPC) (Delacour-Larose et al., 2004). To complete this 
study, we analyzed the mobility of INCENP, in prophase, by FRAP. The overall FRAP data 
indicate the existence of different conformations for the CPC that correlates with the aurora 
kinase activation waves.  
In conclusion, the histone H3 phosphorylation in prophase and the anaphase chromosome 
compaction required the basal activity of aurora B. 
All the above results were accepted for publication in Biology Open. Additional data and 
further discussion will be presented in the article hereafter. 
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CHAPTER 2: 
STRUCTURE-ACTIVITY RELATIONSHIP (SAR) 
STUDY OF BENZO[e]PYRIDOINDOLES 
 
2.1. Improvement of anti-proliferative activity and water-solubility of 
benzo[e]pyridoindoles through SAR study 
2.2. Development of new hydrosoluble benzo[e]pyridoindolones with 
high anti-proliferative activity 
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2.1. IMPROVEMENT OF ANTI-PROLIFERATIVE ACTIVITY AND WATER-
SOLUBILITY OF BENZO[E]PYRIDOINDOLES THROUGH STRUCTURE-ACTIVITY 
RELATIONSHIP (SAR) STUDY 
 Benzo[e]pyridoindoles are a family of tetra-heterocyclic compounds which were identified 
as novel potent inhibitors of aurora kinases. Taking into account that the hit C1 bears 3 possible 
lateral chains that may be modified by the chemist, the initial data described in the Ph.D thesis of 
HongLien VU (2011) suggested some strategies to enhance the aurora B inhibition activity of 
benzo[e]pyrydoindoles. Hereby, a SAR study was performed with modifications in the 3 lateral 
chains of the hit C1. In-cellulo aurora B inhibition potency of alternatives were evaluated 
through the histone H3 phosphorylation by immunoblotting and immunofluorescence. By the 
enlargement of SAR study in molecules of benzo[e]pyridoindole family, we determined the 
requirements for aurora kinase B inhibition as follows: an oxo group at position 11, a large alkyl 
substituent at position 8 and an ether group at position 3 of the tetra-heterocyclic structure.   
In order to improve the water-solubility of benzo[e]pyridoindoles, we introduced an 
amine group on position 3, such a substituent could allow the synthesis of the corresponding 
hydrosuble maleate salt. The methoxy group at position 3 in C1 was replaced by a 
dialkylaminoalkoxy substituent. Dialkylaminoalkoxy-benzo[e]pyridoindolones 13a and 13b were 
synthesized. The question was whether these modifications influenced aurora B inhibitory 
activity in cells. Very interestingly, the results showed the improved activity of these molecules 
in comparison to C1.  
In addition, their effects toward the cell cycle of HeLa cells were also examined. FACS 
experiment showed that cells were arrested longer in G2/M phases (4N populations) upon 13a or 
13b treatment than controls. By immunofluorescence, we observed the bi-nucleation of the cell 
population. These results were confirmed by time-lapse experiments. Hereby, these compounds 
delayed mitotic exit and prevented the separation of the two daughter cells, giving rise to large 
mitotic cells with two connected nuclei. Upon compounds treatment for 48 h, we have noted a 
significant increase of the sub-G0 population, a signature of apoptosis induction. Consequently, 
compound 13a and 13b prevented cell proliferation. Their anti-proliferative potency was also 
confirmed through the viability of tumor HeLa cells. Upon compounds 13a and 13b treatment for 
96h, respective IC50 values of 174 nM and 53 nM were measured for HeLa cell viability. 
More interestingly, the hydrosolute maleate salts, 13aM and 13bM, exhibited similar 
activities than the corresponding free-base counterparts (13a and 13b). The hydrosoluble 13aM 
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and 13bM strongly inhibited aurora B kinase and exhibited a high anti-proliferative potency 
towards HeLa cells, with respective IC50 values of 114 and 63 nM.  
In conclusion, through SAR study, we developed two new benzo[e]pyridoindolones with 
improved activity and solubility compared to the hit C1. Their anti-proliferative potency is 
comparable with the top 10 best aurora kinase inhibitors currently tested in clinical trials. These 
results is thus opening potential approaches in the development of benzo[e]pyridoindole family 
as anti-cancer drugs in the future. The full SAR study is presented in the article recently 
published in ChemMedChem.  
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2.2. DEVELOPMENT OF NEW HYDROSOLUBLE BENZOPYRIDOINDOLONES 
WITH THE HIGH ANTI-PROLIFERATIVE ACTIVITY  
With the aim of developing new hydrosoluble compounds, we continued to focus on the 
alternatives of O-alkylamino chain at position 3 of the benzo[e]pyridoindolone scaffold. Three 
new compounds (named C710, C07, C711) were designed as in Figure 31 and their potencies 
were evaluated through firstly aurora kinase B inhibition and then, anti-proliferation assays in 
cell. 
 
Figure 31: Structure of new benzo[e]pyridoindolones  
At position 3, a piperidine-ethoxy group, morpholin-ethoxy group and methoxy-ethoxy group 
replaced the amino-ethoxy group present in compound 13a. These molecules were respectively 
named C710, C07 and C711. 
2.2.1. Evaluating aurora B inhibition potency of these new compounds in cell 
 Aurora kinase B activity was determined by western blot and by immunofluorescence 
analysis, through the histone H3 phosphorylation on Serine 10 as substrate (Figure 32). 
 
Figure 32: Comparison of the aurora B inhibition in HeLa cell 
(A) HeLa cells were incubated with Nocodazole (0.1 mg/ml, 15 h) in the presence of either 
DMSO (Co) or compounds (0.5 µM, 24 h) as indicated. The western Blot was performed with an 
antibody against phosphorylated histone H3 on serine 10, a marker of aurora B kinase activity. 
The same membrane was also revealed with an antibody against aurora B for estimation of the 
amount of mitotic cells. (B) Immunofluorescence (IF) were performed under the same conditions 
as in (A) and both phospho-Histone H3 and DNA were detected. The percentage of phospho-
Ser10-Histone H3 (H3-P) is qualitatively represented as follows: (+++) indicates strong 
inhibition with no positive mitosis detected, whereas (-) reveals no inhibition. Two different 
experiments were performed and 100 mitotic cells were scored. 
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 From figure 32, we realized that the replacement of the [-O-CH2CH2N-(CH2)2] chain by 
the [-O-CH2CH2-O-CH3] group at position 3 (compound C711) resulted in a complete loss of 
inhibitory potency. The amino group seems therefore to be required for aurora B kinase 
inhibition.  The cyclisation of the amino-chain increases the inhibition potency (comparison of 
C13a with C710 and C07) (Fig. 32A). 
 Based on this result, the corresponding hydrosoluble maleate salts were synthesized and 
named C710M and C07M, respectively (Fig. 33A). Their effect on aurora kinase B was 
evaluated by western blot analysis with phospho-serine10 histone H3 marker. The results in 
Figure 33B showed that both compounds inhibited aurora B activity as their free base 
counterparts. 
 
            Figure 33: Aurora B inhibition efficiency of hydrosoluble compounds. 
(A) The C710M and C07M hydrosoluble maleate salts are shown.  
(B) Western blott revealing aurora B activity in HeLa cells without treatment (Co) or in the 
presence of benzo[e]pyridindolone maleate salts (13aM, 13bM, C710M and C07M; 0.5 µM for 
20 h). Simultaneously, mitotic cells were enriched by Nocodazole (0.1 µg/mL for 14 h). Aurora 
B signal is used to quantify the proportion of mitotic cells. 
2.2.2. Evaluating the anti-proliferative activity of the compounds 
 As aurora kinase B plays a key role in mitotic progression, its inhibition could lead to 
disorders in mitosis and results in non-proliferation of cells. We thus evaluated the anti-
proliferative activity of these new compounds through the viability of tumor HeLa cells, upon 
96h treatment. 
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The anti-proliferative activity of the former identified compound 13a and 13b is recalled in 
Table 11 for comparison.  Among the two novel molecules, C710 is two fold more potent than 
C07 for preventing HeLa cell proliferation, IC50 value of 72 nM and 155 nM were respectively 
determined. The anti-proliferative potencies of C710M and 13bM are quite similar, respective 
cell-IC50 of 83 nM and 77 nM were determined.  
IC50 (nM) in HeLa cell 
 Free-base Hydro-soluble (*M) 
13a 102 ± 20 131 ± 38 
13b 119 ± 49 77 ± 19 
C710 72 ± 6 83 ± 8 
C07 155 ± 45 335 ± 35 
Table 11: Comparision of the anti-proliferative activities of compounds in HeLa cell 
IC50: the concentration of compound that reduced by half cell proliferation after 96 h of 
compound treatment. Both the free base as well as the hydrosoluble maleate salt (-M) of each 
compound were evaluated. Note that most results with the free base and the corresponding salt 
are similar at the exception of a slight increase for CO7M compared to CO7. 
 We have thus identified new hydrosoluble inhibitors of aurora kinase B that exhibited anti-
proliferative activity. Taking into account that 13b was partly described in Le et al. (2013), we 
decided to evaluate the potency and consequences of C710 treatment in cells to compare it with 
13b and to evaluate the possible applications of these new molecules. 
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CHAPTER 3 
CHARACTERIZATION OF  
BENZO[e]PYRIDOINDOLONE C710M 
EXHIBITING HIGH ANTI-PROLIFERATIVE ACTIVITY 
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3.1. ANTI-PROLIFERATIVE EFFICIENCY OF C710M IN CELLS 
 In the previous chapter, we showed that C710M inhibited aurora kinase B and prevented 
efficiently the growth of HeLa cells. To better describe its anti-proliferative potency, we 
continued to evaluate the viability of a panel of cell-lines upon C710M treatment (Table 12).  
 Mahlavu cells, a liver cancer model, showed high sensitivity to C710M with an in-cell 
IC50 of 84 ± 6 nM, similar to data obtained with HeLa cells. Besides, C710M also inhibited 
efficiently the growth of many cancer cell-lines originating from different organs such as Jurkat 
(T lymphocyte), MCF-7 (breast), Hek293 (kidney), Hct116 (colon) and A431 (skin) with IC50 
values of 133 nM, 138 nM, 210 nM, 347 nM and 350 nM, respectively. However, its impact 
seemed not to be identical among cell-lines from the same organs. C710M exhibited poor 
potency towards Focus (liver), SKMel28 (skin), WM793 (skin), BT20 (breast) or BL41 
(lymphoma) cells. Interestingly, its effect was not related to p53 pathway since the cell-
proliferative inhibition by C710M between Hct116 p53(+) and p53(-) cells was not different 
(data not shown). Moreover, C710M had no effect on lung cancer cells (H358), conversely to 
what was observed with C1 in the past.  
Cell line Tissue/Cancer IC50 of C710M (nM) 
HeLa Cervix /carcinoma 83  ± 8 
Malhavu Liver/carcinoma 84 ± 6 
JurKat T lymphocyte/T cell leukemia 133 
MCF-7 Breast/adenocarcinoma 138 
Hek293 Embryonic Kidney 210 
Hct116 Colon/carcinoma 347  ± 4 
A431 Skin/ epidermoid carcinoma 350 
HaCaT Skin/ keratinocyte 480 
Hep3B Liver/ carcinoma 950 
U-251 Brain/ Glioblastoma  1195± 58 
Focus Liver/ carcinoma 1750 
U87 Brain/ Glioblastoma >  1000 
SKMel28 Skin/ Melanoma >2000 
WM793 Skin / Melanoma >2000 
BT20 Breast/carcinoma >2000 
BL41 B cells/ Burkitt’s Lymphoma >2000 
H358 Lung/carcinoma >2500 
Table 12: C710M anti-proliferative efficiency towards different cell-lines 
(IC50: the concentration of compound reducing by half cell proliferation, after 96 hours of 
treatment)  
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2.2. EFFECT OF C710M ON CELL CYCLE PROGRESSION 
 In order to understand how C710M affected cell cycle progression, the behavior of cells in 
the presence of C710M was analyzed by FACS. HeLa cells were synchronized at S phase, and 
C710M (100 nM) was added upon release. The results of kinetics are reported in Figure 34. 
After 3 h of C710M treatment, there was no difference compared to the control, most of cells 
were in S phase (61% upon C710M treatment and 59% in control) and they started to enter 
mitosis. Eight hours after release, the bulk of the population was in mitosis; whereas in the 
control, some cells (16%) started a new cycle. The delay in mitosis exit induced by C710M was 
more clearly visible after 11 hours since 92 % of the cells were still scored as 4N. Meanwhile, in 
the control experiment, cells were cycling normally (52% in 2N population). Following the 
progression in the cell cycle, C710M had induced a major polyploidisation of the population 
after 30 h (65 % of the cells being scored as >4N) and finally, 72h later, the cells were dying (70 
% scored as < 2N). In fact, C710M induced apoptosis since this cell population was stained by 
annexin V (data not shown). 
 Furthermore, the addition of C710M to HeLa cells upon release from a G0/G1 block did not 
influence mitotic entry. There were no differences in cell cycle progression in the presence and 
in the absence of C710M, till the cells were in mitosis (data not shown). Therefore, C710M was 
not involved in G1 and S phase progression. 
 In order to understand how C710M inhibited ongoing mitosis and how polyploid cells 
were formed, time-lapse microscopy was performed on Hek293 cells stably expressing either 
Histone H2A-GFP or tubulin-GFP. 
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Figure 34: Effect of C710M on the cell cycle 
FACS experiments were performed to show cell cycle progression upon C710M treatment in 
comparison to control (without C710M). HeLa cells were synchronized in S phase by serum 
deprivation (48 h) and then, by thymidine block (20 h). Upon release, they were incubated 
subsequently with C710M (100 nM; on the right) or DMSO as a control (on the left) for 3 h, 8 h, 
11 h, 30 h and 72 h. DNA was stained with propidium iodide and samples were analyzed with a 
FACS analyzer. The percentage of cells in the different phases was indicated in each panel.  
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3.3. C710M REDUCES MITOTIC SPINDLES AND INDUCES THE FORMATION OF 
BI-NUCLEATED CELLS  
 Hek293 cells stably expressing tubulin-GFP and histone H2A-GFP were continuously 
imaged upon C710M treatment by Time-lapse microscopy as shown in Figure 35. We observed 
the shortening in pole-to-pole length of the spindle microtubules after 20 minutes of C710M 
treatment versus control (Fig.35A, T0). Cells exhibited only a few kinetochore-microtubles and 
were unable to organize a ordered mitotic spindle as seen in control cells (Fig.35A, T 34 min). 
As a consequence, chromosomes could not be fully separated and cells escaped mitosis as large 
binucleated cells (Fig.35B, T 2 h). 
 
Figure 35: Time-lapse experiments on mitotic cells in the presence or the absence of 
C710M (200 nM) (A) on Hek293 cells stably expressing Tubulin-GFP. C710M was added 20 
minutes before imaging. Mitotic cells were continuously imaged and elapsed time is indicated on 
each photo. Representative cells are shown. (B) Time lapse of mitotic Hek cells stably 
expressing Histone-H2A-GFP in the presence of C710M (200 nM). The prometaphase, imaged 
at T0, gave rise to a binucleated cell within 2 hours.  
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3.4. EFFECT OF C710M ON TUMOR GROWTH 
 The above results revealed the high anti-proliferative potency of compound C710M in 
many cancer cell-lines. However, these experiments were limited cells cultured as mono-layers 
where the compound is in direct contact with the cells. We wanted to know whether the 
compound could diffuse from cell to cell in a tumor. To mimic the 3D-organized structure of a 
tumor, a spheroid model was utilized and finally, cell xenografts were implanted in nude mice. 
3.4.1. In MTS model 
 By the hanging-drop method, we succeeded in producing Hct116 spheroids. In order to 
evaluate the effect of the compound for a long-term period on 3D-organized cells, we treated 
spheroids, for 2 weeks, by C710M, at two concentrations: 350 nM (concentration corresponding 
to the IC50 in Hct116 cells) and 1 µM. The results in Figure 36 and Table 13 showed that in the 
control, spheroids grew exponentially and a 16-fold increase in size was noted at Day 14; 
whereas, both concentrations  of C710M prevented very dramatically the growth of spheroids. 
An immediate effect of C710M (1 µM) was observed from the 2nd day, with a 2/10 reduction of 
spheroid size, demonstrating that C710M diffused easily inside. Long-term effects were noted 
with C710M since the size of the spheroid gradually decreased till Day 14. Meanwhile, at the 
concentration of 350 nM, C710M exhibited a slightly slower inhibitory effect than at 1 µM, 
spheroids still grew on the 2nd day, even moderately, and only started to decrease in size from the 
4th day of treatment. This result was understandable because 350 nM was the minimum 
concentration of C710M reducing cell proliferation by a half, after 4 days. Despite this slight 
difference, the inhibitory potency of both concentrations of C710M was similar in the long-term 
treatment, with the same ratios of spheroid growth from the 6th day of treatment (Table 13). 
Consequently, cells died on prolonged C710M treatment with the spheroids eventually breaking 
into fragments.  Interestingly, the efficiency of C710M seemed similar in 2D- and 3D-cultures, at 
least for the lowest concentration (IC50), indicating an easy diffusion of this compound in 
spheroids. 
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Figure 36: Effect of C710M on the growth of Hct116 spheroids 
Hct116 spheroids (approximately 0.1 mm3) were incubated with C710M (350 nM in red; 1 µM 
in blue) or without compounds (control, in green) from Day 0 to Day14. The spheroid sizes were 
measured each 2 days for 2 weeks. The growth of spheroids was calculated by the formula: [(V-
V0)/V0] with V0 being the volume at Day 0.  For treated spheroids, the error bar was included in 
the label. 
 
Days of treatment Control C710M 350 nM C710M 1000 nM 
0 0 0 0 
2 0.78 ± 0.11 0.10 ± 0.07 -0.24 ± 0.15 
4 1.78 ± 0.30 -0.03 ± 0.10 -0.36 ± 0.11 
6 3.41 ± 0.90 -0.39 ± 0.15 -0.46 ± 0.11 
8 5.71 ± 1.67 -0.66 ± 0.11 -0.63 ± 0.06 
10 7.94 ± 1.84 -0.77 ± 0.07 -0.78 ± 0.07 
12 11.49 ± 2.67 -0.88 ± 0.06 -0.89 ± 0.04 
14 16.11 ± 3.49 -0.89 ± 0.05 -0.89 ± 0.04 
Table 13: The ratio of tumor growth [(Vn – V0)/V0] upon C710M for 14 days. 
(-) meaning the reduction in size of spheroids versus the first day of treatment. 
3.4.2. In Xenograft model in “Nude” mice 
 The efficiency of compound C710M was also evaluated in nude mice bearing tumors 
either U-251 or Mahlavu tumors (Figure 37 and 38). After tumor establishment, the mice were 
randomly dispatched in three batches: the control batch received the vehicule, the others received 
a benzo[e]pyridoindole: either C710M or C21. C21, a kinase inhibitor with different specificity 
from C710M, was analyzed, in this experiment, as a control compound. Mice were healthy after 
repetitive injections of both compounds and grew normally, without difference in body weight 
among batches (Figure 37A, 38A).  Figure 37C and 38C showed the tumor growth upon 
different treatments.  
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 U-251, glioblastoma cells, grew slowly when engrafted in mice (Figure 37C). C710M was 
found to have a slight effect since a 30 % decrease of the tumor volume was noted upon IP 
treatment.  The control compound C21 reduced tumor volume by 2 (Figure 37 B and D) and the 
effect was found significant at days 42, 44 and 48 (Student test, p = 0.03, 0.02 and 0.01, 
respectively). The treatment ended at day 30, long-term effects were thus observed. U-251 
tumors were found homogeneous and poorly vascularized (Figure 37D).  
 Mahlavu tumors derived from liver cells developed quickly in mice and attracted many 
vessels as obvious on the photos (Figure 38D). C21 seems to increase the size of Mahlavu 
tumors, the final average weight increased by 25 %. Conversely, C710M prevented the growth of 
Mahlavu tumors and the final average tumor weight decreased by a half (Figure 38B). The effect 
was still observed at distance from the last injection and was found significant from day 31 to 38 
by the Student test (p < 0.05) (Figure 38C). We did not observe differences of vascularization of 
the Mahlavu tumors according to the different treatments. More interestingly, when the mice 
were autopsied at the end of the experiment, we realized that C710M did not have any impacts 
on internal organs. 
 To note the results obtained with these two examples of xenografts fitted perfectly with the 
data recovered on 2D-cell line cultures (Table 10 and data not shown). Upon C710M treatment, 
in-cell IC50 of viability determined for Mahlavu and U251 were 84 nM and 1195 nM 
respectively (Table 10). Whereas C21 was found to efficiently prevent U251 growth (Hong-Lien 
Vu, PhD thesis, 2011) and we showed that it is efficient towards U251 xenografts. The 
proliferation test conducted on 2D-cultures seemed predictive of the efficiency towards cells 
xenofrafts in mice and this interesting point could indicate that these compounds diffused well in 
the body, when peritonealy injected, meanwhile maintaining their activity.  The contrasting 
results obtained with the two compounds suggested that the different benzo[e]pyridoindoles had 
different potentialities, linked to specific targeting. 
Hence, C710M exhibited potency for preventing tumor growth and its repetitive injection 
in mice seemed not to induce adverse effects. We decided thus to further characterize this 
molecule. We investigated both its pharmacological characteristics and tried to gain some 
information on its mechanism of action. 
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Figure 37: Effect of C710M, C21 on the growth of U251-xenograft. Mice were treated 13 
times by either C710M or C21 (10 µg compound/g of mice weight) or NaCl 0.45% (Control, 
CO), by IP injections, 4 times per week. The period of compound injection was shown as the 
violet bar (A) Comparison of mice weight among groups, on the first day (tumor injection), 10th 
day (the first injection of compound) and 48th day (mice autopsy). The size of tumors in each 
group was presented in (C) in function of the elapsed time (in days). Blue stars indicated 
significant differences of C21 versus the control, determined by the Student test (p < 0.03). At 
the end of the experiment, the final tumor weight was compared to the tumor size in (B) and a 
tumor exhibiting the average weight was shown in (D)  
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Figure 38: Effect of C710M, C21 on the growth of Mahlavu-xenograft. Mice were treated 11 
times by either C710M or C21 (10 µg compound/g of mice weight) or NaCl 0.45% (Control, 
CO), by IP injection, 4 times per week. The period of compound injection was shown as the 
violet bar (A) Comparison of mice weight among groups, on the first day (tumor injection) and 
38th day (mice autopsy). The size of tumors in each group was presented in (C) in function of the 
elapsed time (in days). Green stars indicated significant differences of C710 versus the control, 
determined by the Student test (p < 0.05). At the end of the experiment, the final tumor weight 
was compared to the tumor size in (B) and a tumor exhibiting the average weight was shown in 
(D). 
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3.5. PHARMACOKINETIC CHARACTERISTICS OF C710M  
 To evaluate the possible use in clinical trial, some pharmacokinetic characteristics of 
compound C710M were recorded on the CNRS TechMed platform in Strasbourg (Table 14). The 
reaction with maleic acid formed the hydrosoluble C710M salt; but its solubility in water was 
unknown. We found that the solubility of C710M in water was over 6 mg/mL; but it decreased to 
less than 1 mg/ml in physiological medium (0.9 % NaCl). 
 We checked the passive permeability of C710M compound across artificial barriers at 
physiological, pH 7.4. C710 crossed the lipid barrier slowly (Pe = 4.62x10-9 cm/sec, log Pe =      
-8.34 ± 0.29) in comparison to Antipyrine, a common ear-drop medicine (logPe = - 6.14). 
However the time-lapse experiments suggested that C710 was quickly available inside the cell 
upon addition, indicating its active transportation. 
 C710 was found to poorly attach to reconstituted membrane (around 9 % were retained). It 
is efficiently retained by plasmatic proteins, 80 % of it was stuck on plasma proteins, but similar 
data (83 %) were reported for Propanolol, a common drug used in treatment of high blood 
pressure. In the body, we could expect its transportation by the blood especially as this 
compound was found very stable in mice plasma. After 1 hour of incubation, no loss was noted 
either in mice plasma or in human liver microsomes. 
 These results are encouraging for the potential use of C710 in preclinical trials.  
Test C710M References 
Solubility in NaCl 0.45% 2 mg/ml  
PAMPA pH 7.4 
Passive permeability 
Pe = 4.62x10-9 cm/sec 
logPe = -8.34 ± 0.29 
Antipyrine : 
logPe =  - 6.14 
Binding to plasmatic proteins  80 ± 1% Propanolol 83% 
Binding to membranes  9 ± 7%  
Stability in mice plasma,  1h 100 ± 1 % Procaine 10 % 
Metabolic stability in human 
liver microsomes (cytochrome 
P450), 1h 
100 %  Half-life of 
Testosterone: 40 min 
Table 14: Pharmacokinetic characteristics of C710M 
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3.6. IN-VITRO KINASE PROFILING OF COMPOUND C710 
 To obtain a general view about C710 specificity, we determined the in-vitro kinase 
inhibition profile of this compound. The activity of 138 recombinant kinases was determined in 
the presence of C710 (250 nM). The percentage of remaining activity for each kinase was 
reported in Table 15.  
Kinase Remaining 
activity 
(%) 
Kinase Remaining 
activity 
(%) 
Kinase Remaining 
activity 
(%) 
Kinase Remaining 
activity 
(%) 
NUAK1 1 ± 0 BTK 45 ± 8 LKB1 85 ± 1 IRR 99 ± 3 
TrkA 1 ± 0 MARK1 50 ± 3 TESK1 85 ± 3 JNK1 99 ± 10 
MAP4K3 1 ± 0 RIPK2 52 ± 1 CAMK1 86 ± 12 PIM3 99 ± 10 
TAK1 4 ± 0 Src 52 ± 4 PLK1 86 ± 4 GCK 100 ± 2 
PHK 5 ± 1 ULK1 52 ± 2 CDK2-CycA 87 ± 12 TTBK2 101 ± 4 
SIK2 5 ± 0 TTK1 53 ± 29 TAO1 87 ± 11 EIF2AK3 101± 3 
HIPK1 6 ± 0 MARK2 56 ± 5 CK2 89 ± 6 p38dMAPK 101 ± 5 
CHK2 7 ± 2 MKK6 57 ± 0 EPH-A2 89 ± 10 PKBb 101 ± 5 
MAP4K5 8 ± 1 YES1 58 ± 3 HER4 89 ± 11 MPSK1 103 ± 11 
VEGFR 8 ± 1 HIPK2 61 ± 4 MNK1 89 ± 6 OSR1 103 ± 2 
MELK 9 ± 0 MST2 61 ± 22 TGFBR1 89 ± 1 PAK6 103 ± 2 
JAK2 10 ± 1 RSK2 61 ± 5 NEK2a 90 ± 6 PIM1 103 ± 0 
CAMKKb 12 ± 2 MARK4 64 ± 6 ROCK2 90 ± 9 Lck 104 ± 9 
IR 12 ± 2 FGF-R1 65 ± 3 EPH-B4 91 ± 5 MST4 104 ± 49 
BRSK2 12 ± 1 BRK 66 ± 6 TTBK1 91 ± 11 PKCa 104 ± 5 
IRAK4 13 ± 0 PRK2 68 ± 3 
Aurora A
91 ± 1 SRPK1 104 ± 18 
Aurora B 
14 ± 1 CLK2 69 ± 3 JNK2 92 ± 3 IKKb 105 ± 10 
AMPK-
human 
16 ± 6 PAK4 69 ± 17 SIK3 93 ± 17 MAPKAP-K3 105 ± 8 
IRAK1 17 ± 1 S6K1 69 ± 4 TIE2 93 ± 7 p38gMAPK 105 ± 7 
MLK3 17 ± 4 SmMLCK 69 ± 2 DYRK1A 94 ± 4 p38aMAPK 106 ± 9 
CHK1 19 ± 8 PDK1 70 ± 2 EPH-B2 94 ± 3 ZAP70 106 ± 6 
PKD1 19 ± 4 DDR2 71 ± 1 CSK 95 ± 9 ERK1 107 ± 0 
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MKK1 23 ± 1 PDGFRA 74 ± 1 MNK2 95 ± 7 ERK2 108 ± 4 
STK33 26 ± 9 PRAK 74 ± 1 PAK5 95 ± 15 CK1γ2 108 ± 3 
MARK3 28 ± 7 DAPK1 76 ± 7 PKCz 95 ± 10 TLK1 109 ± 15 
AMPK 30 ± 6 IKKe 76 ± 1 GSK3b 96 ± 8 PKBa 113 ± 0 
ULK2 31 ± 5 MST3 76 ± 2 PKA 96 ± 6 MEKK1 114 ± 19 
BRSK1 37 ± 10 MKK2 77 ± 8 PKCγ 96 ± 1 NEK6 114 ± 4 
MLK1 38 ± 2 JNK3 78 ± 8 EPH-A4 97 ± 3 HIPK3 115 ± 10 
TSSK1 38 ± 6 ABL 79 ± 4 PIM2 97 ± 4 PAK2 115 ± 1 
IGF-1R 40 ± 7 ERK5 80 ± 1 CK1δ 98 ± 5 MAPKAP-K2 121 ± 4 
TBK1 40 ± 16 DYRK2 82 ± 0 DYRK3 98 ± 9 WNK1 125 ± 8 
MINK1 43 ± 0 p38bMAPK 82 ± 1 CDK9-CycT1 98 ± 7 EF2K 134 ± 7 
RSK1 43 ± 4 SGK1 83 ± 4 EPH-B3 99 ± 3   
SYK 43 ± 7 EPH-B1 85 ±3 ERK8 99 ± 5   
Table 15: In-vitro kinase inhibition profile of C710 at the concentration of 250 nM.  
This assay was performed, in duplicate, by the MRC (Dundee University) on 138 recombinant 
kinases. The percentage of remaining activity for each kinase was determinated. Kinases 
belonging to the AMPK pathway affected by C710  are in red; other AMPKr kinases are in blue. 
 The results showed that C710 specifically inhibits few kinases. Among the panel, ten 
kinases were inhibited by more than 90 % in the presence of C710, at 250 nM. We have noted 
the presence of several AMPK-related kinases in this top ten (Nuak, Sik2 and Melk) as well as 
two AMPK upstream regulator kinases (Tak1 and CaMKKß). However, the whole AMPK-
related kinase family was not affected; for example, MARKs, Sik3 and Brsk1 were not inhibited. 
Note that C710 inhibited AMPK and aurora kinase B at the same level. This profiling indicated 
that C710 was a specific aurora kinase B inhibitor, aurora A was not affected (91 % activity in 
the presence of C710, 250 nM). Other major off-targets are MAP4K3, Tak1, Phosphorylase 
kinase Phk, HIPK, Chk2, MAP4K5 as well as VEGFR. 
 Based on kinase profiling, we determined in-vitro IC50 of C710 towards the main kinase 
targets. We compared the kinase inhibitory activity of C710 and compound 13b, the former 
benzo[e]pyridoindolone with similar anti-proliferative potency (Table 16). 
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Kinases In-vitro IC50 (nM) of compound Km ATP 
13b# C710# C710* 
Aurora A 50 58 Sup 250 nM 5 
Aurora B 13 12 118.3 ± 27.9 20 
ARK5/NUAK1 6 0.4 4.8 ± 0.4 20 
CHK1 54 5 ND 20 
CHK2 43 5 13.6 ± 0.5 20 
TAK1 133 6 ND 5 
FLT1/VEGFR1 274 37 ND 20 
SIK2 ND ND 12.4 ± 0.7 50 
MELK ND ND 13.3 ± 2 50 
PHK ND ND 18.5  50 
Table 16: In-vitro IC50 of compounds towards main targeted kinases. 
 (#) This assay was performed by Reaction Biology Corp (USA) with recombinant kinases in the 
presence of 1 µM ATP. Compounds were tested, in duplicate, at 10 various concentrations from 
2 pM to 10 µM with serial 3-fold dilutions. Staurosporine was used as internal control and tested 
at 10 concentrations. In-vitro IC50 was the concentration of compound inhibiting by 50% the 
kinase activity. 
(*) This assay was performed by the MRC (Dundee University) with recombinant kinases. The 
ATP concentration was adjusted at the Km value for each kinase. Compounds were tested in 
duplicate, at 10 concentrations varying from 0.03 nM to 1 µM, with serial 3-fold dilutions. 
 Data in Table 16 revealed that both compounds had the same inhibitory potency towards 
aurora kinases. Especially, both compounds efficiently targeted aurora B than A. In addition, 
they also had similar off-targets but C710 was found to be far more efficient than 13b. Both 
compounds inhibited very efficiently Nuak1, an AMP-related protein kinase whose activation is 
directly regulated by Akt, and that has been reported to be a key player in tumor malignancy 
(Suzuki et al., 2004) and in c-myc deregulated tumors (Liu et al.,2012). An IC50 of 4.8 nM was 
determined for C710 towards Nuak1 whereas IC50 of 12.4 and 13.3 nM were recorded towards 
Sik2 and Melk, two AMPKr members. Both 13b and C710 affected chekpoint kinases 1 and 2 
and nanomolar IC50 values were measured. These compounds might thus interfere with DNA 
reparation in cells. In vitro, both molecules affected the tyrosine kinase receptor VEGF-R and 
phosphorylase kinase. 
 On the whole, C710M was a very potent hydrosoluble kinase inhibitor, targeting many 
kinases. Beside aurora B, it also targeted other kinases, such as AMPK and AMPKr-kinases. In 
fact, we also found that C710 blocked cell progression in mitosis but the observed effects could 
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not be fully accounted for by aurora kinase B inhibition (Figure 35). Upon C710M, cells did not 
escape mitosis through mitotic slippage. As evidence, we observed binucleate cells arose from 
cells without accurate chromosome segregation. We did not observe micronuclei as the 
consequence of known aurora kinase inhibitors (VX-680, C1). One possibility might be the 
presence of a reduced spindle that could not be stabilized due to actomyosin defects. AMPK 
inactivation has recently been shown to create such defects (Thaiparambil et al., 2012). 
Moreover, AMPK and AMPKr were described to play a role in mitosis ongoing (Motoshima et 
al., 2006, Banko et al., 2011). Together with the in-vitro kinase profiling of C710M, we 
hypothesized the possible involvement of AMPK and AMPKr-kinases in C710 action 
mechanism, beside aurora B. This hypothesis has been tested and recently we have had some 
evidence for possible involvement of AMPK in C710M action. 
 For a better description of the C710M impact on mitotic spindles, confocal Z stacks were 
acquired and 3D-reconstitutions were built. 3D views are presented with a depth color code to 
appreciate the relative localisation of the two poles. In control cells, quickly after duplication, 
centrosomes moved to two opposite poles and a nice spindle was constituted. As shown with the 
depth color code, on the 3D-reconstituted views, both spindle poles were at similar z levels in the 
cell (Fig. 39A, T 38 min and 83 min). At 83 min, the two poles moved away and the cell entered 
in anaphase. The orientation of the spindle was conserved during mitosis and figured the 
direction of cytokinesis (T: 100 min). 
Conversely, on C710M treated cells (Fig. 39B and C), mitotic cell started with an oriented 
bipolar spindle (Fig. 39B, T0 and T 27 min). But afterwards, during mitosis ongoing, the spindle 
turned around as indicated by the arrows. The direction of the spindle did not prefigure the sense 
of separation. Note that the two spindle poles were not in exactly the same z as in control (Fig 
39B, T 27min and 65 min, 3Dc as well as Fig. 39C, T 46 min and 48 min, 3D-color forward and 
back). Most of the observed spindles were reduced in size as shown previously (Fig.35). 
Observing Fig. 39B, we might suggest that the spindle could be organized normally, but it is 
progressively reduced (compare between T0 and T 65 min). The lack of stabilisation of the 
spindle by C710M may impair the dynamic of microtubules on the kinetochores and leads to the 
mitotic exit as binucleated cells. This preliminary result showed the possible involvement of 
AMPK in C710M action, but further investigations are required to confirm this hypothesis. 
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Figure 39: Time-lapse microscopy on mitotic Hek cells expressing tubulin-GFP. Control 
cells in the absence of treatment were represented in A and compared to C710M (200 nM) 
treated cells (in B and C). 3D –reconstitution views were shown in green as well as in a depth 
color code (forward and back views, depth values in microM on the bar scale). The elapse time 
was indicated on each photo. 
For treated cells in B and C, in addition to the 3D reconstitution views, a representative plane 
was shown (Tubulin-GFP, Transmission and merge). Moreover, the orientation of the spindle 
was recalled by an arrow (pink and red) on each image. 
A summary of the varying orientations for the three followed spindles (one in B and two in C) is 
shown in (C). 
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DISCUSSION 
Aurora kinases play key roles in mitosis and are overexpressed in many tumors. Hence, 
they have been considered as potential targets in anti-cancer therapy. Several aurora kinase 
inhibitors have been identified and are currently evaluated in clinical trials. Among them, we 
found that benzo[e]pyridoindoles were novel potent ATP-competitive inhibitors of aurora 
kinases. 
Besides their therapeutic potency, these small kinase inhibitors are also interesting tools in 
cell biology research. Therefore, benzo[e]pyridoindole C4 attracted our interest due to its 
abnormal inhibition of histone H3 phosphorylation, only in prophase, and its induction of 
lagging chromosomes in anaphase. Herein, some questions arose: what is the role of histone H3 
phosphorylation in mitotic prophase? Does C4 target aurora kinases? How does aurora kinase B 
activity vary during mitosis?  
In fact, in mitosis, the role of histone H3 phosphorylation is still controversial and our data 
demonstrate that this epigenetic mark is not required for chromosome condensation.  Once the 
cells progress in metaphase, their chromosomes should hold phospho-Ser10- histone H3 for 
ongoing anaphase. This result sustains the tag hypothesis proposed by Stéfan Dimitrov group 
(Hans and Dimitrov, 2001; Prigent and Dimitrov, 2003). 
Which kinase is the target of C4, leading to the inhibition of histone H3 phosphorylation, 
specifically in prophase? C4 belongs to the benzo[e]pyridoindole family that we have identified 
as ATP-competitive aurora kinase inhibitors; but it is less potent than the hit C1. We propose that 
C4 has a lower affinity for the ATP-binding site than C1 and it could only target the basal 
activity of aurora kinases. Indeed, we reproduced its effects by low concentrations of several 
aurora kinase inhibitors and especially with AZD-1152, a specific aurora kinase B inhibitor. 
From these data we could conclude that aurora kinase B activity varies during mitosis. As 
suggested by Xu et al. (2009), the maximal activation of aurora B is necessary for ongoing 
anaphase but then its activation decreases during its transfer on microtubules. We show that 
defects in anaphase are independent of the absence of H3-phosphorylation in prometaphase and 
instead correlate with oscillations of aurora kinase B activation. These waves of activation 
corresponds to different conformations of the CPC complex as shown by the variations in the 
mobility of the proteins evaluated by FRAP. 
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By a combination of different kinase inhibitors and microscopy techniques we described 
aurora kinase B activation in mitosis. We found that aurora kinase inhibitors with low ATP 
affinity did not prevent mitosis ongoing but induced lagging chromosomes in anaphase. This 
might be deleterious for the cells since aneuploidy or DNA mislocalization may arise in the 
daughter cells (Meldi and Brickner, 2011). This situation should be considered in clinical trials 
with patients treated by aurora kinase inhibitors, especially by compounds with long half lives 
whose level gradually decreases over time from the start of the treatment. Therefore, the short-
lived molecules should be priority in the development of these anti-cancer drugs. 
In another approach, we continued to develop new molecules in the bezo[e]pyridoindole 
family for use in clinical applications. From the hit C1 identified through high-throughput 
screening, we performed a structure-activity relationship study to improve the activity and 
solubility of benzo[e]pyridoindoles. These molecules belong to the Institut Curie library and are 
synthesized by the Dr Chi-Hung Nguyen. Benzo[e] pyridoindoles are a privileged scaffold 
exhibiting different biological activities (Hoang et al., 2009) and we have identified 
benzo[e]pyridoindolones as aurora kinase inhibitors. The SAR study was then limited to two 
positions: R8 and R3 of the hit C1. Our data indicate that the bulkiness of the alkyl group at 
position R8 plays a role for aurora B inhibition. The ether group at position R3 is a requirement 
for preventing aurora kinase activity. Our work has highlighted the possible modifications of this 
R3 lateral chain. New derivatives bearing an amine functional group at this position are very 
efficient aurora kinase inhibitors. Especially, these molecules are suitable for producing 
hydrosoluble salts by the reaction to organic acids, like maleic acid in our case.  
Subsequently, we characterized several of these inhibitors: 13a and 13b as well as C710. 
Interestingly, their corresponding salts were found as active as their base counterpart. This is a 
tremendous improvement for preclinal applications. These molecules were shown to be potent 
aurora kinase inhibitors, and were more efficient towards aurora B than aurora A. In fact, they 
prevented histone H3 phosphorylation in mitotic cells, exhibiting the in-cell aurora B inhibition. 
They delayed mitotic exit inducing polyploidisation of the cells and finally induced apoptosis. 
Consequently, these compounds exhibited high anti-proliferative potency in HeLa cells. In the 
comparison with data reported for the best aurora kinase inhibitors currently in clinical trials, 
these molecules are among the top 10 best aurora kinase inhibitors. The more potent inhibitor 
C710M of this series was demonstrated by efficient prevention of Hct116 spheroid growth at the 
concentration of 350 nM and by an decrease in the development of Mahlavu xenograft in nude 
mice. Mice were still healthy and grew normally upon repetitive C710M intraperitoneal 
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injections and the autopsy of mice revealed no adverse visible effects. In other words, these new 
hydrosolube benzo[e]pyridoindoles are promising kinase inhibitors. Therefore, we decided to 
further characterize these compounds. 
Upon 13aM or C710M treatment, aurora B was inactivated and the histone H3 
phosphorylation was inhibited. However, the phenotype of the cells treated by 13aM (Le et al., 
2013) and by C710M did not fit with a specific aurora B kinase inhibition. Indeed, in the absence 
of aurora B activity, we expect cells to escape mitosis without segregating chromosomes and 
then, the appearance of micronuclei (Hoang et al., 2009). However, upon 13aM or C710M 
treatment, the organization of the microtubule spindle was perturbed, such a phenotype has been 
never observed by aurora kinase inhibito. Meanwhile, aurora B was mostly found to be 
concentrated on centromeres, even it was inactive. More interestingly, the chromosomal 
passenger complex was partly transferred to microtubules, probably as a result of SAC 
inactivation. Again the transfer on microtubule was prevented with most aurora kinase inhibitors 
(Hoang, 2009). However, cells could not divide due to the mis-segregation of chromosomes. 
Such defects might be a consequence of a lack of tension on the chromatid pairs due to spindle 
defects. Time-lapse experiments on Hek cells stably expressing tubulin-GFP revealed that the 
spindle orientation varied during mitosis upon C710M. In controls, the bipolar spindle was 
oriented parallel to the substratum, with spindle poles in similar z sections. The oscillation of the 
mitotic spindles might be due to the inhibition of AMPK or AMPK-related kinases. This 
possibility is highly probable since: 1) AMPK was recently shown to be involved in mitosis 
ongoing (Banko et al., 2011), 2) AMPK was reported to prevent the anchorage of the spindle on 
the acto-myosin network (Thaiparambil et al., 2012). Moreover Sik2, an AMPKr kinase seemed 
to be involved in centrosome maturation (Ahmed et al., 2010), 3) C710 compounds was found to 
efficiently target AMPK and AMPKr kinases (like Nuak1, Melk and Sik2), at least in vitro. 
Our hypothesis is that the benzo[e]pyridoindolones studied target both aurora B and 
AMPK, these conjugate inhibitions turn the SAC off and trigger anaphase onset. Then, the 
absence of tension prevents the correct segregation of chromosomes and the presence of 
chromatin in the midzone maintains the No-Cut checkpoint ”on”, leading to binuclate cells. 
Finally, the accumulation of these defects leads to apoptosis. These benzo[e]pyridoindolones 
prevent cell proliferation through a new pathway which was not investigated before. Currently, 
only a few AMPK inhibitors are published, mostly working at micromolar concentrations and 
their possible intervention, as anti-proliferative molecule has not been explored yet.  Conversely, 
AMPK activators were proposed as possible targets in anti-cancer therapy in peculiar 
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applications. AMPK is under the control of a complex signaling network and the situation may 
vary depending on the activation level of upstream kinases like Tak1, CaMKKß or the tumor 
suppressor LKB1. Note that both Tak1 and CaMKKß were identified as C710M targets, in vitro.  
Although  best known for its effects on metabolism, AMPK has many other functions, including, 
regulation of transcription and mitochondrial biogenesis, autophagy, cell polarity, and cell 
growth and proliferation (Hardie, 2011). Their implication in these pathway is quite new and 
needs more investigations. 
The possibility that benzo[e]pyridoindolones are dual kinase inhibitors is very interesting 
since pharmaceutical companies are worried about the side effect of aurora kinase inhibitors. 
Indeed, the clinical trial of VX-680, a known aurora inhibitor, was stopped due to its observed 
QTs-prolongation effect and the death of one patient during treatment. Whether it is a specific 
effect of the molecule or a drawback of aurora kinase inhibitors is an open question. Till now, 
none of aurora kinase inhibitors has been approved by FDA for anti-cancer therapy. Therefore, 
current efforts focus on new inhibitors with combined but selective activity on few targets to 
address the current problem of side effects.  
In conclusion, benzo[e]pyridoindolones were found to be potent antiproliferative drugs 
targeting a new signaling pathway.  Our first preclinical characterizations were encouraging 
further development of these molecules hold promise for anti-cancer therapy. Our group 
registered a patent for these compounds (Nguyen CH, Molla A, Le LTT, “International Patent”, 
April 2012) and in the future, Institut Curie is in charge of their validation in preclinical and 
clinical trials.  
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PERSPECTIVES 
The kinase profiling of new benzo[e]pyridoindolones reveals that these compounds may 
target AMPK and AMPKr, beside aurora kinase B. In future work, we will validate the 
involvement of these targets in the activity of benzo[e]pyridoindolones, in cells. The 
phosphorylation of putative substrates such as MRLC, TORC2, AMPKα1 or AMPKα2, P27 or 
HDAC4 will be investigated to determine the selectivity of these inhibitors. We will combine the 
identification of substrates with time-lapse microscopy to define the mechanism of action of 
these molecules. Our efforts will be dedicated to test the hypothesis of the simultaneous targeting 
of aurora kinase B and AMPK. We also expect to determine precisely which AMPKr kinase is 
involved among those identified by the kinase profiling. The possibility of the simultaneous 
targeting of other kinases could not be dismissed and has to be taken into account. 
We have noted the correlation of the anti-proliferative potency of C710M in cellulo and in 
xenograft models. Therefore, we will enlarge the panel of cell lines to evaluate the possible 
efficiency of these molecules. The analysis of a larger set of data may be helpful for defining the 
application of these molecules as anti-cancer drugs. 
Although the studied benzo(e)pyridoindolones exhibit similar anti-proliferative potency, 
the kinase profiling are slightly different suggesting distinct mechanisms of action. We will 
compare the mechanism of these different molecules in lines with possible applications in anti-
cancer therapy. In collaboration with Dr Chi-Hung Nguyen, the SAR study is still in precess and 
in the future, crystallization of these inhibitors with their targets will be performed in 
collaboration with the Institute of Structural Biology, in Grenoble. 
Till now the efficiency of these compounds has been mostly evaluated as single treatments 
but combined therapy should also be considered. Finally, we will focus on developing an 
accurate drug delivery system. One strategy is to integrate the compounds and nano particles 
within a nano-network. The effectiveness of drugs in this system will also be investigated and 
validated in mice.    
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APPENDIX 
1. Synthesis of compound C07 (3-(2-(Morpholin-4-yl)ethoxy)-8-methyl-7H,10H-
benzo(e)pyrido(4,3-b)indol-11-one) : C07 was synthesized via C05  
11-Chloro-3-(2-(morpholin-4-yl)ethoxy)-8-methyl-7H-benzo(e)pyrido(4,3-b)indole(C05):  
A mixture of 11-chloro-3-hydroxy-8-methyl-7H-benzo(e)pyrido(4,3-b)indole (1,0 g, 3.5 mmol) 
(Vinogradov et al., 2003), n-butanol (60 mL) and water (40 mL) was stirred during 30 min and a 
solution of NaOH (860 mg) in water (10 mL) was then added. After stirring during 15 min, 4-(2-
chloroethyl) morpholine hydrochloride (770 mg, 4,1 mmol) was added and the mixture was 
heated under reflux for 2 h. The reaction mixture was cooled and organic layer was separated. 
The aqueous layer was extracted by AcOEt and the organic layers were combined, washed with 
brine, dried over MgSO4 and evaporated under vacuum. The residue was purified by flash 
chromatography (neutral alumina, gradient of ethanol (0 to 3%) in dichloromethane) to give the 
expected compound as beige solid (660 mg, 47 %). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 
12.94 (br s, 1H), 9.62 (d, 1H), 8.06 (d, 1H), 7.99 (d 1H), 7.80 (d, 1H), 7.59 (d, 1H), 7.35 (dd, 
1H), 4.25 (t, 2H), 3.64-3.58 (m, 4H), 2.78 (t, 2H), 2.56 (s, 3H), 2.54-2.49 (m. overlapped by 
DMSO signals). Microanalyses, calculated for C22H20ClN3O2.0.5 H2O: C, 65.34; H, 5.69; 
N, 10.39, found: C,65.75; H,5.73; N,10.37. MS 394.1 & 396.1 [M-1]. 
3-(2-(Morpholin-4-yl)ethoxy)-8-methyl-7H,10H-benzo(e)pyrido(4,3-b)indol-11-one(C07):  
A mixture of compound C05 (290 mg, 0.82 mmol), sodium acetate (245 mg, 3 mmol) and AcOH 
(20 mL) was heated under reflux for 18 h. The volatile was evaporated under vacuum followed 
by a co-evaporation with toluene. Water (100 mL) was added and the medium was rendered 
basic by addition of 2 N sodium hydroxide. The aqueous layer was extracted by AcOEt and 
EtOH, dried over MgSO4 and evaporated under vacuum to give the exected compound (270 mg, 
100%). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 12.03 (br s, 1H), 10.94 & 10.92 (2 s, 1H), 
10.26 (d, 1H), 7.75-7.64 (m, 2H), 7.42 (d, 1H), 7.18 (dd, 1H), 7.07 (d, 1H), 4.21 (t, 2H), 3.66-
3.56 (m, 4H), 2.77 (t, 2H), 2.57-2.46 (m. overlapped by DMSO signals). Microanalyses, 
calculated for C22H23N3O3.1.2 H2O: C, 66.23; H, 6.37; N, 10.54, found: C, 66.28; H, 6.55; N, 
10.10. MS 400.1 [M+Na]. 
Formation of the maleate salt: A solution of this free base (150 mg) in boiling absolute ethanol 
(10 mL) was poured into a solution of maleic acid (55 mg) in hot absolute ethanol (4 mL). The 
homogenous solution obtained was evaporated under vacuum and the residue was triturated with 
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acetone giving a solid which was collected by filtration, washed with acetone and dried in a 
dessicator affording the maleate salt (160 mg). Microanalyses, calculated for 
C22H23N3O3.C4H4O4.0.4 H2O: C, 62.37; H, 5.56; N, 8.40 ; found: C, 62.66; H, 6.00; N, 7.95. 
2. Synthesis of compound C710 (3-(2-(Piperidin-1-yl)ethoxy)-8-methyl-7H,10H-
benzo(e)pyrido(4,3-b)indol-11-one): C710 was synthesized via C09 
11-Chloro-3-(2-(piperidin-1-yl)ethoxy)-8-methyl-7H-benzo(e)pyrido(4,3-b)indole (C09):  
A mixture of 11-chloro-3-hydroxy-8-methyl-7H-benzo(e)pyrido(4,3-b)indole (1,0 g, 3.5 mmol) 
(Vinogradov et al., 2003), n-butanol (60 mL) and water (40 mL) was stirred during 30 min and a 
solution of NaOH (885 mg) in water (10 mL) was then added. After stirring during 15 min, N-(2-
chloroethyl) piprridine hydrochloride (790 mg, 4,2 mmol) was added and the mixture was heated 
under reflux for 2.5 h. The reaction mixture was cooled and organic layer was separated. The 
aqueous layer was extracted by AcOEt and the organic layers were combined, washed with 
brine, dried over MgSO4 and evaporated under vacuum. The residue was purified by flash 
chromatography (neutral alumina, gradient of ethanol (0 to 4%) in dichloromethane) to give the 
expected compound as beige solid (1.1 g, 79 %). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 12.48 
(br s, 1H), 9.61 (d, 1H), 8.06 (s, 1H), 7.99 (d 1H), 7.79 (d, 1H), 7.58 (d, 1H), 7.34 (dd, 1H), 4.22 
(t, 2H), 2.74 (t, 2H), 2.56 (s, 3H), 2.51-2.45 (m. overlapped by DMSO signals), 1.56-1.47 (m, 
4H), 1.45-1.30 (m, 2H),,. Microanalyses, calculated for C23H24ClN3O2: C, 70.13; H, 6.14; 
N, 10.67, found: C, 69.63; H, 6.38; N, 10.44. MS 394.1 & 396.1[M+1]. 
3-(2-(Piperidin-1-yl)ethoxy)-8-methyl-7H,10H-benzo(e)pyrido(4,3-b)indol-11-one(C710):  
A mixture of compound C09 (300 mg, 0.76 mmol), sodium acetate (278 mg, 3.4 mmol) and 
AcOH (20 mL) was heated under reflux for 18 h. The volatile was evaporated under vacuum 
followed by a co-evaporation with toluene. Water (100 mL) was added and the medium was 
rendered basic by addition of 2N sodium hydroxide. The aqueous layer was extracted by AcOEt 
and EtOH, dried over MgSO4 and evaporated under vacuum to give the exected compound in 
quantative yield (300 mg). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 12.03 (br s, 1H), 10.94 & 
10.92 (2 br s, 1H), 10.26 (d, 1H), 7.73-7.63 (m, 2H), 7.41 (d, 1H), 7.17 (dd, 1H), 7.08 (d, 1H), 
4.18 (t, 2H), 2.73 (t, 2H), 2.56-2.43 (m, overlapped by DMSO signals), 2.29 (s, 3H), 1.57-1.48 
(m, 4H), 1.44-1.35 (m, 2H). Microanalyses, calculated for C23H25N3O2.H2O: C, 70.22; H, 6.87; 
N, 10.68, found: C, 70.16; H, 6.92; N, 10.42. MS 376.2 [M+1]. 
Formation of the maleate salt: A solution of this free base (160 mg) in boiling absolute ethanol 
(14 mL) was poured into a solution of maleic acid (60 mg) in hot absolute ethanol (4 mL). The 
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homogenous solution obtained was evaporated under vacuum and the residue was triturated with 
acetone giving a solid which was collected by filtration, washed with acetone and dried in a 
dessicator affording the maleate salt (180 mg). Microanalyses, calculated for 
C23H25N3O2.C4H4O4.0.5 H2O: C, 64.80; H, 6.00; found: C, 64.41; H, 6.37. 
3. Synthesis of compound C711 (3-(2-Methoxyethoxy)-8-methyl-7H,10H-
benzo(e)pyrido(4,3-b)indol-11one): C711 was synthesized via C08 
11-Chloro-3-(2-methoxyethoxy)-8-methyl-7H-benzo(e)pyrido(4,3-b)indole (C08):  
A mixture of 11-chloro-3-hydroxy-8-methyl-7H-benzo(e)pyrido(4,3-b)indole (1,0 g, 3.5 mmol) 
(Vinogradov et al., 2003), n-butanol (60 mL) and water (40 mL) was stirred during 30 min and a 
solution of NaOH (914 mg) in water (10 mL) was then added. After stirring during 15 min, 1-
chloro-2-methoxyethane (460 mg, 4,8 mmol) was added and the mixture was heated at 70°C for 
4 h. The reaction mixture was cooled and organic layer was separated. The aqueous layer was 
extracted by AcOEt and the organic layers were combined, washed with brine, dried over 
MgSO4 and evaporated under vacuum. The residue was purified by flash chromatography 
(neutral alumina, gradient of ethanol (0 to 2%) in dichloromethane) to give the expected 
compound as beige solid (50 mg, 4 %). 1H NMR (300 MHz, CDCl3) δ (ppm): 9.78 (d, 1H), 8.70 
(br s, 1H), 8.11 (s, 1H), 7.86 (d, 1H), 7.63 (d, 1H), 7.41 (dd, 1H), 7.36 (d, 1H), 4.30 (t, 2H), 
3.86(t, 2H), 3.51 (s, 3H), 2.57 (s, 3H). MS 341.0 & 343.0 [M-1]. 
3-(2-Methoxyethoxy)-8-methyl-7H,10H-benzo(e)pyrido(4,3-b)indol-11-one (C711):  
A mixture of compound C08 (39 mg, 0.11 mmol), sodium acetate (48 mg, 0.6 mmol) and AcOH 
(2 mL) was heated under reflux for 18 h. The volatile was evaporated under vacuum followed by 
a co-evaporation with toluene. Water (100 mL) was added and the medium was rendered basic 
by addition of 2N sodium hydroxide. The aqueous layer was extracted by AcOEt and EtOH, 
dried over MgSO4 and evaporated under vacuum to give the exected compound (30 mg, 81%). 
1H NMR (300 MHz, DMSO-d6) δ (ppm): 12.09 (br s, 1H), 11.01 & 10.99 (2 s, 1H), 10.33 (d, 
1H), 7.80-7.70 (m, 2H), 7.46 (d, 1H), 7.26 (dd, 1H), 7.15 (d, 1H), 4.28 (t, 2H), 3.80 (t, 2H), 3.41 
(s, 3H), 2.35 (s, 3H). MS 345.2 [M+Na]. 
110 
 
 
 
 
 
 
 
 
 
REFERENCES 
111 
 
Ahmed, A.A., Lu, Z., Jennings, N.B., Etemadmoghadam, D.L., Jacamo, R.O., et al. (2010). 
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides 
a potential target for therapy in ovarian cancer. Cancer Cell. 18, 109-21. 
Aihara, A., Tanaka, S., Yasen, M., Matsumura, S., Mitsunori, Y., et al. (2010). The selective 
Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. 
J Hepatol. 52, 63-71. 
Archambault, V. and Carmena, M. (2012). Polo-like kinase-activating kinases: Aurora A, 
Aurora B and what else?. Cell Cycle. 11, 1490-5.  
Arlot-Bonnemains, Y., Baldini, E., Martin, B., Delcros, J.G., Toller, M., et al. (2008). Effects of 
the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. 
Endocr Relat Cancer. 15, 559-68.  
Baek, S.H. (2011).When signaling kinases meet histones and histone modifiers in the nucleus. 
Mol Cell. 42, 274-84.  
Banko, M.R., Allen, J.J., Schaffer, B.E., Wilker, E.W., Tsou, P., (2011). Chemical genetic 
screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol 
Cell. 44, 878-92.  
Bastos, R.N., Barr, F.A. (2010). Plk1 negatively regulates Cep55 recruitment to the midbody to 
ensure orderly abscission. J Cell Biol. 191, 751-60. 
Bird, A.W., Hyman, A,A. (2008). Building a spindle of the correct length in human cells 
requires the interaction between TPX2 and Aurora A. J Cell Biol.182, 89-300. 
Bischoff, J.R., Plowman G.D. (1999). The Aurora/Ipl1p kinase family: regulators of 
chromosome segregation and cytokinesis. Trends Cell Biol. 9, 454-9. 
Blangy, A., Lane, H.A., d'Hérin, P., Harper, M., Kress, M., Nigg, E.A. (1995). Phosphorylation 
by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor 
essential for bipolar spindle formation in vivo. Cell. 83,1159-69. 
Bonet, C., Giuliano, S., Ohanna, M., Bille, K., Allegra, M., Bertolotto, C. et al. (2012). 
Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in 
melanoma cells. J Biol Chem. 287, 29887-98.  
Bothos, J., Tuttle, R.L., Ottey, M., Luca, F.C., Halazonetis, T.D. (2005). Human LATS1 is a 
mitotic exit network kinase. Cancer Res. 65, 6568-75. 
Bringmann, H. (2005). Cytokinesis and the spindle midzone. Cell Cycle. 4, 1709-12.  
112 
 
Brito, D.A., Rieder, CL. (2006). Mitotic checkpoint slippage in humans occurs via cyclin 
B destruction in the presence of an active checkpoint. Curr Biol. 16, 1194-200. 
Campbell, C.S., Desai, A. (2013). Tension sensing by Aurora B kinase is independent of 
survivin-based centromere localization. Nature. 497, 118-21.  
Carmena, M., Earnshaw, W.C. (2003). The cellular geography of aurora kinases. Nat Rev Mol 
Cell Biol. 4, 842-54.  
Carmena, M., Ruchaud, S., Earnshaw, W.C. (2009). Making the Auroras glow: regulation 
of Aurora A and B kinase function by interacting proteins. Curr Opin Cell Biol. 21, 
796-805.  
Carmena, M. (2012). Abscission checkpoint control: stuck in the middle with Aurora B. Open 
Biol.  2, 120095.  
Cerutti, H., Casas-Mollano, J.A. (2009). Histone H3 phosphorylation: universal code or lineage 
specific dialects?. Epigenetics. 4, 71-5.  
Cimini, D., Degrassi, F. (2005). Aneuploidy: a matter of bad connections. Trends Cell Biol. 15, 
442-51. 
Chan, E.H., Santamaria, A., Silljé, H.W., Nigg, E.A. (2008). Plk1 regulates mitotic Aurora A 
function through βTrCP-dependent degradation of hBora. Chromosoma. 117, 457–69.  
Chan, C.S., Botstein, D. (1993). Isolation and characterization of chromosome-gain and 
increase-in-ploidy mutants in yeast. Genetics. 135, 677-91. 
Chan,  G.K., Jablonski, S.A., Sudakin, V., Hittle, J.C., Yen, T.J. (1999). Human BUBR1 is a 
mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds 
the cyclosome/APC. J Cell Biol. 146, 941-54. 
Cheeseman, I.M,, Desai, A. (2008). Molecular architecture of the kinetochore-microtubule 
interface. Nat Rev Mol Cell Biol. 9, 33-46. 
113 
 
Cheetham, G.M., Knegtel, R.M., Coll, J.T., Renwick, S.B., Swenson, L., Weber P., Austen, 
D.A. et al. (2002). Crystal structure of aurora-2, an oncogenic serine/threonine kinase. J 
Biol Chem. 277, 42419-22.  
Chen, H.L., Tang, C.J., Chen, C.Y., Tang, T.K. (2005). Overexpression of an Aurora-C kinase-
deficient mutant disrupts the Aurora-B/INCENP complex and induces polyploidy. J 
Biomed Sci. 12, 297-310. 
Chen, C.T., Hehnly, H., Doxsey, S.J. (2012). Orchestrating vesicle transport, ESCRTs and 
kinase surveillance during abscission. Nat Rev Mol Cell Biol.13, 483-8 
Chen, Y.J., Chen, C.M., Twu, N.F., Yen, M.S., Lai, C.R., Yuan. C.C. et al., (2009). 
Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian 
cancerpatients. Virchows Arch.  455, 431-40.  
Chu, Y., Yao, P.Y., Wang, W., Wang, D., Wang, Z., Yao, X. et al. (2011). Aurora B kinase 
activation requires survivin priming phosphorylation by PLK1. J Mol Cell Biol. 3, 260-
7.  
Dar, A.A., Goff , L.W., Majid, S., Berlin, J., El-Rifai, W. (2010). Aurora kinase inhibitors: 
rising stars in cancer therapeutics?. Mol Cancer Ther. 9, 268-78. 
Davis, D.A., Sarkar, S.H., Hussain, M., Li, Y., Sarkar, F.H. (2006). Increased therapeutic 
potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 
human prostate cancer cell line. BMC Cancer. 6, 22. 
De la Barre, A.E., Angelov, D., Molla, A., Dimitrov, S. (2001). The N-terminus of histone H2B, 
but not that of histone H3 or its phosphorylation, is essential for chromosome 
condensation. EMBO J. 20, 6383-93. 
Delacour-Larose, M., Molla, A., Skoufias, D.A., Margolis, R.L., Dimitrov, S. (2004). Distinct 
dynamics of Aurora B and Survivin during mitosis. Cell Cycle. 3, 1418-26.  
DeLuca, J.G., Musacchio, A. (2012). Structural organization of the kinetochore-microtubule 
interface. Curr Opin Cell Biol.  24, 48-56.  
DeLuca,  J.G., Gall, W.E., Ciferri, C., Cimini, D., Musacchio, A., Salmon, E.D. (2006). 
Kinetochore microtubule dynamics and attachment stability are regulated by Hec1. Cell. 
127, 969-82. 
114 
 
Dieterich, K., Zouari, R., Harbuz, R., Vialard, F., Martinez, D., Ray, P.F. et al. (2009). The 
Aurora Kinase C c.144delC mutation causes meiosis I arrest in men and is frequent in 
the North African population. Hum Mol Genet. 18, 1301-9. 
Dodson, C.A., Bayliss, R. (2012). Activation of Aurora-A kinase by protein partner binding and 
phosphorylation are independent and synergistic. J Biol Chem. 287, 1150-7.  
Dodson, C.A., Kosmopoulou, M,, Richards ,M.W., Atrash, B., Bavetsias, V., Blagg, J., Bayliss, 
R. (2010). Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to 
MLN8054: insights into selectivity and drug design. Biochem J. 427, 19-28.  
Dunleavy, E.M., Roche, D., Tagami, H., Lacoste, N., Ray-Gallet, D.,  Almouzni-Pettinotti, G. et 
al. (2009). HJURP is a cell-cycle-dependent maintenance and deposition factor of 
CENP-A at centromeres.  Cell. 137, 485-97.  
Dutertre, S., Cazales, M., Quaranta, M., Froment, C., Ducommun, B. et al. (2004). 
Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M 
transition. J Cell Sci. 117, 2523-31.  
Dutertre, S., Hamard-Péron, E., Cremet, J.Y., Thomas, Y., Prigent, C. (2005).The absence of 
p53 aggravates polyploidy and centrosome number abnormality induced by Aurora-
Coverexpression. Cell Cycle.  4, 1783-7. 
Elkins,  J.M., Santaguida, S., Musacchio, A., Knapp, S. (2012). Crystal structure of human 
aurora B in complex with INCENP and VX-680. J Med Chem.  55, 7841-8.  
Enserink, J.M., Kolodner, R.D. (2010). An overview of Cdk1-controlled targets and processes. 
Cell Division. 5, 11-52.  
Escude, C., Nguyen, C.H., Mergny, J.L., Sun, J.S., Bisagni, E., Garestier, T. and Helene, C. 
(1995). Selective Stabilization of DNA Triple Helixes by Benzopyridoindole 
Derivatives. J. Am. Chem. Soc. 117, 10212-10219. 
Eyers, P.A., Erikson, E., Chen, L.G., Maller, J.L..(2003). A novel mechanism for activation of 
the protein kinase Aurora A. Curr Biol. 13, 691-7. 
Fink, J., Sanders, K., Rippl, A., Finkernagel, S., Beckers, T.L., Schmidt, M. (2007). Cell type-
dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box 
interference in cancer cell lines. Mol Cancer Ther. 6, 3189-97. 
Fu,  J., Bian, M., Liu, J., Jiang, Q., Zhang, C. (2009). A single amino acid change 
converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular 
function. Proc Natl Acad Sci U S A. 106, 6939-44.  
115 
 
Gabillard, J.C., Ulisse, S., Baldini, E., Sorrenti, S., Cremet, J.Y., Arlot-Bonnemains, Y. et al. 
(2011). Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 
1 protein. Biochem Biophys Res Commun. 408, 647-53.  
Gadea, B.B., Ruderman JV.(2006). Aurora B is required for mitotic chromatin-induced 
phosphorylation of Op18/Stathmin. Proc Natl Acad Sci U S A. 103, 4493-8.  
Galons, H., Oumata, N., Gloulou, O., Meijer, L. (2013). Cyclin-dependent kinase inhibitors 
closer to market launch?. Expert Opin Ther Pat.  [Epub ahead of print] 
Gontarewicz, A., Balabanov, S., Keller, G., Colombo, R., Brümmendorf, T.H. et al. (2008). 
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule 
inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations 
including T315I. Blood. 111, 4355-64.  
Guan, R., Tapang, P., Leverson, J.D., Albert, D., Giranda, V.L., Luo, Y. (2005). Small 
interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the 
survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in 
animals. Cancer Res. 65, 2698-704. 
Guse, A., Mishima, M., Glotzer, M. (2005). Phosphorylation of ZEN4/ 
MKLP1 by aurora B regulates completion of cytokinesis. Curr Biol. 15, 778-86. 
Guse,  A., Carroll, C.W., Moree, B., Fuller, C.J., Straight, A.F. (2011). In-vitro centromere and 
kinetochore assembly on defined chromatin templates. Nature. 477, 354-8.  
Giet, R., Prigent, C. (1999). Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic 
serine-threonine kinases. J Cell Sci. 112, 3591-601.  
Giles,  F.J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H., Freedman, S.J. (2007). MK-
0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or 
acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 109, 500-2.  
Girdler, F., Gascoigne, K.E., Eyers, P.A., Hartmuth, S., Crafter, C., Foote, K.M., Keen, N.J., 
Taylor, S.S. (2006). Validating Aurora B as an anti-cancer drug target. J Cell Sci. 119, 
3664-75.  
Girdler, F., Sessa, F., Patercoli, S., Villa, F., Musacchio, A,, Taylor, S. (2008). Molecular basis 
of drug resistance in aurora kinases. Chem Biol. 15, 552-62.  
116 
 
Giubettini, M., Asteriti, I.A., Scrofani, J., De Luca, M., Lindon, C., Lavia, P., Guarguaglini, G. 
(2011). Control of Aurora-A stability through interaction with TPX2. J Cell Sci. 124, 
113-22.  
Gizatullin, F., Yao, Y., Kung, V., Harding, M.W., Loda, M., Shapiro, G.I. (2006). The Aurora 
kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells 
with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 66, 
7668-77. 
Han,  Z., Riefler, G.M., Saam, J.R., Mango, S.E., Schumacher, J.M. (2005). The C. elegans 
Tousled-like kinase contributes to chromosome segregation as a substrate and regulator 
of the Aurora B kinase. Curr Biol. 15, 894-904. 
Hans, F., Skoufias, D.A., Dimitrov, S., Margolis, R.L. (2009). Molecular distinctions between 
Aurora A and B: a single residue change transforms Aurora A into correctly localized 
and functional Aurora B. Mol Biol Cell. 20, 3491-502.  
Hans,  F., Dimitrov, S. (2001). Histone H3 phosphorylation and cell division. Oncogene. 20, 
3021-7.  
Hardie, D.G. (2011). AMP-activated protein kinase: an energy sensor that regulates all aspects 
of cell function. Genes Dev. 25, 1895-908. 
Hari, M., Loganzo, F., Annable, T., Tan, X., Musto, S., Morilla, D.B., Greenberger, L.M. et al. 
(2006). Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of 
beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther. 5, 270-8. 
Harrington, E.A., Bebbington, D., Moore, J., Rasmussen, R.K.,  Miller, K.M. et al. (2004). VX-
680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses 
tumor growth in vivo. Nat Med. 10, 262-7.  
Hauf,  S., Watanabe, Y. (2004). Kinetochore orientation in mitosis and meiosis. Cell. 119, 317-
27. 
Herzog , F., Primorac, I., Dube, P., Lenart, P., Sander, B., Mechtler, K., Stark, H., Peters, J.M. 
(2009). Structure of the anaphase-promoting complex/cyclosome interacting with a 
mitotic checkpoint complex. Science.  13, 1477-81.  
Hewitt,  L., Tighe, A., Santaguida, S., White, A.M.,  Taylor, S.S. (2010). Sustained Mps1 
activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. J 
Cell Biol. 190, 25-34. 
Hirano, T. (2005). Condensins: organizing and segregating the genome. Curr Biol. 15, 265-75. 
117 
 
Hirota,  T., Kunitoku, N., Sasayama, T., Marumoto, T., Zhang, D.,  Saya, H. et al. (2003). 
Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic 
commitment in human cells. Cell. 114, 585-98. 
Hoang, T.M., Favier, B., Valette, A., Barette, C., Nguyen, C.H., Molla, A. et al. (2009). 
Benzo[e]pyridoindoles, novel inhibitors of the aurora kinases. Cell Cycle. 8, 765-72.  
Honda,  K., Mihara, H., Kato,Y., Yamaguchi, A., Tanaka, H.,  Urano, T. et al. (2000). 
Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-
ubiquitin-proteasome pathway. Oncogene. 19, 2812-9. 
Honda, R., Körner, R., Nigg, E.A. (2003). Exploring the functional interactions 
between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell.14, 3325-41.  
Honma,  K., Nakanishi, R., Nakanoko, T., Ando, K., Maehara, Y. et al. (2013). Contribution of 
Aurora-A and -B expression to DNA aneuploidy in gastric cancers. Surg Today. [Epub 
ahead of print]. 
Hu, C.K., Coughlin, M., Field, C.M., Mitchison, T.J. (2011). KIF4 regulates midzone length 
during cytokinesis. Curr Biol. 21, 815-24. 
Hu, C.K., Coughlin, M., Mitchison, T.J. (2012). Midbody assembly and its regulation during 
cytokinesis. Mol Biol Cell. 23, 1024-34.  
Hutterer,  A., Berdnik, D., Wirtz-Peitz, F., Zigman, M., Schleiffer, A., Knoblich, J.A. (2006). 
Mitotic activation of the kinase Aurora-A requires its binding partner Bora. Dev Cell.  
11, 147-57. 
Hutterer, A., Glotzer, M., Mishima, M.. (2009). Clustering of centralspindlin is essential for its 
accumulation to the central spindle and the midbody. Curr Biol. 19, 2043-9. 
Ikezoe, T. (2008). Aurora kinases as an anti-cancer target. Cancer Lett. 262, 1-9.  
Ikezoe,T., Nishioka, C., Tasaka, T., Yang ,Y., Komatsu, N., Togitani, K., Koeffler, H.P., 
Taguchi, H. (2006). The antitumor effects of sunitinib (formerly SU11248) against a 
variety of human hematologicmalignancies: enhancement of growth inhibition via 
inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther. 5, 2522-30. 
Jabbour, E., Cortes, J.E., Ghanem, H., O'Brien, S., Kantarjian, H.M. (2008). Targeted therapy 
in chronic myeloid leukemia. Expert Rev Anticancer Ther.  8, 99-110. 
Jares,  P., Donaldson, A., Blow, J.J. (2000). The Cdc7/Dbf4 protein kinase: target of the S phase 
checkpoint?. EMBO Rep.  1, 319-22.  
Jeremy, P. H. C. and Randy. Y. C. P. (2010). DNA Damage and Polyploidization. From the 
book “Polyploidization and Cancer”. 
118 
 
Johnson, N., Shapiro, G.I. (2010). Cyclin-dependent kinases (cdks) and the DNA damage 
response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer 
strategy for solid tumors. Expert Opin Ther Targets. 14, 1199-212. 
Karess, R. (2005). Rod-Zw10-Zwilch: a key player in the spindle checkpoint. Trends Cell Biol. 
15, 386-92. 
Katayama, H., Brinkley, W.R., Sen, S. (2003). The Aurora kinases: role in cell transformation 
and tumorigenesis. Cancer Metastasis Rev. 22, 451-64.  
Katayama, H., Sasai, K., Kawai, H., Yuan, Z.M.,  Sen, S. et al. (2004). Phosphorylation by 
aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat 
Genet. 36, 55-62.  
Kawajiri, A., Yasui, Y., Goto, H., Tatsuka, M., Takahashi, M., Nagata, K., Inagaki, M.. (2003). 
Functional significance of the specific sites phosphorylated in desmin at cleavage 
furrow: Aurora-B may phosphorylate and regulate type III intermediate filaments during 
cytokinesis coordinatedly with Rho-kinase. Mol Biol Cell. 14, 1489-500. 
Keating, P., Rachidi, N., Tanaka, T.U., Stark, M.J. (2009). Ipl1-dependent phosphorylation of 
Dam1 is reduced by tension applied on kinetochores. J Cell Sci.122, 4375-82.  
Kelly, A.E., Ghenoiu, C., Xue, J.Z., Zierhut, .C, Kimura, H., Funabiki, H. (2010). Survivin reads 
phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science. 
330, 235-9.  
Kimmins,  S., Crosio, C., Kotaja, N., Hirayama, J., Monaco, L., Höög, C.,  Sassone-Corsi, P. et 
al. (2007). Differential functions of the Aurora-B and Aurora-C kinases in mammalian 
spermatogenesis. Mol Endocrinol. 21, 726-39. 
Knowlton, A.L., Lan, W., Stukenberg, P.T. (2006). Aurora B is enriched at merotelic 
attachment sites, where it regulates MCAK. Curr Biol. 16, 1705-10. 
Kufer, T.A., Silljé, H.H., Körner, R., Gruss, O.J., Meraldi, P., Nigg, E.A.(2002). Human TPX2 
is required for targeting Aurora-A kinase to the spindle. J Cell Biol.  158, 617-23.  
Lacroix,  M., Toillon, R.A., Leclercq, G. (2006). p53 and breast cancer, an update. Endocr Relat 
Cancer.13, 293-325.  
Lan,  W., Cleveland, D.W. (2010). A chemical tool box defines mitotic and interphase roles for 
Mps1 kinase. J Cell Biol. 190, 21-4. 
Lapenna, S., Giordano, A. (2009). Cell cycle kinases as therapeutic targets for cancer. Nat Rev 
Drug Discov. 8, 547-66. 
119 
 
Lawo,  S., Hasegan, M., Gupta, G.D., Pelletier, L. (2012). Subdiffraction imaging of 
centrosomes reveals higher-order organizational features of pericentriolar material. Nat 
Cell Biol.  14, 1148-58.  
Le, L.T, Vu, H.L., Naud-Martin, D., Bombled, M., Nguyen, C.H., Molla, A.(2013). 
Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases. 
ChemMedChem. 8, 289-96.  
Lee, E.C., Frolov, A., Li, R., Ayala, G., Greenberg, N.M. (2006).Targeting Aurora kinases for 
the treatment of prostate cancer. Cancer Res. 66, 4996-5002. 
Lee, S., Schmitt, C.A. (2003).Chemotherapy response and resistance. Curr Opin Genet Dev. 13, 
90-6. 
Lénárt, P., Petronczki, M., Steegmaier, M., Di-Fiore, B.,  Peters, J.M. et al. (2007). The small-
molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 
1. Curr Biol. 17, 304-15.  
Lin, Y.G., Immaneni, A., Merritt, W.M., Mangala, L.S.,  Sood, A.K. et al. (2008). Targeting 
aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res, 14, 
5437–5446. 
Lin,  Z.Z., Jeng, Y.M., Hu, F.C., Pan, H.W., Tsao, H.W., Lai, P.L., Lee, P.H., Cheng, A.L., Hsu, 
H.C. (2010). Significance of Aurora B overexpression in hepatocellular carcinoma. 
Aurora B Overexpression in HCC. BMC Cancer. 10, 461 
Lipp, J.J., Hirota, T., Poser, I., Peters, J.M. (2007). Aurora B controls the association 
of condensin I but not condensin II with mitotic chromosomes. J Cell Sci. 120,  1245-
55.  
Lister-Sharp, D., McDonagh, M.S., Khan, K.S., Kleijnen, J. (2004). A rapid and systematic 
review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of 
advanced breast and ovarian cancer. Health Technol Assess, 4, 1-113. 
Liu, X., Gong, H., Huang, K.. (2013). Oncogenic role of kinesin proteins and 
targeting kinesin therapy. Cancer Sci.  [Epub ahead of print] 
Liu, D., Lampson, M.A. (2009). Regulation of kinetochore-microtubule attachments 
by Aurora B kinase. Biochem Soc Trans. 37, 976-80.  
120 
 
Liu, L., Ulbrich, J., Müller, J., Wüstefeld, T., Aeberhard, L.,  Murphy, D.J. (2012). 
Deregulated MYC expression induces dependence upon AMPK-related kinase 5. 
Nature. 483, 608-12. 
Liu, Q., Kaneko, S., Yang, L., Feldman, R.I., Nicosia, S.V., Chen, J., Cheng, J.Q. (2004). 
Aurora-A abrogation of p53 DNA binding and transactivation activity by 
phosphorylation of serine 215. J Biol Chem. 279, 52175-82. 
Liu, X., Erikson, R.L.(2003). Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. 
Proc Natl Acad Sci U S A. 100, 5789-94.  
Liu, Y., Gray, N.S. (2006). Rational design of inhibitors that bind to inactive kinase 
conformations. Nat Chem Biol. 2, 358-64. 
López-Ríos, F., Ladanyi, M..  (2006). Malignant mesothelioma. N Engl J Med. 354, 305-7. 
Lowery, D.M., Lim, D., Yaffe, M.B. (2005), Structure and function of Polo-like kinases. 
Oncogene, 24, 248–59 
Maciejowski, J., George, K.A., Terret, M.E., Zhang, C., Shokat, K.M., Jallepalli, P.V. (2010).  
Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis 
to control M phase timing and spindle checkpoint signaling. J Cell Biol. 190, 89-100.  
Macůrek, L., Lindqvist, A., Lim, D., Lampson, M.A.,  Medema, R.H. et al. (2008). Polo-like 
kinase-1 is activated by aurora A to promote checkpoint recovery. Nature. 455, 119-23.  
Macurek, L., Lindqvist, A., Medema, R.H. (2009). Aurora-A and hBora join the game of Polo. 
Cancer Res. 69, 4555-8.  
Maerki, S., Olma, M.H., Staubli, T., Steigemann, P., Gerlich, D.W., Quadroni, M., Sumara, I., 
Peter, M. (2009). The Cul3-KLHL21 E3 ubiquitin ligase targets aurora B to midzone 
microtubules in anaphase and is required for cytokinesis. J Cell Biol. 187, 791-800.  
Mahadevan, D., Stejskal, A., Cooke, L.S., Manziello, A., Morales, C., Persky, D.O., Fisher, 
R.I., Miller, T.P., Qi, W. (2012). Aurora A inhibitor (MLN8237) plus vincristine plus 
rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-
Hodgkin lymphoma. Clin Cancer Res. 18, 2210-9.  
Malvezzi,  F., Litos, G., Schleiffer, A., Heuck, A., Mechtler, K., Clausen, T., Westermann, S. 
(2013). A structural basis for kinetochore recruitment of the Ndc80 complex via two 
distinct centromere receptors. EMBO J. 32, 409-23.  
Manley, P.W., Cowan-Jacob, S.W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, 
T., Zimmermann, J. (2002). Imatinib: a selective tyrosine kinase inhibitor. Eur J 
Cancer. 38, 19-27.  
121 
 
Mao, Y., Desai, A., Cleveland, D.W. (2005). Microtubule capture by CENP-E silences BubR1-
dependent mitotic checkpoint signaling. J Cell Biol. 170, 873-80. 
Mao, Y., Varma, D., Vallee, R. (2010). Emerging functions of force-producing kinetochore 
motors. Cell Cycle. 9, 715-9. 
Martin, M.P., Zhu, J.Y., Lawrence, H.R., Pireddu, R., Schönbrunn, E. et al. (2012). A novel 
mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. ACS 
Chem Biol. 7, 698-706.  
May, K.M., Hardwick KG. (2006). The spindle checkpoint. J Cell Sci. 119, 4139-42. 
Mayer , T.U., Kapoor, T.M., Haggarty, S.J., King, R.W., Schreiber, S.L., Mitchison, T.J. (1999). 
Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based 
screen. Science. 286, 971-4. 
Meldi, L., Brickner, J.H. (2011). Compartmentalization of the nucleus. Trends Cell Biol. 21, 
701-8.  
Meraldi,  P., Honda, R., Nigg, E.A. (2002). Aurora-A overexpression reveals tetraploidization 
as a major route to centrosome amplification in p53-/- cells. EMBO J. 21, 483-92. 
Molla, A. (2010). Aurora kinases orchestrate mitosis; who are the players?. BioMolecular 
Concepts. 1, 147-155. 
Molli,  P.R., Li, D.Q., Bagheri-Yarmand, R., Pakala, S.B.,  Kumar, R. et al. (2010). Arpc1b, a 
centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol. 190, 
101-14.  
Motoshima, H., Goldstein, B.J., Igata, M., Araki, E. (2006). AMPK and cell proliferation: 
AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol. 574, 63-71.  
Musacchio, A., Salmon, E.D. (2007). The spindle-assembly checkpoint in space and time. Nat 
Rev Mol Cell Biol. 8, 379-93.  
Nachury, M.V., Maresca, T.J., Salmon, W.C., Waterman-Storer, C.M., Heald, R., Weis, K. 
(2001). Importin beta is a mitotic target of the small GTPase Ran in spindle assembly. 
Cell.104, 95-106. 
Nair, J.S., Tse, A., Keen, N. et al. (2004). A novel Aurora B kinase inhibitor with potent 
anticancer activity either as a single agent or in combination with chemotherapy. J Clin 
Oncol. 22. 
Nasmyth, K., Haering, C.H. (2009). Cohesin: its roles and mechanisms. Annu Rev Genet. 43, 
525-58.  
122 
 
Nigg,  E.A.,  Raff, JW.(2009). Centrioles, centrosomes, and cilia in health and disease. Cell.  
139, 663-78.  
Nilsson, J., Yekezare, M., Minshull, J., Pines, J. (2008). The APC/C maintains the spindle 
assembly checkpoint by targeting Cdc20 for destruction. Nat Cell Biol. 10, 1411-20.  
Nguyen, C.H. , Marchand, C., Delage, S. ,  Sun, J.S. , Garestier, T. , Hélène, C. and Bisagni, E. 
(1998). Synthesis of 13H-Benzo[6,7]- and 13H-Benzo[4,5]indolo[3,2-c]- quinolines: A 
New Series of Potent Specific Ligands for Triplex DNA. J. Am. Chem. Soc. 120, 2501–
2507. 
Nguyen, C.H., Bisagni, E., Lavelle, F., Bissery, M.C., Huel, C. (1992). Synthesis and antitumor 
properties of new 4-methyl-substituted- pyrido[4,3-b]indoles (gamma-carbolines). 
Anticancer Drug Des. 7, 219-33. 
Nguyen, C.H., Lhoste, J.M., Lavelle, F., Bissery, M.C., Bisagni, E. (1990). Synthesis and 
antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-
b]benzo[e]- and -benzo[g])indoles- A new class of antineoplastic agents. J Med 
Chem. 33, 1519-28. 
Nguyen, H.G., Chinnappan, D., Urano, T., Ravid, K. (2005). Mechanism of Aurora-B 
degradation and its dependency on intact KEN and A-boxes: identification of an 
aneuploidy-promoting property. Mol Cell Biol. 25, 4977-92. 
O'Connor, C. (2008). Cell Division: Stages of Mitosis. Nature Education, 1. 
Olmos, D., Barker, D., Sharma, R., Brunetto, A.T., Yap, T.A.,  Blagden, S.P. (2013). 
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, 
in patients with advancedsolid malignancies. Clin Cancer Res. 17, 3420-30.  
O'Shaughnessy, J., Gradishar, W.J., Bhar, P., Iglesias, J. (2013). nab-Paclitaxel for first-line 
treatment of patients with metastatic breast cancer and poor prognostic factors: a 
retrospective analysis. Breast Cancer Res Treat. 138, 829-37.  
Pan, C., Yan, M., Yao, J. et al. (2008). Aurora kinase small molecule inhibitor destroys mitotic 
spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. 
Oral Oncol. 44, 639 – 645. 
Pan, D. (2010). The hippo signaling pathway in development and cancer. Dev Cell. 19, 491-505. 
Petersen, J., Paris, J., Willer, M., Philippe, M., Hagan, I.M. (2001). The S. pombe aurora-related 
kinase Ark1 associates with mitotic structures in a stage dependent manner and is 
required for chromosome segregation. J Cell Sci.  114, 4371-84. 
123 
 
Petsalaki , E., Akoumianaki, T., Black, E.J., Gillespie, D.A., Zachos, G. (2011). 
Phosphorylation at serine 331 is required for Aurora B activation. J Cell Biol. 195, 449-
66.  
Petretti, C., Savoian, M., Montembault, E., Glover, D.M., Prigent, C., Giet, R. (2006). The 
PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar 
spindle formation. EMBO Rep. 7, 418-24.  
Petronczki, M., Lénárt, P., Peters, J-M. (2008). Polo on the rise-from mitotic entry to 
cytokinesis with Plk1. Dev Cell. 14, 646–59. 
Pihan, G.A., Wallace, J., Zhou, Y., Doxsey, S.J. (2003). Centrosome abnormalities and 
chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 63, 
1398-404. 
Prigent,  C., Dimitrov, S. (2003). Phosphorylation of serine 10 in histone H3, what for?. J Cell 
Sci. 116, 3677-85. 
Przewloka, M.R., Venkei, Z., Bolanos-Garcia, V.M., Debski, J., Dadlez, M, Glover, D.M. 
(2011). CENP-C is a structural platform for kinetochore assembly. Curr Biol.  21, 399-
405. 
Pugacheva, E.N., Jablonski, S.A., Hartman, T.R., Henske, E.P., Golemis E.A. (2007). HEF1-
dependent Aurora A activation induces disassembly of the primary cilium. Cell.  129, 
1351-63. 
Qi,  W., Liu, X., Cooke, L.S., Persky, D.O., Miller, T.P., Squires, M., Mahadevan, D. (2012). 
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-
cell lymphomas. Int J Cancer. 130, 2997-3005. 
Reboutier, D., Troadec, M.B., Cremet, J.Y., Fukasawa, K., Prigent, C. (2012). 
Nucleophosmin/B23 activates Aurora A at the centrosome through phosphorylation of 
serine 89. J Cell Biol. 197, 19-26.  
Remeseiro, S., Losada, A. (2013). Cohesin, a chromatin engagement ring. Curr Opin Cell Biol. 
25, 63-71.  
124 
 
Rosasco-Nitcher, S.E., Lan, W., Khorasanizadeh, S., Stukenberg,  P.T. (2008). Centromeric 
Aurora-B activation requires TD-60, microtubules, and substrate priming 
phosphorylation. Science. 319, 469-72.  
Sabino, D., Brown, N.H., Basto, R. (2011). Drosophila Ajuba is not an Aurora-A activator but is 
required to maintain Aurora-A at the centrosome. J Cell Sci. 124, 1156-66. 
Sakurikar,  N., Eichhorn, J.M., Chambers, T.C. (2012). Cyclin-dependent kinase-1 
(Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of 
antiapoptotic Bcl-2 proteins. J Biol Chem. 287, 39193-204. 
Sampath, S.C., Ohi, R., Leismann, O., Salic, A., Pozniakovski, A., Funabiki, H. (2004). The 
chromosomal passenger complex is required for chromatin-induced microtubule 
stabilization andspindle assembly. Cell. 118, 187-202. 
Sasai, K., Katayama, H., Stenoien, D.L., Fujii, S., Honda, R., Sen, S. et al. (2004). Aurora-
C kinase is a novel chromosomal passenger protein that can complement Aurora-B 
kinase function in mitotic cells. Cell Motil Cytoskeleton. 59, 249-63. 
Screpanti, E., De Antoni, A., Alushin, G.M., Petrovic, A., Melis, T., Nogales, E., Musacchio, A. 
(2011). Direct binding of Cenp-C to the Mis12 complex joins the inner and outer 
kinetochore. Curr Biol.  21, 391-8.  
Schmitt, A., Gutierrez, G.J., Lénárt, P., Ellenberg, J., Nebreda, A.R. (2002). Histone H3 
phosphorylation during Xenopus oocyte maturation: regulation by the MAP 
kinase/p90Rsk pathway and uncoupling from DNA condensation. FEBS Lett., 518, 23-
8. 
Schumacher, J.M., Ashcroft, N., Donovan, P.J., Golden, A. (1998). A highly conserved 
centrosomal kinase, AIR-1, is required for accurate cell cycle progression and 
segregation of developmental factors in Caenorhabditis elegans embryos. Development. 
125, 4391-402. 
Schumacher, J.M., Golden, A., Donovan, P.J. (1998). AIR-2: An Aurora/Ipl1-related protein 
kinase associated with chromosomes and midbody microtubules is required for polar 
body extrusion and cytokinesis in Caenorhabditis elegans embryos. J Cell Biol. 143, 
1635-4.  
Seki, A., Coppinger, J.A., Du, H., Jang, C.Y., Yates, J.R., Fang, G. (2008). Plk1- and β-TrCP-
dependent degradation of Bora controls mitotic progression. J Cell Biol.  181, 65–78.  
Seki, A., Coppinger, J.A., Jang, C.Y., Yates, J.R., Fang, G. (2008). Bora and the kinase Aurora a 
cooperatively activate the kinase Plk1 and control mitotic entry. Science. 320, 1655-8.  
125 
 
Sessa, F., Mapelli, M., Ciferri, C., Tarricone, C., Areces, L.B., Schneider, T.R., Stukenberg, 
P.T.,, Musacchio, A. (2005). Mechanism of Aurora B activation by INCENP and 
inhibition by hesperadin. Mol Cell. 18, 379-91. 
Sharma, A., Madhunapantula, S.V., Gowda, R., Berg, A., Neves, R.I., Robertson, G.P.. (2013). 
Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of 
(V600E)B-RAF in melanoma. Am J Pathol. 182, 1151-62.  
Signorovitch, J.E., Wu, E.Q., Betts, K.A., Parikh, K.,  DeAngelo, D.J. et al. (2011). 
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid 
leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res 
Opin. 27, 1263-71. 
Socinski, M.A., Govindan, R., Spigel, D. (2012). Clinical roundtable monograph: Recent 
advances in taxanes for the first-line treatment of advanced non-small cell lung cancer. 
Clin Adv Hematol Oncol. 10, 1-16. 
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Rettig. W.J. et al.  (2007). 
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor 
growth in vivo. Curr Biol. 17, 316-22.  
Steigemann, P., Wurzenberger, C., Schmitz, M.H., Held, M., Guizetti, J., Maar, S., Gerlich, 
D.W. (2009). Aurora B-mediated abscission checkpoint protects against 
tetraploidization. Cell. 136, 473-84. 
Stein, MA., Rubin, E.H., Scott, P.D., Fernandez, R., Wilding, G.  et al. (2006). Phase I clinical 
and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 
in cancer patients. Journal of Clinical Oncology. 24. 
Strebhardt, K., Ullrich, A. (2006). Targeting polo-like kinase 1 for cancer therapy. Nat Rev 
Cancer. 6, 321-30. 
Sumara, I., Giménez-Abián, J.F., Gerlich, D., Hirota, T., Peters, J.M. (2004). Roles of polo-like 
kinase 1 in the assembly of functional mitotic spindles. Curr Biol. 14, 1712-22. 
Sumara, I., Quadroni, M., Frei, C., Olma, M.H., Sumara, G., Ricci, R., Peter, M. (2007). 
A Cul3-based E3 ligase removes Aurora B from mitotic chromosomes, regulating 
mitotic progression and completion of cytokinesis in human cells. Dev Cell. 12, 887-
900. 
Suzuki, A., Lu, J., Kusakai, G., Kishimoto, A., Ogura, T., Esumi, H. (2004). ARK5 is a tumor 
invasion-associated factor downstream of Akt signaling. Mol Cell Biol. 24, 3526-35. 
126 
 
Takai, N., Hamanaka, R., Yoshimatsu, J., Miyakawa, I. (2005). Polo-like kinases (Plks) and 
cancer. Oncogene. 24, 287-91.  
Takemoto,  A., Murayama, A., Katano, M., Urano, T., Kimura, K. et al. (2007). Analysis of the 
role of Aurora B on the chromosomal targeting of condensin I. Nucleic Acids Res. 35, 
2403-12.  
Takeuchi, K., Fukagawa, T. (2012). Molecular architecture of vertebrate kinetochores. Exp Cell 
Res.  318, 1367-74. 
Tanaka, R., Squires, M.S., Kimura, S. et al. (2008). Activity of the multi-targeted kinase 
inhibitor, AT9283 on Imatinib-resistant CML models.  Blood. 112. 
Tang, C.J., Lin, C.Y., Tang, T.K. (2006). Dynamic localization and functional implications 
of Aurora-C kinase during male mouse meiosis. Dev Biol. 290, 398-410.  
Tao, Y., Zhang, P., Girdler, F. et al. (2008). Enhancement of radiation response in p53-deficient 
cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene. 27, 3244 –3255. 
Tao, W., South ,V.J., Zhang, Y., Davide, J.P., Farrell, L., Kohl, N.E., Sepp-Lorenzino, L., 
Lobell, R.B. (2005). Induction of apoptosis by an inhibitor of the mitotic 
kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic 
slippage. Cancer Cell. 8, 49-59. 
Tao, W., South, V.J., Diehl, R.E., Davide, J.P., Sepp-Lorenzino, L., Fraley, M.E., Arrington, 
K.L., Lobell, R.B. (2007). An inhibitor of the kinesin spindle protein activates the 
intrinsic apoptotic pathway independently of p53 and de novo protein synthesis.  Mol 
Cell Biol.27, 689-98.  
Tsai,  Y., Wiese, C., Cao, K., Martin, O., Zheng, Y. et al. (2003). A Ran signalling pathway 
mediated by the mitotic kinase Aurora A in spindle assembly. Nat Cell Biol. 5, 242-8. 
Tsou, J.H., Chang, K.C., Chang-Liao, P.Y., Yang, S.T., Hung, L.Y. et al. (2011). Aberrantly 
expressed AURKC enhances the transformation and tumourigenicity of epithelial cells. 
J Pathol. 225, 243-54. 
127 
 
Thaiparambil, J.T., Eggers, C.M., Marcus, A.I. (2012). AMPK regulates mitotic spindle 
orientation through phosphorylation of myosin regulatory light chain. Mol Cell Biol. 32, 
3203-17.  
Trakala, M., Fernández-Miranda, G., Pérez de Castro, I., Heeschen, C., Malumbres, M. (2013). 
Aurora B prevents delayed DNA replication and premature mitotic exit by repressing 
p21(Cip1). Cell Cycle. 12, 1030-41.  
Ueda,  Y., Enomoto, T., Matsuzaki, S., Kobayashi, E., Kimura, T., Yoshino, K., Fujita, 
M., Tsutsui, T., Kimura, T. (2013). Taxane-sensitivity of ovarian carcinomas previously 
treated with paclitaxel and carboplatin. Cancer Chemother Pharmacol. [Epub ahead of 
print] 
Vader,  G., Lens, S.M. (2008). The Aurora kinase family in cell division and cancer. Biochim 
Biophys Acta. 1786, 60-72.  
Van der Waal, M.S., Hengeveld, R.C., van der Horst, A., Lens, S.M. (2012). Cell 
division control by the Chromosomal Passenger Complex. Exp Cell Res. 318, 1407-20.  
Van Hooser, A., Goodrich, D.W., Allis,C.D., Brinkley, B.R., Mancini, M.A. (1998). Histone H3 
phosphorylation is required for the initiation, but not maintenance, of mammalian 
chromosome condensation. J Cell Sci. 111. 3497-506. 
Van Vugt, M.A., Brás, A., Medema, R.H. (2004). Polo-like kinase-1 controls recovery from a 
G2 DNA damage-induced arrest in mammalian cells. Mol Cell. 15, 799-811. 
Van Vugt,  M.A., Medema, R.H. (2005). Getting in and out of mitosis with Polo-like kinase-1. 
Oncogene.  24, 2844-59. 
VanderPorten, E.C., Taverna, P., Hogan, J.N., Ballinger, M.D., Flanagan, W.M., Fucini, R.V. 
(2009). The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with 
chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma 
model. Mol Cancer Ther. 8, 930-9.  
Veerakumarasivam,  A., Goldstein, L.D., Saeb-Parsy, K., Scott, H.E., Warren, A.,  Kelly, J.D. 
et al. (2008). AURKA overexpression accompanies dysregulation of DNA-damage 
response genes in invasive urothelial cell carcinoma. Cell Cycle. 7, 3525-33.  
Vu, H.L. (2011). Les Benzo[e]pyridoindoles, une novelle famille d’inhibiteurs de kinase à 
activité anti-proliférative. Ph.D thesis, UJF. 
 
128 
 
Walter,  A.O., Seghezzi, W., Korver, W., Sheung, J., Lees, E. (2000). The mitotic 
serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. 
Oncogene. 19, 4906-16. 
Wang,  F., Ulyanova, N.P., van der Waal, M.S., Patnaik, D., Lens, S.M., Higgins, J.M. (2011). 
A positive feedback loop involving Haspin and Aurora B promotes CPC accumulation 
at centromeres in mitosis. Curr Biol. 21, 1061-9.  
Warner, S.L., Munoz, R.M., Stafford, P., Koller, E., Hurley, L.H., Von Hoff, D.D., Han, H. 
(2006).Comparing Aurora Aand Aurora B as molecular targets for growth inhibition of 
pancreatic cancer cells. Mol Cancer Ther. 5, 2450-8. 
Weaver, B.A., Bonday, Z.Q., Putkey, F.R., Kops, G.J., Silk, A.D., Cleveland, D.W. (2003). 
Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to 
prevent aneuploidy due to single chromosome loss. J Cell Biol. 162, 551-63. 
Wei, Y., Yu, L., Bowen, J., Gorovsky, M.A., Allis, C.D. (1999). Phosphorylation of histone 
H3 is required for proper chromosome condensation and segregation. Cell. 97, 99-109. 
Westermann, S., Schleiffer, A. (2013). Family matters: structural and functional conservation of 
centromere-associated proteins from yeast to humans. Trends Cell Biol. [Epub ahead of 
print] 
Wilson, L., Jordan, MA. (2004). New microtubule/tubulin-targeted anticancer drugs and novel 
chemotherapeutic strategies. J Chemother. 16, 83-5. 
Woessner, R., Tunquist, B., Lemieux, C., Chlipala, E.,  Walker, D. (2009). ARRY-520, a novel 
KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. 
Anticancer Res. 29, 4373-80. 
Wordeman, L. (2010). How kinesin motor proteins drive mitotic spindle function: Lessons from 
molecular assays. Semin Cell Dev Biol. 21, 260-8.  
Xu, Z., Ogawa, H., Vagnarelli, P., Bergmann, J.H., Samejima, K. (2009). INCENP-aurora B 
interactions modulate kinase activity and chromosome passenger complex localization. 
J Cell Biol. 187, 637-53.  
Yabe, T., Ge, X., Lindeman, R., Nair, S., Runke, G., Mullins, M.C., Pelegri, F. (2009). The 
maternal-effect gene cellular island encodes aurora B kinase and is essential for furrow 
formation in the early zebrafish embryo. PLoS Genet. 5, e1000518. 
Yabuta, N., Okada, N., Ito, A., Hosomi, T., Nojima, H. et al. (2007). Lats2 is an essential 
mitotic regulator required for the coordination of cell division. J Biol Chem. 282, 
19259-71.  
129 
 
Yang, J., Ikezoe, T., Nishioka, C. et al.  (2007). AZD1152, a novel and selective aurora B kinase 
inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing 
agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. 
Blood. 110, 2034 –2040. 
Yang, H., Ou, C.C., Feldman, R.I., Nicosia, S.V., Kruk, P.A., Cheng, J.Q. (2004). Aurora-A 
kinase regulates telomerase activity through c-Myc in human ovarian and breast 
epithelial cells. Cancer Res. 64, 463-7. 
Yasui, Y., Urano, T., Kawajiri, A., Nagata, K., Tatsuka, M., Saya, H., Furukawa, K., Takahashi 
,T., Izawa, I., Inagaki, M. (2004). Autophosphorylation of a newly identified site 
of Aurora-B is indispensable for cytokinesis. J Biol Chem. 279, 12997-3003. 
Young, M.A., Shah, N.P., Chao, L.H., Seeliger. M., Kuriyan, J. et al. (2006). Structure of 
the kinase domain of an imatinib-resistant Abl mutant in complex with 
the Aurora kinase inhibitor VX-680. Cancer Res. 66, 1007-14. 
Yuan, K., Li, N., Huo, Y., Yan, F., Yang, Y., Ward, T., Jin, C., Yao, X. (2009). Recruitment 
of separase to mitotic chromosomes is regulated by Aurora B. Cell Cycle. 8, 1433-43.  
Zeng, W.F., Navaratne, K., Prayson, R.A., Weil, R.J. (2007). Aurora B expression correlates 
with aggressive behaviour in glioblastoma multiforme. J Clin Pathol. 60, 218-21. 
Zhao, Z.S., Lim, J.P., Ng, Y.W., Lim, L., Manser, E. (2005). The GIT-associated kinase PAK 
targets to the centrosome and regulates Aurora-A. Mol Cell. 20, 237-49. 
Zhou, B.B., Bartek, J. (2004). Targeting the checkpoint kinases : chemosensitization  
versus chemoprotection. Nat Rev Cancer.  4, 216-25. 
Zhou, J., Giannakakou, P. (2005). Targeting microtubules for cancer chemotherapy. Curr Med 
Chem Anticancer Agents. 5, 65-71. 
Zou, J., Luo, S.D., Wei, Y.Q., Yang, S.Y. (2011). Integrated computational model of cell cycle  
and checkpoint reveals different essential roles of Aurora-A and Plk1in mitotic entry. 
Mol Biosyst.  7, 169-79. 
 
 
 
 
 
ABSTRACT 
Benzo[e]pyridoindoles are novel potent inhibitors of aurora kinases. We performed a 
SAR study to improve their activity and water solubility. Amino-benzo[e]pyridoindolones 
were found to be potent hydrosoluble anti-proliferative molecules. They induced a massive 
arrest in mitosis, prevented histone H3 phosphorylation as well as disorganizing the mitotic 
spindles.  Upon a delay, cells underwent binucleated and finally died. Taking into account their 
interesting preclinal characteristics, their efficiency towards xenografts in nude mice and their 
apparent safety in animals, these molecules are promising new anti-cancer drugs. They 
probably target a metabolic signaling pathway, besides aurora B inhibition. 
In addition to their possible applications, these inhibitors are tools for cell biology 
studies. C4, a low ATP affinity inhibitor of aurora B kinase, revealed that the basal activity of 
the kinase is required for histone H3 phosphorylation in prophase and for chromosome 
compaction in anaphase. These waves of activation/deactivation of the kinase, during mitosis, 
corresponded to different conformations of the passenger chromosomal complex. 
Key words: Cancer, mitotic kinases, kinase inhibitor, histone H3 phosphorylation, 
chromosome compaction. 
RÉSUMÉ 
Les benzo[e]pyridoindoles sont de puissants inhibiteurs des kinases aurora. Nous avons 
réalisé une étude structure/activité pour améliorer leur activité et leur solubilité. Les amino-
benzopyridoindolones se révèlent être des puissantes molécules antiprolifératives. Elles 
induisent un fort arrêt mitotique qui s’accompagne de l’absence de phosphorylation de 
l’histone H3 ainsi que de la désorganisation du fuseau mitotique. Après un délai, les cellules 
deviennent binuclées puis, elles meurent. Compte tenu de leurs caractéristiques précliniques, de 
leur efficacité sur des xénogreffes implantées chez la souris nude et de leur absence apparente 
de toxicité chez l’animal, ces molécules sont prometteuses pour les traitements anticancéreux. 
Elles ciblent probablement une voie métabolique tout en inhibant la kinase Aurora B. 
 Au de là de leurs possibles applications, ces inhibiteurs sont des outils pour la biologie 
cellulaire. La molécule C4, un inhibiteur d’Aurora de faible affinité pour l’ATP, révèle 
l’existence d’une activité basale de la kinase requise pour la phosphorylation de l’histone H3 
en prophase et pour la compaction des chromosomes en anaphase. Ces vagues 
d’activation/désactivation de la kinase Aurora B correspondent à différentes conformations du 
complexe passager.  
Mots clés : Cancer, kinases mitotiques, inhibiteur de kinase, phosphorylation de l’histone H3, 
compaction des chromosomes 
